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AdoHcy   S-adenosyl-L-homocysteine 
AdoMet   S-adenosyl-L-methionine 
ALS    Amyotrophic lateral sclerosis 
ASF/SF2   Serine/arginine-rich splicing factor 1 
ASO    Antisense oligonucleotide    
ASO-10-27   2’-O-2-methoxyethyl-modified ASO 
AAV    Adeno-associated virus 
C    Cytosine 
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GTF2H2   General transcription factor IIH subunit 2 
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wmd    Drosophila Unrip orthologue p 
WRAP53   Human telomerase cajal body protein 1  
YG box   Tyrosine/glycine-rich motif 
 
  
 
 
ABSTRACT 
 
Spinal Muscular Atrophies (SMAs) are genetic neurodegenerative disorders characterized by 
progressive muscle wasting and loss of muscle function due to severe motor neuron dysfunction. 
SMAs are phenotypically heterogeneous groups of diseases distinguished by the pattern of features, 
severity of muscle weakness, age of onset and mode of inheritance. The majority of patients present 
autosomal recessive inheritance with proximal manifestation, secondary to mutations in survival 
motor neuron 1 (SMN1) gene. SMA represents one of the most common genetic causes of infant 
death with an incidence of 1 in 6000.  
This study was carried out to investigate a possible involvement of a new gene in the pathogenesis of 
SMA disease. Trimethylguanosine Synthase 1 (TGS1) gene encodes an enzyme responsible for the 
nuclear importation and maturation of snRNPs. TGS1 function is closely related to SMN function 
since both proteins are essential for snRNPs biogenesis. Even if the molecular pathway underlying 
SMA is still not fully understood, disruption of snRNP biogenesis followed by pre-mRNA misplacing 
is the most likely explanation for the pathogenesis of SMA. 
The discovery of two TGS1 gene mutations in two patients with type IV SMA clinical features has 
been the starting point of this project. Functional studies have been performed to understand the 
functional consequences of these variants and their involvement in SMA disease. Our preliminary 
studies, mainly performed on one mutation (p.Gly259Ser), seem to confirm our initial theory 
highlighting a possible relationship between TGS1 mutations and SMA-like phenotypes.  
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1. INTRODUCTION 
1.1 SPINAL MUSCULAR ATROPHY 
The term Spinal Muscular Atrophies (SMAs) is applied to a wide group of genetic disorders that 
affect the anterior horn cells and selective motor cranial nerve nuclei1. SMAs are phenotypically 
heterogeneous groups of diseases with autosomal recessive, autosomal dominant, or X-linked 
recessive mode of inheritance. The majority of patients present autosomal recessive inheritance with 
proximal manifestation. 
Autosomal recessive SMA (or 5q-SMA) is a neurodegenerative disorder, which is the most common 
genetic cause of death in infants, with an incidence of about 1.2 per 10000 live births2. More recent 
studies estimate that the incidence of SMA to be higher about 1 in 6000 with a carrier frequency of 
1:383. Spinal muscular atrophy is characterised by progressive symmetrical muscular atrophy and 
weakness as a result of degeneration of α-motor neurones in spinal cord4. 
The first clinical descriptions were published in 1891 by Guido Werding from University of Vienna 
5, which described the disease in two infant brothers. The following year, Johann Hoffmann of 
Heidelberg University used the term "spinal muscular atrophy" in his paper (“Familiar Progressive 
Spinal Muscular Atrophy”). Hoffmann credited the two cases described by Guido Werding and 
placed himself in full agreement with Werding conclusions regarding the familiar and progressive 
nature of the disease. In the following years Hoffmann described seven cases in four families6. 
Werding’s and Hoffmann's papers presented the clinical and pathologic aspects of infantile SMA, 
one of the different types of spinal muscular atrophy. But only in 1961 the wide spectrum in SMA 
was observed, thanks to Byers and Banker1. They found that life expectations were not always less 
than 4 years old, as originally described. Some years after, Dubowitz and Munsat studies helped to 
figure out the age of onset, prognosis and clinical features of SMA, which can be classified into 
different clinical grades based on the age of onset and severity of the disease7,8. 
 In the beginning of 1990, the gene responsible of SMA was mapped to chromosome 5q13.2 and in 
1995, the gene was identified as the Survival Motor Neuron (SMN) gene9. This gene is localized in a 
particular chromosome region, characterized by an inverted duplication region with 4 genes (SERF1, 
GTF2H2, NAIP and SMN) presents in telomeric and centromeric copies10. For this reason, SMN exists 
in two paralogue genes: SMN1 the telomeric copy and SMN2 the centromeric copy (Fig. 1).
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Fig 1: Gene locus of the centromeric and telomeric copy of Survival Motor Neuron gene in human chromosome 5. 
Both genes encode for SMN protein, which is important during the assembly of small nuclear 
ribonucleoproteins (snRNPs) involved in pre-mRNA splicing. However, the gene responsible for the 
selective degeneration of lower motor neurons followed by atrophy of proximal skeletal muscle is 
only SMN1. Mutations in SMN2 do not lead to disease. Spinal muscular atrophy is due in 95% of 
cases by biallelic loss of SMN1 followed by the loss of the encoded protein. While the other 5% of 
cases by mutations as missense, small deletions and splice site mutations that lead to non-functional 
protein generation. In both cases, the centromeric copy SMN2 is still present. This gene differs from 
SMN1 gene by several exonic and intronic SNPs. Among them, the transition C>T at position +6 of 
exon 7 leads to disrupt an exonic splice enhancer11,12. As a result, ~90% of the generated mRNAs are 
with exon 7 skipping (SMNΔ7) and produce an unstable protein. While only ~10% of the transcripts 
are fully functional. However, the low abundance of the resulted protein from SMN2 is not sufficient 
to fully compensate for the loss of the SMN1 gene. Even if SMN2 is not enough to sustain the function 
and the survival of spinal motor neurons, it acts as a positive modifier. This is because there are 
variable copy numbers of SMN2 gene in the population and exists an inverse correlation between the 
numbers of copies and the severity of the disease13,14. 
1.2 CLINICAL CLASSIFICATION 
Since the severity of SMA is highly variable among different cases, the International SMA 
Consortium defined four clinical groups, based on the age of onset and motor function achieved15 
(Tab.1). 
SMA type I (MIM #253300) or even called Werding-Hoffmann disease is the most common and 
severe form of SMA. The incidence is estimated to be between four and ten per 100 000 live births16. 
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The onset is from birth to 6 months, affected infants are hypotonic with a symmetric pattern of 
weakness (“floppy infant”). It is more proximal than distal, with lower limbs usually weaker than 
upper limbs. Patients with SMA type I are characterised by absence of deep tendon reflexes, 
breathing, sucking and swallowing difficulties and inability to sit unsupported. Without mechanical 
ventilation, death occurs before 2 years old. Patients with SMA type I carry only two copies of SMN2 
gene. 
More precisely, the most severe form is SMA type 0 or Prenatal SMA, where the intrauterine 
movements are decreased, severe weakness and joint contractures are common at birth too. SMA type 
0 has prenatal onset and patients need respiratory support at birth17. About 95% of the affected babies 
are characterized by the presence of only one copy of SMN2 and deletion of exon 7 and 8 in both 
SMN copies. 
SMA type II (MIM #253550) or Dubowitz disease (chronic spinal muscular atrophy) is the 
intermediate form of childhood SMA, the age of onset is between 6 and 18 months and individuals 
survive until 5 years. The most important clinical feature, that is not present in Werding-Hoffmann 
form, is postural hand tremor. Patients with SMA type II are able to sit unsupported but they cannot 
walk independently. In this form at least three copies of SMN2 gene are present. 
SMA type III (MIM #253400) or Kugelberg-Welander disease is the juvenile form with age of onset 
after 18 months and it is characterized by normal lifespan18. SMA type III could be divided into IIIa 
and IIIb, classification based on the age of onset. In type IIIa symptoms appear before 3 years old 
while in type IIIb after. Patients with SMA type III are able to sit and walk unsupported, but some of 
them lose the ability to walk during the life. Patients carry from four to eight copies of SMN2 gene. 
SMA type IV (MIM #271150) is the adult form with adult onset and is associated with normal life 
expectancy19. Patients are able to walk and they have not respiratory and nutritional problems. Like 
in SMA type III, four/eight copies of SMN2 gene are present. 
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Tab 1: Clinical classification of SMA disease. 
1.2 THERAPEUTIC APPROACHES IN SMA DISEASE 
Even if SMA disease is currently incurable, significant progresses in the development of therapeutic 
strategies have been achieved. 
To date, most of the therapeutic strategies are focusing on increasing the expression of SMN protein, 
since the disease is due to a deficiency of this protein. It has been demonstrated that the increase of 
SMN protein can be achieved by increasing the transcriptional activity of SMN2 gene or introducing 
exogenous SMN1 gene using viral vector20. The most promising vector in SMA disease is adeno-
associated viral (AAV) vector based on double strand genome. For the central nervous system (CNS), 
the vector of choice is a self-complementary adeno-associated virus serotype 9 (scAAV9). This vector 
has a remarkable capacity to transduce both neurons and astrocytes in adult mice following 
intravenous delivery21. Thanks to gene therapy, mice showed striking life expectation increase. SMA 
mice normally survive about 13 days while the ones treated with a single systemic delivery of 
scAAV9 the average lifespans increase to 199 days22,23. 
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In addition to gene therapy, to achieve an increase in SMN protein levels it is possible to modulate 
SMN2 gene transcription with antisense oligonucleotide (ASO) or drugs to stimulate promoter 
activity. Several ASOs are tested in preclinical models, they promote exon 7 retention and increase 
full-length SMN2 transcript. This is possible for the presence of several splice silencing motifs in 
SMN2 that are used as targets for antisense oligonucleotide. A strong intronic splicing silencer, ISS-
N1, is located in SMN2 intron 7 and this motif has been targeted by a number of ASOs with different 
chemical modifications. Due to the linkage between the specific ASO with ISS-N1, the negative 
splicing factor is unable to interact with the SMN2 pre-mRNA leading the inclusion of exon 7 in the 
transcript followed by a complete functional protein generation. 
One of these is phosphorodiamidate morpholino oligonucleotides (PMO), which promotes exon 7 
retention in the mature SMN transcripts24. It has been shown that one of the PMOs tested increased 
the level of the full-length transcript of SMN protein in vitro and prolonged the survival in vivo, 
rescuing the phenotype in a severe mouse model SMA after intracerebroventricular delivery. Another 
promising ASO is 2’-O-2-methoxyethyl-modified ASO (ASO-10-27), which corrects effectively 
SMN2 splicing and restores SMN expression in motor neurons after intracerebroventricular injection. 
Systemic administration of ASO-10-27 to neonates, robustly rescued severe SMA mice25,26. 
However, even if ASOs are highly effective at promoting inclusion of exon 7 splicing in SMN2 
transcripts and at increasing SMN protein levels both in vitro and in vivo, they are not capable of 
crossing the blood-brain barrier. Then, repeated intrathecal administration are required27. Another 
way to modulate SMN2 transcription is to use drugs to stimulate promoter activity. For example, 
histone deacetylases inhibitors (HDACIs) are a group of small molecules that promote gene 
transcription by chromatin remodelling. Various drugs in this class have been studied in SMA. Some 
HADC inhibitors are able to activate SMN expression in vitro and they are able to improve motor 
performance, attenuate weight loss and increase survival in SMA model mice28,29. Worth to mention 
small molecule therapy with mechanism on modulating SMN2 exon 7 splicing. These studies are 
sponsored by Norvatis and Roche with promising pre-clinical efficacy30. There are currently 3 phase 
2 trials using Roche’s small molecule RG7916 that is a splicing modifier able to increase SMN2 
protein production. In addition, other strategies are being used including neuroprotection with 
transplantation of neuron stem cells. These have resulted in improved phenotype and extended 
survival in SMA model mice31,32. 
In December 2016, FDA announced the approval of Spinraza (previously known as Nusinersen) to 
treat spinal muscular atrophy, an 2’-O-methoxyethyl modified ASO (2’MOE)33. 1st June of 2017 
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Spinraza was also approved in the European Union as the first treatment for spinal muscular 
atrophy34. Spinraza is now available on the market from Biogen35. 2’MOE is designed to bind to the 
SMN2 pre-mRNA complementary to ISS-N1 in intron 7. Since ASOs cannot cross blood brain 
barriers, to target motor neurons Spinraza has to be administrated via intrathecal injection, which 
delivers therapies directly to the cerebrospinal fluid around the spinal cord36. Treatment with Spinraza 
reduces the severity of the disease, allowing children with SMA type I to reach development 
milestones normally associated with less severe types of SMA, like the ability to sit and stand without 
any support. Furthermore, children survive longer than they would previously succumb to respiratory 
failure without invasive ventilation. However, this drug is not a complete cure for SMA. Patients 
treated with Spinraza have improved, however, still defected motor function. Another issue to be 
solved is how to deliver the drug efficiently into spinal cord in a less invasive delivery method. All 
these should be considered in future for SMA therapy37. 
1.4 SURVIVAL MOTOR NEURON (SMN) 
As shown previously, SMN gene exists in two copies, the telomeric copy SMN1 and the centromeric 
copy SMN2, localised within a duplicated and inverted segment on the long arm of chromosome 5 
(5q13), consisting of approximately 500kb. Both the centromeric and telomeric copies consist of nine 
exons (1, 2a, 2b, 3, 4, 5, 6, 7, 8) and five nucleotides distinguish SMN2 from SMN1, but only one is 
localised within the coding region. This base pair exchange is the transition C to T at position +6 of 
exon 7 (c.840C>T). c.840C>T is a silent mutation but results in alternative splicing of exon 7 
(SMNΔ7). SMNΔ7 transcript encodes for a shorter protein in which the last 16 residues encoded by 
exon 7 are replaced by 4 residues encoded by exon 8. This truncated and unstable protein shows a 
reduced oligomerization capacity, which is essential for proper SMN function11. The alteration of the 
normal splicing with the presence of the transition c.840C>T is due to the disruption of an exonic 
splicing enhancer (ESE), which is recognised by serine/arginine-rich splicing factor 1 (SF2/ASF), 
and/or creation an exon splice suppressor (ESS) recognised by heterogeneous nuclear 
ribonucleoparticule A1/A2 (hnRNP A1/A2). Normally, exon 7 inclusion is due to the binding of 
SF2/ASF in a sequence encompassing nucleotides + 6 to +11 of exon 7. The transition c.840C>T is 
followed by a binding decrease of SF2/ASF due to the generation of ESS recognized by hnRNP 
A1/A2, which antagonize SF2/ASF-dependent ESE activity and promote exon 7 skipping. The 
skipping of exon 7 occurs in ~90% of mRNA transcripts. Nevertheless, SMN2 still preserves the 
ability in ~10% of mRNA transcripts to generate the full-length isoform of SMN (Fig 2). 
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Fig 2: Difference in SMN1 and SMN2 splicing. (Image modified from Farooq et al., 201338) 
Compared to the full-length isoform, SMNΔ7 is characterised not only by the skipping of exon 7, 
which encodes for 16 amino acid, but also by the addition of four amino acid (EMLA) encoded by 
exon 8. The presence of these four amino acids can explain the decreased stability of this truncated 
protein since EMLA represents a degradation signal39. 
1.4.1 SMN protein structure 
SMN protein is a ubiquitously expressed protein, consists of 294 amino acids with a molecular weight 
of 38 kDa. The N-terminus region coded by exons 2A and 2B represents the nucleic acid binding 
domain, it is conserved and overlaps with the binding site of SMN-Interacting Protein 1 (also known 
as Gemin 2). The middle of the protein, comprising amino acids 90-160, is characterised by the 
presence of a Tudor domain that is encoded by exon 3, which binds symmetrically dimethylated 
arginines, found within many SMN binding proteins. Tudor domain exhibits a conserved negatively 
charged surface that is shown to interact with C-terminus Arg and Gly-rich (RG and RGG domains) 
tails of Sm proteins40. While downstream of the Tudor domain, SMN contains a proline-rich sequence 
and a tyrosine/glycine-rich motif (YG box). YG box (encoded by exon 6, from amino acid 258-279) 
together with the last sixteen amino acid encoded by exon 7 facilitate the self-association of SMN41,42. 
That appears to be crucial for stability and subcellular localisation of SMN. Moreover, QNQKE motif 
inside the sequence encoded by exon 7 is a nuclear export signal, important for cytoplasmic 
localisation of SMN and axon function as well43 (Fig 3). 
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Fig 3: Domains of SMN protein. (Image modified from Singh et al., 2017) 
The overall structure of the protein is critical for the function since small mutations, such as small 
deletions, splice mutations and missense mutations in these domains have been linked to SMA. This 
occurs in ~5% of SMA cases. Small mutations are found throughout the length of the protein, but 
the 3D structure of SMN reveals the mutations to be clustered. Three clustered groups of mutations 
are presented, one in the N-terminal domain, the second in the Tudor domain and the last within and 
near the YG box of SMN41.  
1.4.2 SMN protein 
SMN protein is localised in the cytoplasm as well as in the nucleus and is particularly abundant in 
motor neurones of spinal cord44. Also, high levels of SMN protein are presented in brain, kidney and 
liver, while moderate levels in skeletal and cardiac muscle. Both in the nucleus and the cytoplasm 
SMN form a large multiprotein complex of 1MDa, consist of Gemins 2-8, Unr-interacting protein 
(UNRIP) and SMN. 
Within the nucleus, SMN protein is concentrated in structures called Gems, dot-like structures 
associated with Cajal bodies (CBs)45–47. Gems and Cajal bodies are distinct nuclear structures since 
they do not colocalize in the fetal tissues but only in some cell lines in adult tissue48. The interaction 
between the two structures may be mediated by the binding capacity of SMN and Coilin (marker of 
Cajal bodies)49 (Fig 4). 
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Fig 4: SMN and Coilin staining in Hela cells shows that SMN proteins, concentrated in Gems structure, colocalize with 
Coilin of Cajal bodies (Hearst et al.,200950) 
Cajal bodies structures were discovered in both plants and animal cells in 190351. CBs are one of the 
nuclear bodies (NBs) existing, together with splicing speckles, paraspeckles, nuclear stress bodies 
and histone locus bodies52–56. Nuclear bodies spatially compartmentalise the nuclear environment, 
they are steady-state structures that dynamically respond to basic physiological process52. In 
particular, Cajal bodies are the sites where many proteins and RNA molecules are modified and 
assembled. CBs represent a meeting place and factory for ribonucleoprotein (RNP)54. They contain 
high levels of factors involved in the transcription and processing of many types of nuclear RNAs, 
including the three eukaryotic RNA polymerases, small nucleolar ribonucleoproteins (snoRNPs) and 
small nuclear ribonucleoproteins (snRNPs)57. 
SMN protein is involved in large numbers of different pathways, but its major housekeeping function 
is the biogenesis of snRNP58. In addition to this, SMN has also an essential role in snoRNPs 59, 
miRNPs60 and telomerase RNPs biogenesis 61. Over the last decades, an additional non-canonical 
function has been identified, that is a role in the assembly of mRNA-binding proteins (mRBPs) and 
their target mRNAs into a messenger ribonucleoprotein complexes (mRNPs)62,63. SMN protein seems 
to be involved in regulation of the axonal localisation of mRNPs64–67. 
1.4.3 Role of SMN in axonal mRNA metabolism  
SMN protein is abundant in axons, dendrites and axonal growth cones of motoneurons. SMN is 
localised in granules associated with cytoskeletal filament systems, SMN granules are actively 
transported both retro- and antero-gradely in a microtubule-dependent manner68–70. The involvement 
of SMN protein in axonal transport has been shown in motoneurons isolated from SMA mouse model, 
which exhibit normal survival but reduced axons growth in which SMNΔ7 is confined to the 
nucleus71. In fact, the distribution of SMN-Gemin complex through the cytoplasm is due to the 
QNQKE motif (nuclear export signal) that is encoded by exon 7. That motif leads to the exportation 
from the nucleus to the cytoplasm where SMN is localised in granules within neurites43. It has been 
shown that SMN interacts with some mRBPs and in SMA disease the loss of this interactions can 
affect targets mRNAs stability and their transport through the axon72 (Fig 5). 
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Fig 5: Role of SMN in mRNP assembly (Fallini et al., 201263). 
The first clue about the function of SMN in axons came from the significant reduction in β-actin 
mRNA levels at the axon tip of motoneurons derived from severe SMA mice71,73. Translocation of β-
actin mRNA at the axon tip results necessary for the neurite outgrowth. Reduction in the level of β-
actin mRNA is due to the absence in SMA mice of the linkage between Smn and RNA-binding 
heterogeneous nuclear ribonucleoproteins R (hnRNP R)74. This interaction allows the following 
association between hnRNP R and β-actin mRNA, which leads to translocation of this mRNA into 
axons and axon terminals. Therefore, Smn-hnRNP R linkage is crucial for the transport of β-actin 
mRNA to the distal part of the axon and probably it is important for the control of the stability of β-
actin mRNA in motor growth cones. Mutations in hnRNP R, which affect the binding with Smn and 
β-actin mRNA, lead to the reduction in neurite outgrowth in differentiating PC12 cells line71. Smn 
and hnRNP R interaction has been studied also in vivo in zebrafish and in vitro and in vivo in mice. 
It has been shown that these two proteins contribute to the differentiation and maintenance of 
neuromuscular endplate and depletion of Smn or hnRNP R leads to comparable phenotypes67,75,76. 
The interaction described is not the only one to be crucial for β-actin mRNA transport. The insulin-
like growth factor mRNA-binding protein 1 (IMP1) is actively transported in motor neuron axon due 
to the association with the Tudor domain of SMN. IMP1 directly controls the transport and local 
translation of β-actin mRNA in fibroblasts and neurons and shows a dramatic reduction in motor 
neurons but not in the brain lysate from SMA mice72,77. This suggests that the role of IMP1 in β-actin 
mRNA transport could be a specific phenomenon occurring to motor neurons and not a general 
phenomenon occurring in all cell types. 
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Translation of β-actin mRNA is also under the control of neuronal mRNA binding protein HuD, 
which interacts with the Tudor domain of SMN and the survival motor neuron protein is co-
transported with HuD in axonal granules65,78 (Fig 6). 
 
Fig 6: Colocalization of HuD protein (red) with smn granules (green) along the mouse motor neuron axon. (Image taken 
from Akten et al,. 201178). 
 HuD in neurons is involved in the neuronal development and plasticity. It binds to AU-rich elements 
in the 3’UTR of target mRNAs and controls their stability and translation79. A missense mutation in 
SMN Tudor domain, which is known to cause SMA, impaired the interaction with HuD and even a 
deficiency of SMN in primary motor neuron leads to a reduction of HuD levels followed by important 
impairment of poly(A)-mRNA localisation in axon80. One of the HuD targets is β-actin mRNA but is 
not the only one, other HuD targets are the candidate plasticity-related gene 15 (cpg15) mRNA and 
growth-associated protein 43 (GAP43) mRNA. It has been shown that cpg15 mRNA interacts with 
HuD and SMN as well since colocalizes with both proteins in motor neurons. HuD and SMN are 
involved in the transport of cpg15 mRNA through the axons followed by its translation inside the 
growth cones. cpg15 is highly expressed in the developing ventral spinal cord and it has a role in the 
development of motor axons and neuromuscular junctions78. Interestingly, neurons with SMN 
deficiency are characterised by decreased levels of cpg15 mRNA and its overexpression in zebrafish 
partially rescues SMA phenotype. That shows a possible role of cpg15 mRNA as a modifier of SMA 
deficiency78. Moreover, even the growth-associated protein 43 (GAP43) mRNA is a target of HuD 
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and it plays a key role in regulating growth cone stability and axon growth and its levels are reduced 
in motor neurones from SMA mouse model64,81,82. 
These observations show that SMN, in association with the binding of mRNA-binding proteins such 
as HuD, hnRNP R and IMP1, plays a crucial role in the axonal transport of some mRNAs involved 
in axon outgrowth. 
1.4.4 SMN and snRNPs assembly 
Spliceosomal snRNPs assembly is a well-characterized function of SMN, where it is involved in Sm 
core assembly and in snRNPs nuclear importation. 
snRNPs are best known for their role in RNA splicing complexes, involving in the maturation of pre-
mRNAs. Spliceosomal snRNP assembly is a multistep process and requires a nucleus and 
cytoplasmic phase. In most of the eukaryotes, two spliceosomes coexist: the U2-dependent 
spliceosome, composed of U1, U2, U4/U6 and U5 snRNPs and the less abundant U12-dependent 
spliceosome, composed of U11, U12, U4atac/U6atac and U5 snRNPs. The first one catalyses the U2-
type introns removal, while the other catalyses the splicing of the rare U12-type class of introns83. 
Each spliceosomal snRNP consists of one (U1, U2, U11, U12 and U5) or two (U4/6 and 
U4atac/U6atac) small nuclear RNAs (snRNAs), eight Sm proteins (B, D1, D2, D3, E, F, and G) and 
specific polypeptides that are associated with only one individual U snRNP84. 
The first step for spliceosomal snRNP assembly is the transcription of pre-snRNAs that occurs in the 
nucleus by RNA polymerase II (Pol II), with the exception of U6 snRNA and U6atac generated by 
RNA polymerase III (Pol III). After transcription, pre-snRNAs are exported to the cytoplasm by their 
m7G cap. This structure is recognised by the nuclear cap-binding complex (CBC) composed by 
CBP20 and CBP80. CBC complex and pre-snRNAs are recognised by the adaptor protein PHAX 
(phosphorylated adaptor for RNA export) that mediates with the export receptor CRM1 the 
exportation of newly transcribed snRNAs48. In the meantime, in cytoplasm, Sm proteins (B, D1, D2, 
D3, E, F, and G) interact with chloride conductance regulatory protein (pICIn). This interaction leads 
to the prevention of premature RNA associations with Sm proteins85. pICIn exists in a complex 
known as the PRMT5 complex, responsible together with PRMT7 for the methylation of specific 
arginine residues in D1 and D3 Sm proteins allowing the transferring of Sm proteins to SMN 
complex86,87, in which SMN directly binds B, D1 and D3 Sm proteins with the Tudor domain. SMN 
complex consists of UNRIP and seven Gemin proteins (Gemin 2-8). After the interaction of SMN 
with Gemin proteins, Gemin7 recruits Gemin 6 and UNRIP. In addition to these interactions, self-
associations were observed for SMN and Gemin 2. The self-association of SMN proteins occurs with 
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the N-terminal domain but for the stabilisation of SMN oligomerization is essential Gemin 2-Gemin 
2 interaction88,89. SMN oligomerization allows the formation of higher-order complexes ranging from 
20S to 80S, which is impaired in SMA patients (Fig 6). 
 
Fig 6: SMN complex. Image taken from Pellizzoni et al., 200790. 
After the SMN complex formation and the exportation of snRNAs into the cytoplasm, PHAX is 
dephosphorylated bringing to the release of snRNAs. Now SMN complex plays a key role in 
assembling Sm proteins onto the just exported snRNAs to produce an active snRNP84,87,91. Sm 
proteins by the linkage with the Sm sites of snRNAs lead to the formation of a heptameric ring around 
Sm site (Sm core)92. A properly assembled Sm core is required for cap hypermethylation and 3’-end 
maturation. 
snRNP assembly is followed by nuclear importation, that occurs after the hypermethylation of m7G 
cap to a 2,2,7-trimethylguanosine (TMG) cap and trimming of the 3’-extension. The enzyme 
responsible for m7G cap conversion is Trimethylguanosine Synthase 1 (TGS1), also known as PIMT 
in higher eukaryotes93,94. It has been shown that there is an interaction between SMN and TGS1, 
which could indicate that SMN recruits TGS1 to the snRNAs95. This interaction appears to be 
essential for TMG cap formation96, that represents together with Sm core a bipartite nuclear 
localisation signal required to promote the nuclear uptake of snRNPs. The importation inside the 
nucleus is due to the binding of Snurpotin-1 to TMG cap and the association of SMN with importin 
β, that is facilitated by WRAP5397–99 (Fig 7).  
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Fig 7: Maturation of snRNPs requires nuclear and cytoplasmatic regulatory steps. (Image taken form Burghes and Beattie 
200987). 
Once inside the nucleus, the imported complex undergoes to the dissociation and snRNPs and SMN 
transiently localised to Cajal bodies 93,96,100. Inside these structures, CB specific ribonucleoproteins 
(scaRNPs) complete the maturation of snRNPs with 2’-O-methylation and pseudouridylation 
followed by the association with individual snRNP-specific proteins. After the completed maturation 
process, that occurs in the Cajal bodies, mature snRNPs are localized to speckles or nucleoplasm, 
where they are stored until they are required for pre-mRNA splicing101. 
SMN protein hence becomes extremely important for the assembly of snRNPs and the further 
maturation, for this reason, SMN deficiency causes widespread defects in splicing42,102. SMN 
mutations lead to disruption of the binding between Sm core proteins and snRNAs, followed by a 
defect in Cajal bodies accumulation of snRNPs and SMN103,104. Defects in Cajal bodies accumulation 
and their disruption are not only due to depletion of SMN protein but also the lack of other proteins 
involved in snRNPs maturation, like TGS1 and PHAX105. Knockdown of any one of these proteins 
leads to the dispersion of coilin, the marker protein for CBs, into numerous small foci in the 
nucleoplasm and nucleolus and the colocalization of snRNPs with coilin is lost. This indicates that 
CBs are lost when the biogenesis of snRNPs is blocked. 
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1.4.5 SMN and snoRNPs 
SMN complex is also involved in the biogenesis of snoRNPs. The small nucleolar ribonucleic protein 
consists of snoRNA and a number of common core proteins. These complexes are localised in the 
cell nucleolus and they are required for the maturation of pre-rRNA by chemical modifications of 
rRNA during ribosome biogenesis (methylation and pseudouridylation) and post-transcriptional 
processing. snoRNPs are categorised into two main classes based on their function and structure: the 
box C/D and box H/ACA snoRNAs106. The C/D class of snoRNPs carries out 2’-O-methylation, 
whereas the H/ACA class is responsible for pseudouridylation of their RNA targets. C/D snoRNAs 
are associated with a set of small proteins: 15.5K, Nop56, Nop58 and fibrillarin, while H/ACA 
snoRNAs are associated to Nhp2, Nop10, Gar1 and dyskerin107,108. snoRNAs can be transcribed by 
Pol II, like snRNAs, but even as polycistronic units. In this case, when snoRNAs are transcribed as 
polycistronic units they do not require hypermethylation process for completing the maturation. 
Instead, snoRNAs transcribed by Pol II, m7G cap needs the hypermethylated by TGS1 that take place 
into CBs109,110. 
SMN is involved in the snoRNP assembly and their biogenesis inside the CBs111. SMN complex 
interacts with both box C/D and H/ACA snoRNPs, due to the binding with fibrillarin and Gar1 that 
are specific markers of the two classes of snoRNPs59. In contrast with snRNAs, the biogenesis of 
snoRNAs does not require a cytoplasmic phase, but the maturation happens through Cajal bodies and 
nucleolus. The assembly of snoRNAs starts in the CBs, but for the localisation of snoRNA precursors 
inside these nuclear bodies the association of the adaptor PHAX with m7G cap is required. Inside the 
Cajal bodies, they acquire TMG cap after hypermethylation process by TGS1113. TMG cap is then 
linked to chromosome region maintenance 1 (CRM1) that is required for the nucleolar transport of 
the mature snoRNPs112. 
The role of SMN in snoRNPs biogenesis is still not well characterised, SMN might be involved in a 
late assembly step. It has been shown that SMN is required for accumulation of snoRNPs chaperone 
Nopp140 in CBs. Nopp140 interacts with both classes of snoRNPs, acting as a chaperone of snoRNPs 
in yeast and vertebrate cells114. Moreover, the presence of Nopp140 into the CBs is inversely 
correlated with SMA disease severity115. However, the clear function of Nopp140 and SMN in CBs 
is unknown but SMN seems to be important for some aspects of snoRNP biogenesis in CBs that 
involves Nopp140. Decreased level of Nopp140 in CBs leads to a specific reduction of H/ACA 
snoRNPs. The reduction of H/ACA versus C/D snoRNPs in SMA cells is due to a tighter association 
of Nopp140 with box H/ACA snoRNPs compared to the association with box C/D class114. 
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In conclusion, SMN protein plays a key role in the assembly and the maturation of both snRNPs and 
snoRNPs and it is one of the essential proteins for these processes. Another important protein during 
the biogenesis of both complexes is TGS1, an enzyme responsible for the hypermethylation m7G cap. 
With the hypermethylation snRNPs acquire the nuclear localisation signal, which is required to 
promote their nuclear uptake, while in snoRNPs leads to nucleolar transport of the mature snoRNPs. 
Therefore, TGS1 plays a critical role in targeting sn- and snoRNA precursors to their final maturation 
and function site. 
1.5  TRIMETHYLGUANOSINE SYNTHASE 1 (TGS1) 
TGS1 protein was first discovered in yeast in 2002 as the enzyme responsible for hypermethylation 
of snRNPs and snoRNPs m7G cap structure synthesised by RNA polymerase II93, as well as the 
telomerase RNA116 and selenoprotein mRNA117. TGS1 is an S-adenosyl-L-methionine (S-AdoMet)-
dependent methyltransferase. The gene coding TGS1 was discovered in 2001 and it was called PIMT 
since its ability to interact with the receptor PRIP118. This gene maps to chromosome 8q12.1, it covers 
52.40kb and it is composed of 13 exons encoding for 853 amino acids. 
TGS1 is highly conserved in metazoan, plants, lower eukaryotes, bacteria and archaebacteria. The 
highest conserved region is the C-terminal part of the protein, which contains the catalytic 
methyltransferase domain between the amino acid 576-853119. While the N-terminal domain varies 
in size between different species and is required for self-association of the protein. It is not clear if 
TGS1 association leads a dimer formation or higher order oligomers. This event greatly enhances the 
efficiency of snRNPs and snoRNPs trimethylation120. Furthermore, the N-terminal domain contains 
two nuclear export signals: NES1 and NES2109. NES2 is required for the shuttle of TGS1 between 
the nuclear and the cytoplasm compartments in a CRM1-dependent manner. In yeast mutant Tgs1 
lacking N-terminus domain is localised into the nucleus but fails to be enriched in the nucleolus and 
also leads to undermethylation of snRNAs and snoRNAs120. 
1.5.1 TGS1 function 
TGS1 is involved in methylation steps for the conversion of the m7G caps to TMG cap structure. 
Functions conserved in yeast, Drosophila and human somatic cells93,105,121. Eukaryotic mRNAs, 
synthetized by Pol II, are characterised by the presence of m7G cap structure at their 5’-end. The TMG 
cap is a signature feature of eukarya mRNA that protects against exonucleolytic decay and promotes 
translation initiation. TGS1 catalyses two successive methy-trasfer reactions from S-adenosyl-L-
methionine (AdoMet) to the exocyclic NH2 group of the N7-methylguanine, generating two S-
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adenosyl-L-methionine molecules (AdoHcy) and the modified m2,2,7G (m3G)-cap. TGS1 is a guanine 
specific methyltransferase and compared to the other RNA guanine-N2 methyltransferases the 
methylation of guanine N2 is strictly dependent on prior methylation of guanine N7122. For its activity, 
TGS1 requires AdoMet as the methyl donor and the binding with snRNP or snoRNP, which represent 
the methyl acceptor. In snRNP it seems that the SmB/B’ protein facilitates hypermethylation of 
snRNAs by providing a docking site for the MTase123. 
In addition to the hypermethylation of snRNPs and snoRNPs, TGS1 is involved in m3G cap structure 
formation in telomerase RNA. The first discovery of this additional function was done in 
Saccharomyces cerevisiae in 2008116. Telomerase component 1 (TLC1) encodes the template RNA 
of telomerase and it shares with snRNA and snoRNA the presence of a m3G cap structure at the 5’ 
end124. It has been shown that the lack of Tgs1 activity leads to a premature ageing due to a 
modification in telomere length, structure and function. Even in human telomerase RNP biogenesis, 
TGS1 is involved to TMG cap formation. After the transcription of the human TER, designed as hRT 
in the original identification125, and the assembly with H/ACA core proteins, the hRT precursor is 
then processed at its 3’-end followed by the transport to the Cajal bodies by the transporter factor 
PHAX and Nopp140114. Where, one of the two isoforms of TGS1 (TGS1 short isoform,TGS1 SF) 
gives hTR its TMG cap126,127. 
1.5.2 TGS1 isoforms 
TGS1 exists as two isoforms: full-length isoform (TGS1 LF) with a molecular weight of 110kDa and 
the shorter isoform (TGS1 SF) with a molecular weight of 65-70kDa. The full-length isoform of 
TGS1 is located predominantly in the cytoplasm while the shorter is located in the nuclear 
compartment95,126. The nuclear isoform (TGS1 SF) is not generated by alternative splicing but it is 
the result from a post-translational mechanism, and lacks between 320 and 400 residues in the N-
terminal region. With immunoprecipitation experiments, it has been shown that TGS1 SF binds 
preferentially to common proteins of C/D and H/ACA snoRNPs, while TGS1 LF to snRNPs126. TGS1 
LF is responsible for the acquisition of the trimethylguanosine cap structure in snRNPs into the 
cytoplasm. While TGS1 SF is involved in snoRNPs hypermethylation inside the CBs, since snoRNPs 
do not require a cytoplasmic transit for the acquisition of the trimethylguanosine cap structure123,128 
(Fig 8).  
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Fig 8: TGS1 LF is responsible for TMG cap formation in snRNPs followed by their uptake into the nucleus while TGS1 
SF is involved in the maturation of snoRNPs. With the acquisition of TMG cap structure, snoRNPs complete their 
maturation into the nucleolus (Image modified from Ogg et al., 2002129). 
TMG cap formation required first the interaction between TGS1 and snRNPs or snoRNPs. This 
occurs with N-terminal region of TGS1 full-length for snRNPs and with the C-terminal region of 
TGS1 short isoform for snoRNPs. With snRNPs, TGS1 LF is able to interact with only the C-terminal 
extension of SmB and SmD1 proteins93. The common feature of SmB and SmD1 compared to the 
other Sm proteins is a basic rich C-terminal tail. This means that TGS1 interacts with highly charged 
regions. At the same time, TGS1 is able to bind with C-terminal domain SMN protein. SMN interacts 
with TGS1 LF in the region encoded by exons 4-7, interaction lost in the spinal muscular atrophy for 
the inability of SMNΔ7 to bind TGS1 LF95. This direct binding between TGS1 LF and SMN 
highlights a role of the latter in m3G cap formation. SMN could allow the engagement of TGS1 LF 
with the m7G-capped snRNP particle.  
For the hypermethylation of snoRNPs the interaction occurs in the C-terminal extensions of C/D and 
H/ACA box that, like C-terminal tail of snRNPs, is rich in basic amino acid. These interactions with 
C-terminal extensions of box C/D and H/ACA occurs with C-terminal domain of the short isoform 
of TGS1126. TGS1 interacts with snoRNPs inside the Cajal bodies followed by hypermethylation of 
m7G structure. In CBs there is not only the short TGS1 isoform but also the full-length, which binds 
the C-terminal domain of Nop58 and Nop56 in snoRNPs. This interaction is regulated by CRM1 and 
this highlights a new role of TGS1 LF in the snoRNPs biogenesis unrelated to cap 
hypermethylation109. TGS1 LF in CBs is not required for the hypermethylation but the binding with 
C-terminal domain of snoRNPs hides the nucleolar localisation signal (NoLS). With this linkage, 
snoRNPs are held in the Cajal bodies to complete their assembly. While for hypermethylation is 
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required the short isoform of TGS1. After cap hypermethylation, NoLS has uncovered thanks to 
CRM1 which removes TGS1 LF. With the exposure of NoLS, mature snoRNPs are targeted to the 
nucleolus109. 
1.5.3 TGS1 studies in model organisms 
The first mutagenesis studies were performed in yeast in 200293. Yeast snRNPs and snoRNPs acquire 
their TMG cap structure inside the nucleolus. For a correct localisation of Tgs1 within the nucleolus 
and efficient sn(o)RNPs trimethylation, the N-terminus region of the protein is required 120. In N-
terminous region a bipartite NLS signal and the domain essential for self-association are present and 
both are needed for the correct nucleolar localisation and efficient sn(o)RNPs trimethylation activity. 
Deletion of yeast Tgs1 produces only a cold-sensitive splicing defect but does not interfere with the 
viability of the yeast93. In the absence of Tgs1, the conversion of the m7G cap to the m3G structure is 
missing, resulting in a splicing defect at the restrictive temperature that correlates with the retention 
of U1 snRNA in the nucleolus. In contrast to yeast, in mouse and Drosophila Tgs1 is an essential 
gene. The lack of this protein in mouse leads to early embryonic lethality as well as in Drosophila to 
early pupal lethality121,130. In Drosophila Tgs1 is required in both muscle and motor neurons to sustain 
the development of an adult viable organism. Not only disruption but even an overexpression of Tgs1 
is toxic and leads to lethality96.  
In vitro experiments in HeLa cells showed that lack of TGS1 is not essential for cell viability but 
leads to loss of canonical CBs. With the disruption of TGS1, coilin (CBs marker) is distributed 
throughout the entire nucleus in numerous smaller foci and partially is accumulated in nucleoli, where 
it forms more predominant structure105. Loss of CBs is due to inhibition of cytoplasmatic maturation 
of snRNPs since they are not able to complete their biogenesis without TMG cap structure. 
1.6 PATHOGENESIS 
Although the genetic defect in SMA is well defined, its underlying molecular pathway is still not 
fully understood. For example, how mutations in the ubiquitously expressed SMN genes cause a 
neurodegenerative condition where only motoneurons become dysfunctional and degenerated while 
other types of neurons are spared or much less affected. Whether SMA results from a disruption of 
snRNP biogenesis followed by pre-mRNA misplacing of genes that are critical for the function of the 
neuromuscular system is still unclear. It is not well understood why the loss of snRNP biogenesis in 
all cells leads to a selective damage in neuromuscular system, only some suggestions have been 
proposed87,97,131. It is possible that, relative to other cell types, neuromuscular tissues have a greater 
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requirement or sensitivity for SMN function. An alternative hypothesis that could explain the extreme 
tissue-specificity observed in SMA patients is that the disruption of snRNPs biogenesis leads to 
inappropriate or inefficient splicing of some mRNA transcripts crucial for the survival of 
neuromuscular tissues. Which kind of mRNAs are affected are still to be determined. Interestingly, 
SMN deficiency changes the snRNP profile of tissues in a non-uniform manner and appears to 
preferentially reduce accumulation of U12-dependent spliceosomal28,132. It has been discovered that 
SMN is required for U4atac/U6atac/U5 formation since in type I SMA patients is dramatically 
decreased, even splicing events of some U12-type class of introns is inhibited133. Then SMN 
deficiency perturbs splicing and decreases the expression of a subset of U12 intron-containing genes 
both in mammalian cells and Drosophila larvae134. So far, the only SMN-dependent U12 splicing 
event that could be linked to the SMA phenotype, is the splicing of stasimon gene. This gene is a 
target of SMN and encodes for a protein required for the regulation of synaptic transmission of motor 
neurons. This event could be linked with SMA phenotypes since the restoration of Stasimon 
expression corrects defects in motor neurons in both invertebrate and vertebrate models of SMA. But 
it remains unclear the precise mechanism by which reduced Stasimon perturbs motor circuit 
activity134. 
In the last decade, another hypothesis is becoming increasingly widespread that is the explanation of 
SMA phenotypes with the disruption of the non-canonical function of SMN63,87. As previously 
described SMN interacts with some mRBPs as HuD, hnRNP R and IMP1 and in SMA disease loss 
of these interactions can affect targets mRNAs stability and their transport through the axon72. So far, 
defect in β-actin, cpg 15 and GAP-43 mRNA transport through axon have been described64,69,78. All 
these mRNA are involved in the development and axon outgrowth, then defect in translocation and 
transduction of these mRNA could explain the defective motor axon growth typically present on 
depletion of SMN76. 
Moreover, similar phenotype observed with SMN loss is shown with knockout or overexpression of 
other factors involved in snRNP biogenesis. In addition to SMN, many other proteins are implicated 
in snRNPs biogenesis. Lack of proteins that are part of SMN complex most likely leads to the motor 
dysfunction. For example, loss of the orthologue protein of Unrip in Drosophila (wmd) gives rise to 
viability and/or motor defects96. Even the disruption in all tissue of the other component of SMN-
complex, like Gemin 2, Gemin 3 and Gemin 5 leads lethality in a variety of organisms as yeast, worm, 
fly and mouse89. In Drosophila loss of these proteins in all tissues results in death at larval and/or 
prepupal stages, while if the loss of function is restricted to CNS or muscle confers loss of mobility 
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and a flightless phenotype. In mouse, loss of function of Gemin 2 in all tissues results in early 
embryonic lethality while the loss of function in CNS and/or in muscle leads to motor neuron 
degeneration135–137. Not only knockout but also overexpression of SMN complex protein leads to 
motor defects. Overexpression of Gemin 2 in Drosophila is sufficient to depress normal motor 
function and its enhanced upregulation in all tissues interferes in fly viability138. Even in yeast 
S.pombe the toxicity is conserved and Gemin 2 overexpression leads Sm proteins increased in the 
cytoplasm. Sm proteins accumulation inside the cytoplasm is due to a block in snRNPs biogenesis, 
followed by a decreased levels of snRNPs in the nucleus138.  
In addition to the proteins that compound SMN-complex, there are other proteins, which are not 
strictly involved in SMN complex formation but still important for snRNPs biogenesis. Altered 
expression of these proteins leads to motor dysfunction as well. For example, the disruption of either 
Tgs1 and plCln mirror the motor phenotypes that is observed with the loss of the constituent members 
of the SMN-complex96. It has been shown in HeLa cells that the absence of TGS1 leads to the same 
phenotypes observed with the lacking of SMN or PHAX105. Lack of function of these proteins results 
in coilin dispersion followed by the loss of CBs, which could be explained with a block in snRNPs 
biogenesis105. Moreover, overexpression of both Tgs1 and plCln factors has deleterious effects on 
adult viability and in neuromuscular activity in Drosophila, situation analogous to that reports for 
overexpression of Gemin 296,138. In particular, plCln overexpression results in an accumulation of Sm 
proteins in the cytoplasm, similar to the overexpression of Gemin 2 in S.pombe. Overexpression of 
Tgs1 in Drosophila leads to a failure to contract adequately during puparation as reflected by 
significant difference in the puparial axial ratio. This phenotype mimics that secondary to disruption 
of SMN, Gemin 2 or Gemin 3 and overexpression of plCln96,135,136,138–140. The similar phenotypic 
outcomes following disruption of Tgs1, plCln or any member of SMN-complex points out the 
participation of these factors in a shared pathway. 
Therefore, all these studies highlight the importance of snRNP biogenesis, which is required for 
normal motor behaviour, since disruption and/or overexpression of proteins involved in this pathway 
results in a motor dysfunction similar to what occurs in SMA disease. Defects in snRNPs biogenesis 
are the most likely explanation for SMA pathogenesis.  
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2. AIM OF THE PROJECT 
 
Two genetic variations in TGS1 gene (NC_000008.11) were discovered in patients by the next 
generation sequencing. These two patients, who are negative for SMN genetic defects, share SMA-
like clinical features. They showed symptoms similar to SMA type IV phenotypes. One of the 
variations is a missense nucleotide substitution in heterozygous state (p.Gly259Ser), localised in N-
terminal region of the protein. While another, is also a missense variation in heterozygous state 
(p.Asn704Ser) but is localised in the C-terminal region of TGS1.  
Trimethylguanosine Synthase 1 (TGS1) gene encodes an enzyme responsible for the nuclear 
importation and maturation of snRNPs. As reported in literature, the disruption of other proteins, 
correlates with snRNPs biogenesis, can lead to the SMA-like phenotype at least in the model 
organisms. Thus, the present study was carried out to investigate the possible involvement of this new 
gene in the pathogenesis of SMA disease. So far there are no studies about that, it is not yet described 
a possible direct correlation between spinal muscular atrophy and loss and/or gain of function in 
TGS1 protein. Then the aim of this project was to clarify the possible involvement of TGS1 in spinal 
muscular atrophy and to investigate the functional consequences of two different TGS1 genetic 
variations in patients with SMA-like phenotypes. 
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2. MATERIAL AND METHODS 
 
3.1 ETHICS 
Human cells were obtained with written informed consent of patients. The Declaration of Helsinki 
protocols were followed. 
3.2 CELL CULTURE MAINTENANCE 
Cell lines used: 
HEK 293T (Human embryonic kidney cells 293, this cell line expresses a mutant version of the SV40 
large T antigen)  
SH-SY5Y (Human neuroblastoma cell line) 
Fibroblast cell lines:  
L1266: the patient’s cell line with TGS1 p.Gly259Ser variant. 
7384: SMA type III patient with 3 copies of SMN2 gene.  
7215: SMA type III patient with 3 copies of SMN2 gene. 
6141: SMA type II patient with 2 copies of SMN2 gene. 
6142: SMA type II patient with 2 copies of SMN2 gene 
6076: healthy control fibroblast. 
8230: healthy control fibroblast. 
33F: control fibroblast with neuromuscular condition excluded. 
Lymphoblastoid cell lines: 
BW343: patient’s cell line with TGS1 p.Asn704Ser variant. 
BW344: cell line with TGS1 p.Asn704Ser variant.  
BW345: cell line in which the variant is not present. 
CTRL-E: control cell line with neuromuscular condition excluded. 
HEK 293T cells, fibroblast cell lines from patients and SH-SY5Y cells were cultured at 37°C in 
DMEM (D5671, Sigma) supplemented with 10% fetal bovine serum (D8537, Sigma), 1% 
GlutaMAXTM Supplement (35050061, Thermo Fisher Scientific) and 1% Penicillin-Streptomycin 
(P4458, Sigma). Cells were split when ~80% confluence was reached. 
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Lymphoblastoid cell lines were cultured at 37°C in RPMI Medium 1640 (61870010, Thermo Fisher 
Scientific) and 20% fetal bovine serum (D8537, Sigma). Cells were split every 3-4 days. 
3.3 CLONING VECTORS 
Wild-type and mutant plasmid carrying p.Gly259Ser mutation were obtained from an Italian research 
group. TGS1 was cloned into the vector pCDH-CMV-MCS-EF1-Puro under CMV promoter. It is a 
mammalian Flag-tagged construct carrying ampicillin as bacterial resistance and puromycin as a 
selectable marker. Molecular cloning was performed in One Shot® TOP10 Chemically Competent E. 
coli (C404006, Thermofisher). 50ng of each plasmids were used for chemically transformation and 
pUC19 as a positive control. Vials incubated on ice for 30 minutes and then heated for exactly 30 
seconds at 42°C in a water bath followed by 2 minutes on ice. The cells were then mixed in 250µl of 
pre-warmed SOC medium (15544034, Thermofisher) and incubated horizontally at 37°C for 1 hour 
at 225rpm in a shaking incubator. After the incubation, 50µl from each transformation were spread 
on a pre-warmed selective LB agar plate and incubated at 37°C overnight. Each selective LB agar 
plate (L2897 Sigma) contained 100µl/ml of ampicillin (A9393, Sigma). The following day, single 
E.Coli colonies were picked from agar plates into 5ml LB Broth (L3522 Sigma) containing the 
appropriate antibiotic (100µl/ml of ampicillin) and incubated at 37°C overnight at 225rpm in a 
shaking incubator. 
DNA was extracted using QIAprep Spin Miniprep Kit (27106, QIAGEN), according to standard 
protocols and sequencing was performed using 5’-GGTCAAGCACTATCTTCTGAACC-3’ primer 
to check TGS1 insert. After confirming the presence of TGS1 insertion inside the colonies picked, 
QIAGEN Plasmid Maxi Kit (12163, QIAGEN) was used to obtain a high amount of plasmids for a 
lentivirus generation. 
3.4 LENTIVIRAL VECTORS (PCDH-CMV-MCS-EF1-PURO)  
Lentiviral vectors (pCDH-CMV-MCS-EF1-Puro) were produced by co-transfecting 1.8 x 107 HEK 
293T cells with transgene plasmids and the packaging and enveloping constructs, pCMV delta R8.2 
and pMD2.G, respectively (Addgene). For 1.8 x 107 HEK293T cells plated in a 15 cm dish, 40µg 
plasmid DNA were co-transfected with 30µg of pCMV delta R8.2 and 10µg of pMD2.G. DNA was 
mixed in 5ml Opti-MEM® (31985-070, Thermofisher) and combined with 5ml Opti-MEM® 
containing 1µM polyethyleneimine (408727, Sigma). The mixtures obtained was applied to HEK 
293T cells after 20 minutes incubation at room temperature. After 4 hours of incubation, the mixture 
was removed and fresh medium was added to the cells. Medium containing the virus was collected 
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after 48 hours post-transfection. After each collection, the supernatant was filtered through a cellulose 
acetone membrane (0.22µm pore) and then was centrifuged (4°C) at 21900 X g for 20 hours. 
Following centrifugation, the supernatant was removed and the pellet was resuspended in 50µl of 
Opti-MEM®. 
3.4.1 Virus titration 
Virus titration was done in frozen samples in order to obtain an accurate result since lentivirus titer 
decreasing after defrosting. For virus titration, 2 x 105 HEK 293T cells were plated into each well of 
a 6 well plate and transduced with a range of volumes of the concentrated lentivirus. After seventy-
two hours of transduction, genomic DNA was extracted with DNeasy Blood & Tissue Kit (69504, 
QIAGEN) and the proviral titre was calculated by qPCR. 20ng/µl of the sample was used in qPCR 
and each sample was run duplicately together with a standard curve. TaqMan Universe PCR 
MasterMix (4304437, Thermo Fisher Scientific) was used in qPCR, together with 5µM of each primer 
and the probe. 
3.4.2 Transduction experiments 
Transduction was performed in twelve-well matrigel coated plates. SH-SY5Y cells were seeded at 
1x105 cells in each well. The following day, wild-type and mutant lentivirus vectors were used with 
a multiplicity of infection (MOI) of 1, 15 and 70. Cells were transduced for 24 hours before being 
replaced with the medium containing puromycin for 10 days. Survival cells were then isolated. 
Transduction of fibroblast cell lines was performed in twelve-well matrigel coated plates. Fibroblast 
cells were seeded at a density of 5x104 cells per well. The day after, cells were transduced for 24 
hours with a multiplicity of infection of 1, followed by puromycin selection for 10 days. Survival 
cells were then isolated. 
3.4.3 Puromycin selection 
In order to figure out the optimum concentration of puromycin (P8833, Sigma) for SH-SY5Y cells 
and fibroblast cells, 15 different concentrations were used for each cell lines. Cells were seeded into 
a 24 well plate in order to have 30-40% confluent at the following day. 15 different concentrations, 
from 0.1µg/ml to 2µg/ml of puromycin were used for fibroblast cells while from 1µg/ml to 6µg/ml 
for SH-SY5Y cells. Medium with antibiotic was replaced every 2 days. The optimum concentration 
to be used for each cell lines is the lowest concentration which kills 100% of untreated control cells 
exactly at day 5. 
26 
 
3.4.4 In vitro SH-SY5Y cells differentiation  
Transduced SH-SY5Y cells were seeded at a density of 1x104 cells in a 6-well matrigel coated plate 
with DMEM 10%. The day after media was replaced by complete Neurobasal TM medium (21103049, 
Thermo Fisher Scientific) supplemented with 1% GlutaMAXTM Supplement, 2% B27 (17504044, 
Thermo Fisher Scientific) and 10µM of fresh retinoic acid (R2625, Sigma-Aldric). Complete 
Neurobasal media were replaced every 2 to 3 days. 
3.5 LENTIVIRAL VECTORS WITH GREEN FLUORESCENT PROTEIN 
Three other lentiviral vectors, produced by a scientist at the Institute of Child Health, were used to 
transduce both SH-SY5Y cells and fibroblast cell lines: 
- pCCL-SFFV-TGS1.WT-IRES-EGFP (WT vector) 
- pCCL-SFFV-TGS1.p.Gly259Ser-IRES-EGFP (MUT vector) 
- pCCL-SFFV-EGFP (CT vector) 
 These lentivirus vectors differed from the previous ones in the presence of enhanced green 
fluorescent protein (EGFP) tag instead of FLAG tag. Moreover, the full-length TGS1 was under the 
control of the spleen focus forming virus (SFFV) promoter instead of CMV promoter. The third 
lentivirus vector was used as a negative control since it expresses only the green fluorescent protein 
and not full-length TGS1. These three vectors were trited by flow cytometric readout of GFP-
positive cells, following HEK 293T transduction. Vector tritation was completed by flow 
cytometry: 1x105 HEK293T cells were plated into each well of a 6-well plate and transduced with a 
range of volumes of concentrated lentivirus. After 72 hours of transduction, cells were trypsinized 
and EGFP-positive cells were quantified. 
3.5.1 Transduction experiments 
SH-SY5Y cells were plated at a density of 1x105 cells in six-well plates. The following day the three 
lentiviruses were then added to give a multiplicity of infection of 10. After 24 hours, the medium was 
changed and cells sorting were performed after 3 days of transduction. GFP-positive cells were sorted 
on a MoFlo sorting machine. Cells sorting allowed to obtain two different cell populations: cells with 
low and high GFP expression. Then, transduced cells were plated at a density of 1x104 cells in a 6-
well matrigel coated plate with DMEM 10%. The day after media was replaced by complete 
Neurobasal TM medium supplemented with 1% GlutaMAXTM Supplement, 2% B27 and 10mM of 
fresh retinoic acid. Complete Neurobasal media were replaced every 2 to 3 days. 
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3.6 IMMUNOSTAINING 
For TGS1 and SMN immunofluorescence staining in fibroblast cell lines from patients, controls and 
in transduced fibroblast cells, 2x104 cells were seeded in 8-well chamber slides with 500µl of DMEM 
10%. After 48 hours, cells were fixed in 4% paraformaldehyde (15710, Emigrd) diluted in PBS 
(D8537, Sigma) at room temperature (RT) for 15 minutes. Ice cold methanol were added in fixed 
cells for 1 hour at -20°C. Then cells were washed with PBS 1X for 5 minutes and blocked in 5% goat 
serum (G9023, Sigma) diluted in PBS 1X for 1 hour at RT. After the blocking, cells were incubated 
with mouse anti-SMN antibody (1:200) (610646, BD Transduction LaboratoriesTM), rabbit anti-TGS1 
antibody (1:100) (HPA025024, Atlas Antibodies) diluted in PBS/ 0.1% Triton X-100 (X100, Sigma) 
for 1 hour at RT. The cells were then washed with PBS 1X three times for 5 minutes each and 
incubated with Alexa 594 goat anti-mouse (1:200) (R37121, Thermo Fisher Scientific) and Alexa 
488 goat anti-rabbit (1:200) (R37116, Thermo Fisher Scientific) secondary antibodies for 1 hour at 
RT. They were washed three times for 5 minutes each with PBS 1X and mounted with mounting 
medium/DAPI. 
For TGS1 and SMN immunofluorescence in differentiated SH-SY5Ycells, the procedure is almost 
the same as described above. There was only one difference in the fixation procedure. The cells were 
seeded onto a matrigel-coated glass coverslips at 1x105 cells in 12-well plates. The day after, they 
were fixed in pre-warmed 2% paraformaldehyde in PBS 1X for 10 minutes at RT followed by 30 
minutes at -20°C with ice cold methanol. Fixed cells were stained as described above. 
For β-tubulin III immunofluorescence staining in differentiated SH-SY5Y cells, 1x104 cells were 
seeded onto matrigel-coated glass coverslips in 12-well plates. The following day, cells were washed 
with PBS 1X once and then fixed in pre-warmed 2% paraformaldehyde in PBS 1X for 10 minutes at 
RT. Fixed cells were blocked in 5% goat serum diluted in PBS 1X for 1 hour at RT. After the 
blocking, cells were incubated with mouse anti- β-tubulin III antibody (1:500) (MAB1195, R&D 
System) for 1 hour at RT. The cells were then washed with PBS 1X three times for 5 minutes each 
and incubated with Alexa 594 goat anti-mouse for 1 hour at RT. They were washed three times for 5 
minutes each with PBS 1X and mounted with mounting medium/DAPI. 
Images were captured with a Leica microscope using Metamorph software. 
3.6.1 Gems count 
SMN staining was followed by gems count. This analysis was assessed in two different ways, each 
performed duplicately. The counts were performed at a magnification of 63X in 200 cells for each 
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cell lines. The first method used was to count the number of gems in 200 cells. While the second 
was to count the number of positive cells, that means cells with at least one gem inside the nucleus, 
in 200 cells. 
3.7 PROTEIN EXTRACTIONS 
For whole cells extraction, cells were counted, washed with PBS and then lysed in an appropriate 
volume of lysis buffer. As a ratio cell/lysis buffer: approximately 10-20 x 106 cells per 200µl lysis 
buffer was used. The buffer used consist of: RIPA buffer (R0278, Sigma) + 75mMTris/HCl SDS 1% 
+ protease inhibitor cocktail buffer (11697498001, Roche). Samples were centrifuged for 10 minutes 
at 12000 g at 4°C. The supernatant was transferred to a fresh tube and the protein concentration was 
determined by PierceTM BCA Protein Assay Kit (23225, Thermo Fisher Scientific) according to the 
manufacturer’s protocol. Then protein concentration was measured with BioPhotometer Eppendorf.  
3.7.1 Western blot analysis 
Protein extracts were fractionated by NuPAGE TM 4-12% Gel (NP0322BOX, Thermo Fisher 
Scientific) using 1 X NuPAGE TM MOPS SDS Running Buffer (NP0001, Thermo Fisher Scientific). 
This buffer was used for fill the external chamber, while in the inner chamber was added Running 
Buffer 1X with 0.25% NuPAGE TM Antioxidant (NP0005, Thermo Fisher Scientific). 40µg of protein 
samples were mixed with 1X NuPAGE TM LDS Sample Buffer (NP0007, Thermo Fisher Scientific) 
and 1X NuPAGE TM Sample Reducing Agent (NP0009, Thermo Fisher Scientific). Then the samples 
were loaded on 4-12% gel with SeeBlue TM Pre-staining Protein Standard (LC5625, Thermo Fischer 
Scientific). Gels were run at 150 V for 90 minutes before blotted onto polyvinylidene difluoride 
membrane (03010040001, Roche) at 350mA for 2 hours using 1X NuPAGE TM Transfer Buffer 
(NP00061, Thermo Fischer Scientific), 5% methanol and 0.1% NuPAGE TM Antioxidant. The 
membranes were blocked in Odyssey blocking solution (P/N 927-40100, LI-COR Biosciences) for 1 
hour at RT, before incubated overnight at RT with primary antibodies: 
- Rabbit anti-TGS1 antibody (1:500) (HPA025024, Atlas Antibodies) 
- Mouse anti-SMN antibody (1:500) (610646, BD Transduction Laboratories TM) 
- Mouse anti-β-tubulin antibody (1:3000) (236-10501, Thermo Fischer Scientific) 
The following day membranes were washed three times for 10 minutes with PBS containing 1% 
Tween 20 (PBST) before incubation with secondary antibodies for 1 hour at RT. 
- Anti-rabbit secondary antibody, HRP (1:50000) (65-6120, Thermo Fischer Scientific) 
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- Anti-mouse secondary antibody, HRP (1:50000) (65-6520, Thermo Fischer Scientific) 
Membranes were washed three times for 10 minutes at RT with PBST and Clarity TM Western ECL 
Substrate (1705060, Bio-Rad) was used according to the manufacturer’s instructions and visualised 
with ChemiDoc Imaging System (Bio-Rad). 
3.8 3D MODELING 
TGS1 3D structure was predicted by utilizing Automated Mode of SWISS-MODEL software 
(http://swissmodel.expasy.org/). The 3D structure was generated with the alignment of 
methyltransferase domain of human trimethylguanosine synthase 1 (3GDH) and it was displayed by 
PyMol (PyMOL v.1.7.0.1; Python v.2.7.2).  
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4. RESULTS 
4.1 PROTEIN EXPRESSION 
4.1.1 SMN expression 
SMN expression levels were analysed only in fibroblast cell lines and not in lymphoblastoid cell 
lines. Western blot of SMN from whole cell lysates showed no reduction in L1266 (TGS1 patient 
carrying p.Gly259Ser mutation) cell line (Fig.9). 
 
Fig.9: Western blot shows SMN protein expression levels from whole cell lysate in TGS1 patient carrying p.Gly259Ser 
(L1266), SMN patient (7384) and two healthy controls (6076, 33F). Results obtained with β-tubulin are shown as 
controls for the amount of protein loading in each lane. 
4.1.2 TGS1 expression  
TGS1 expression levels were detected by western blot analysis from whole cell lysate in both TGS1 
patients and relative controls. By staining with the Atlas TGS1 antibody, two bands of TGS1 
protein were detected, at approximately 96kDa and 65kDa. The top band is supposed to be the full-
length isoform present mainly in the cytoplasm while the lower band could be the short isoform 
located in the nucleus. β-tubulin was used as sample loading control. No difference of TGS1 
expression was observed in L1266 patient carrying p.Gly259Ser mutation and 343 patient carrying 
p.Asn704Ser mutation compared to the healthy controls. Interestingly, SMA patient (7384) showed 
a decreased expression of the short isoform of TGS1, when compared to both L1266 and the other 
two controls (6076 and 33F) (Fig.10).  
 
31 
 
Fig.10: Panel A: Western blot shows TGS1 protein expression levels from whole cell lysate in TGS1 patient carrying 
p.Gly259Ser (L1266), SMN patient (7384) and two healthy controls (6076, 33F). Results obtained with β-tubulin are 
shown as controls for the amount of protein loading in each lane. Panel B: Western blot shows TGS1 protein expression 
levels from whole cell lysate in TGS1 patient carrying p.Asn704Ser (343), in cell line with p.Asn704Ser mutation (344) 
and two healthy controls (345, CT-E). Results obtained with β-tubulin are shown as controls for the amount of protein 
loading in each lane.  
Western blot analysis was extended further to other SMN patients: two SMA type II patients (6141 
and 6142) and one SMA type III patient (7215). As in 7384 SMA sample, the sample 6141 showed a 
decreased expression of the short isoform of TGS1. The ratio of the full-length isoform to the short 
isoform highlighted the decreased expression of the short isoform in two of four SMN patients 
(Fig.11).  
 
Fig.11: Panel A: Western blot shows TGS1 protein expression levels from whole cell lysate in three SMN patients (6141, 
7215, and 6142). Results obtained with β-tubulin are shown as controls for the amount of protein loading in each lane. 
Panel B: Ratio of the full-length isoform to the short isoform of TGS1. 
4.2 IMMUNOFLUORESCENCE 
Immunofluorescence experiments were performed only in the fibroblast cell lines and not in 
lymphoblastoid cell lines. 
4.2.1 TGS1 staining 
With TGS1 immunostaining in fibroblast cell lines, no obvious difference was observed between 
L1266 and the three control cell lines. The staining showed that TGS1 is evenly distributed both in 
nucleus and cytoplasm. However, a decrease of the nuclear staining of TGS1 short isoform was 
observed in 7384 and 6141 samples (Fig.12). Immunostaining results with TGS1 antibody 
confirmed the western blot results, which showed a reduction of the short isoform, corresponding to 
the nuclear isoform, in these two SMA patients.  
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Fig.12: Staining with TGS1 antibody in fibroblast cell lines: three healthy controls (6076, 8230 and 33F), TGS1 patient 
carrying p.Gly259Ser mutation (L1266) and four SMA patients (7384, 6141, 7215 and 6142). The arrows highlight the 
fibroblast cells with lower TGS1 short isoform expression. Images took at 63x magnification. 
4.2.2 SMN staining and gems count 
SMN staining was performed only in fibroblast cell lines due to the small dimension of 
lymphoblastoid cell lines in which it was not possible to highlight any gems. Three healthy controls, 
one SMN patient and TGS1 patient carrying p.Gly259Ser mutation (L1266) were used for the 
staining. As expected, SMN patient showed no gems or very low gem numbers. Interestingly, 
L1266 sample showed a significant increase of gem numbers inside the nucleus, with gems bigger 
compared to controls (Fig.13). 
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Fig.13: SMN staining in three healthy controls (6076, 8230 and 33F), one SMN patient (7384) and TGS1 patient 
carrying p.Gly259Ser mutation (L1266). The arrow in 7384 sample highlights the absence of gems inside the nucleus 
while in L1266 patient highlights the presence of numerous gems. Images took at 63x magnification. 
In order to confirm the increased amount of gems number, gems count and the number of positive 
cells (at least one gem inside the nucleus) were performed in 200 cells. These analyses were 
performed twice and showed a significant increase of gems number in L1266 fibroblast cell line, 
which is 40% higher than controls. While SMA patient (7384) showed a reduction of gems number 
of 50% of the controls. Moreover, the count of positive cells highlighted that the percentage of cells 
with at least one gem inside the nucleus, as for gems count, is less than 50% compared to controls 
in 7384 sample. Whereas, the percentage of positive cells in L1266 sample is only 20% higher than 
controls. This means that in L1266 sample the higher number of gems is due to an increased gems 
number inside each nucleus differently from 7384 sample, in which the lower gems number is due 
to a reduction of 50% of positive cells (Fig.14). 
 
Fig.14: Panel A: Histograms show the percentage of positive cells in L1266 sample (shown in red), SMA patient 
(shown in yellow) and three healthy controls. Count performed in 200 cells in two different staining. Panel B: 
Histograms show the gems number in L1266 sample (shown in red), SMA patient (shown in yellow) and three healthy 
controls. Count performed in 200 cells in two different staining. 
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4.3 LENTIVIRUS (PCDH-CMV-MCS-EF1-PURO)  
4.3.1 Lentivirus titration 
Proviral titre was calculated by qPCR that allowed to measure the number of integrated DNA 
lentiviral copies per cell. The number of lentiviral vector copies was calculated by absolute 
quantification. Absolute DNA titers were achieved by comparing crossing point values derived 
from DNA samples to those obtained from a standard curve of known concentrations of plasmid 
lentivirus DNA. Lentiviral titer obtains by qPCR was of 1.71x107 in lentivirus carrying WT 
construct while 7.38x106 in lentivirus carrying construct with p.Gly259Ser mutation. 
4.3.2 Puromycin selection in SH-SY5Y cells and fibroblast cells 
The optimum concentration of puromycin in SH-SY5Y cells and fibroblast cells was obtained using 
15 different concentrations of puromycin antibiotic, from 0.1µg/ml to 2µg/ml for fibroblast cells 
and from 1 µg/ml to 3.8 µg/ml for SH-SY5Y cells. The right antibiotic concentration was the lowest 
concentration that killed all cells exactly at day 5. After day 5, all SH-SY5Y cells died with 
1.4µg/ml and 1.6µg/ml of puromycin, while fibroblast cells died with 0.5 µg/ml and 0.6µg/ml. In 
order to be sure that no more cells were still alive in these wells, DMEM 10% was added for 6 days. 
After 6 days, SH-SY5Y cells with 1.4µg/ml and fibroblast cells with 0.5µg/ml started to grow. 
While no cells were detected in wells with 1.6µg/ml and 0.6µg/ml of puromycin. Then, the 
optimum concentration of puromycin was 1.6µg/ml for SH-SY5Y cells and 0.6µg/ml for fibroblast 
cells (Fig.15) 
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Fig.15: Panel A: Puromycin selection in fibroblast cell line at day 5. Panel B: Fibroblast cells selected with 0.5 µg/ml 
and 0.6µg/ml of puromycin at day 5 followed by 6 days in DMEM 10%. In red is shown the optimum concentration of 
puromycin antibiotic for the selection of fibroblast cell line. Panel C: Puromycin selection in SH-SY5Y cells at day 5. 
Panel D: SH-SY5Y cells selected with 1.4 µg/ml and 1.6µg/ml of puromycin at day 5 followed by 6 days in DMEM 
10%. In red is shown the optimum concentration of puromycin antibiotic for the selection of SH-SY5Y cells.  
4.3.3 Transduction experiments in SH-SY5Y cells 
SH-SY5Y cells were transduced with the two lentiviruses carrying wild-type and mutant constructs 
using MO1 1, MOI 15 and MOI 70. After 24 hours of transduction, cells were selected with 
medium containing 1.6µg/ml of puromycin for 10 days. The presence of the constructs inside the 
cells was detected by DNA and cDNA samples sequencing. In both DNA and cDNA samples, a 
couple of primers were designed to amplify specifically the coding region between exon 3 and exon 
5, where the p.Gly259Ser variant is localised. Amplification of DNA samples with primers 
specifically designed for cDNA has allowed confirming the integration of the two constructs within 
the DNA of SH-SY5Y cells (Fig.16). 
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Fig.16: Panel A: DNA sequence of SH-SY5Y cells transduced with lentivirus carrying the mutant construct. 
Electropherogram shows the variant c.775G>A in homozygous state. Panel B: DNA sequence of SH-SY5Y cells 
transduced with lentivirus carrying the wild-type construct. Electropherogram shows the wild-type sequence. Panel C: 
cDNA sequence of SH-SY5Y cells transduced with lentivirus carrying the mutant construct. As expected 
electropherogram shows the variant c.775G>A in heterozygous state. 
The selection of cells with puromycin was followed by differentiation with the complete neurobasal 
medium. SH-SY5Y cells were cultured for 10 days prior to being utilized for further experiments. 
In the first experiments performed, retinoic acid was not used for the differentiation but after βIII-
tubulin staining, not all cells were differentiated. Then, retinoic acid was added in the complete 
neurobasal medium in order to promote the differentiation. 
4.3.3.1 Transduction experiments in SH-SY5Y cells with MOI 1 
At the beginning, transduced experiments were performed with MOI 1 but no significant 
differences were observed in SH-SY5Y cells transduced with wild-type and mutant lentiviral 
vectors compared to untreated cells. Lentiviral transduction was followed by differentiation for 10 
days, however, no variations in neurite outgrowth in both wild-type and mutant SH-SY5Y cells 
compared to untreated cells were observed (Fig.17). 
 
Fig.17: Untreated SH-SY5Y cells and SH-SY5Y cells transduced with MOI 1 at day 10 with neurobasal complete 
medium. 
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After cells differentiation, TGS1 and SMN staining were performed. These staining did not show 
differences in localization and amount of TGS1 and SMN proteins in transduced cells compared to 
untreated cells (Fig.18). 
 
Fig.18: Panel A: Single and merged staining for TGS1 (green), SMN (red) and DAPI (blue) in SH-SY5Y cells not 
transduced. Panel B: Single and merged staining for TGS1 (green), SMN (red) and DAPI (blue) in SH-SY5Y cells 
transduced with lentivirus carrying mutant construct with MOI 1. Panel C: Single and merged staining for TGS1 
(green), SMN (red) and DAPI (blue) in SH-SY5Y cells transduced with lentivirus carrying wild-type construct with 
MOI 1. Images took at 20x magnification 
After TGS1 and SMN staining, gems count and the count of positive cells were performed for each 
cell lines in 200 cells, twice. Both these analyses showed no differences in wild-type and mutant 
SH-SY5Y cells compared to untreated cells (Fig.19). 
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Fig.19: Panel A: Histograms show the gems number in SH-SY5Y_untreated (shown in blue), SH-SY5Y_wild-type 
(shown in yellow) and SH-SY5Y_mutant (shown in red). Count performed in 200 cells in two different staining. Panel 
B: Histograms show the percentage of positive cells in SH-SY5Y_untreated (shown in blue), SH-SY5Y_wild-type 
(shown in yellow) and SH-SY5Y_mutant (shown in red). Count performed in 200 cells in two different staining. 
4.3.3.2 Transduction experiments in SH-SY5Y cells with MOI 15 
Transduction experiments performed with MOI 15 showed differences in cells transduced with 
wild-type and mutant lentiviral vectors compared to the untreated cells. Transduction and the 
selection of the transduced cells were followed by differentiation. After 10 days in complete 
neurobasal medium, alterations in neurite outgrowth were observed. SH-SY5Y cells transduced 
with lentivirus carrying wild-type and mutant vectors showed shorter neurites with a high number 
of branch points compared to the untreated cells (Fig.20).  
 
Fig.20: Untreated SH-SY5Y cells and SH-SY5Y transduced with MOI 15 at day 10 with complete neurobasal medium. 
These cells were stained with βIII-Tubulin to highlight better the differences in neurite outgrowth. 
As shown in figure 21, SH-SY5Y transduced with wild-type and mutant vectors shown in the 
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majority of cells defects in neuron development with short neuritis, characterized by numerous 
ramification and branch points. 
 
Fig.21: Panel A: βIII-Tubulin staining in SH-SY5Y cells untreated and SH-SY5Y cells transduced with wild-type and 
mutant constructs. Images were taken at 20X magnification. Panel B: βIII-Tubulin staining in SH-SY5Y cells untreated 
and SH-SY5Y cells transduced with wild-type and mutant constructs. Images were taken at 40X magnification.  
After SMN staining, gems count and the number of positive cells were measured for each cell lines 
in 200 cells, twice. Both analyses showed no differences in wild-type and mutant SH-SY5Y cells 
compared to untreated cells (Fig.22). 
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Fig.22: Panel A: Histograms show the gems number in SH-SY5Y_untreated (shown in blue), SH-SY5Y_wild-type 
(shown in yellow) and SH-SY5Y_mutant (shown in red). Count performed in 200 cells in two different staining. Panel 
B: Histograms show the percentage of positive cells in SH-SY5Y_untreated (shown in blue), SH-SY5Y_wild-type 
(shown in yellow) and SH-SY5Y_mutant (shown in red). Count performed in 200 cells in two different staining.  
4.3.3.3 Transduction experiments in SH-SY5Y cells with MOI 70 
Transduction experiments performed with MOI 70 showed the same differences observed in cells 
with MOI 15. SH-SY5Y cells transduced with wild-type and mutant lentiviral vectors presented 
phenotype features diverge from the untreated phenotype (Fig.23) 
 
Fig.23: SH-SY5Y cells transduced with MOI 70 at day 10 with complete neurobasal medium. 
βIII-Tubulin staining presented better the phenotype features in this case. These cells showed 
numerous short neurites with numerous branch points (Fig.24). 
 
Fig.24: Panel A: βIII-Tubulin staining in SH-SY5Y cells untreated and SH-SY5Y cells transduced with wild-type and 
mutant constructs. Images were taken at 20X magnification. Panel B: βIII-Tubulin staining in SH-SY5Y cells untreated 
and SH-SY5Y cells transduced with wild-type and mutant constructs. Images were taken at 40X magnification.  
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4.3.4 Transduction experiments in fibroblast cell lines 
Transduction experiments in fibroblast cell lines were performed with MOI 1 in: 
8230: healthy control fibroblasts. 
7384: SMA type III patient with 3 copies of SMN2 gene.  
7215: SMA type III patient with 3 copies of SMN2 gene. 
6141: SMA type II patient with 2 copies of SMN2 gene. 
After 24 hours of transduction followed by selection with puromycin for 10 days, 6141 fibroblast 
cell line died while only a few cells survived in the other two SMA fibroblast cell lines. Moreover, 
these cells showed reduced cell growth and not spindle shape that is characteristic of fibroblast cell 
lines. However, this was not observed in the fibroblast cell line of a healthy control, in which 
growth and cell shape were similar to the untreated cells (Fig.25). 
 
Fig.25: Panel A: Fibroblast cell lines from two SMA patients (7215 and 7384) and fibroblast cell line from a healthy 
control (8230) transduced with lentivirus carrying wild-type construct after puromycin selection. Panel B: Fibroblast 
cell lines from two SMA patients (7215 and 7384) and fibroblast cell line from a healthy control (8230) transduced with 
lentivirus carrying mutant construct after puromycin selection. 
SMN and TGS1 staining allowed to point out differences in SMN expression in transduced 
fibroblast cell lines. Compared to untreated cells, the amount of SMN protein seems to be high 
especially within the nucleus of cells transduced with both wild-type and mutant lentivirus. SMA 
cell lines are characterized by few numbers of gems inside the nucleus but after transduction of both 
lentiviral vectors led to increasing of SMN protein. However, even though SMN level was 
increased in 7215 and 7384 cell lines, SMN seems not to be organized in gems structures. Similar 
character, although less evident than in SMA cell lines, was observed in control cell line (8230), 
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which showed increased amount of SMN protein inside the nucleus. Even in this cell line, SMN 
seems not to be organized in gems structure (Fig.26) 
 
Fig.26: Panel A: TGS1 (green) and SMN (red) staining in untreated fibroblast cell lines of two SMA type III patients 
(7384, 7215) and healthy control (8230). The white arrow highlights the presence of gems inside the nucleus. Panel B: 
TGS1 (green) and SMN (red) staining in fibroblast cell lines of two SMA type III patients (7384, 7215) and healthy 
control (8230) after transduction with wild-type lentiviral vector. The red arrowhead highlights the increased level of 
SMN staining without the presence of gems. Panel C: TGS1 (green) and SMN (red) staining in fibroblast cell lines of 
two SMA type III patients (7384, 7215) and healthy control (8230) after transduction with mutant lentiviral vector. The 
red arrowhead highlights the increased level of SMN staining without the presence of gems. 
4.4 LENTIVIRUS TRANSDUCTION WITH GREEN FLUORESCENT PROTEIN 
4.4.1 Transduction experiments in SH-SY5Y cells 
SH-SY5Y cells were transduced with MOI 10 and cell sorting has been performed after three days 
from transduction. Cell sorting showed the efficiency of transduction for each lentiviral vectors 
(Fig.27B). Moreover, during the cell sorting, two populations were sorted. One population with 
slightly increased fluorescence over the untransfected control and a GPF bright population with 
high expression of GPF (Fig.27A).  
First populations sorted: 
- SH-SY5Y_WT_low GFP 
- SH-SY5Y_MUT_low GFP 
- SH-SY5Y_CT_low GFP 
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Second populations sorted: 
- SH-SY5Y_WT_high GFP 
- SH-SY5Y_MUT_ high GFP 
- SH-SY5Y_CT_ high GFP 
 
 
Fig.27: Panel A: Sorting of two populations in SH-SY5Y cells. In green is shown the cell population with low 
expression of GFP while in blue the cell population with high expression of GFP. Panel B: The first column of the table 
represents the percentage of SH-SY5Y cells transduced, the second column is the percentage of cells with low GFP 
expression while the third column is the percentage of cells with high GFP expression. 
 
4.4.1.1 SH-SY5Y cells differentiation  
After cell sorting, each population of SH-SY5Y cells have been differentiated together with 
untreated cells. At day 5, untreated cells (Fig.28A) and SH-SY5Y_ CT_low GFP (Fig.28F) showed 
the same neurite outgrowth. While in SH-SY5Y_CT_high GFP (Fig.28G) and SH-SY5Y cells 
transduced with WT and MUT vectors in both populations with low and high GPF expression 
(Fig.28B-C-D-E), shorter neurite outgrowth was observed compared the untreated or SH-
SY5Y_CT_low GFP.  
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Fig.28: Images took at day 5 of differentiation in untreated SH-SY5Y cells (A), SH-SY5Y cells transduced with wild-
type vector with low GFP expression (B) and high GFP expression (C), SH-SY5Y cells transduced with mutant vector 
with low GFP expression (D) and high GFP expression (E) and SH-SY5Y cells transduced with CT vector with low 
GFP expression (F) and high GFP expression (G)  
 
4.4 3D MODELING 
It has been possible only to analyze p.Asn704Ser variation within 3D structure since the N-terminal 
sequence of the protein where p.Gly259Ser is located was not available in PDB database. C-
terminal region of TGS1 is characterized by the presence of AdoMet-binding site composed of 
694VVDAFCGVGGN704 and 717IAIDI721 motifs and m7G binding site composed of 
763SPPWGG768141 motif. p.Asn704Ser is located in one α-helix within the AdoMet-binding site and 
it is one of the residues directly involved with the linkage between the protein and AdoHcy. 
Therefore, p.N704 residue results essential for a correct enzymatic activity of the protein. For the 
difference in size of Asparagine and Serine, the amino acid substitution p.Asn704Ser could modify 
the binding between AdoHcy and TGS1 interfering with the enzymatic activity of the protein 
(Fig.29).  
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Fig.29: Panel A: Representation of TGS1 3D structure. In yellow is shown the m7G binding site, in blue the AdoMet-
binding site and in red p.N704 residue. Panel B: In red is shown p.N704 residue within of TGS1 3D structure. Panel C: 
representation of p.S704 using PyMol mutagenesis tool. 
 
  
N704S 
Serine is a smaller amino acid compared to Asparagine 
therefore it could modify the AldoMet-binding and the 
binding in 3D structure of the protein 
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5. DISCUSSION AND CONCLUSION 
 
Spinal muscular atrophy is due to the loss of survival motor neuron (SMN) protein, caused, in 95% 
of patients, by homozygous deletions in the survival motor neuron 1 (SMN1) gene. SMN protein is 
crucial for motor neuron survival since lack of this protein leads to the spinal motor neuron death 
followed by skeletal muscle atrophy and paralysis. However, the molecular pathway underlying 
SMA is still not fully understood. It is not clear why the loss of snRNP biogenesis in all cells leads 
to a selective damage in neuromuscular system, only some suggestions have been proposed. 
Experiments in model organisms highlighted that similar phenotype observed with SMN loss 
occurs even with knockout or overexpression of other factors involved in snRNP biogenesis. This 
was the starting point of the project. The discovery, in two unrelated patients with SMA type IV-
like clinical features, of two different mutations in one gene involved in snRNP biogenesis pointed 
out a possible involvement of this gene in the pathogenesis of SMA disease. Two missense 
mutations were found in trimethylguanosine synthase 1 (TGS1) gene: p.Gly259Ser (c.496G>A) and 
p.Asn704Ser (c.2111A>G). TGS1 gene encodes for TGS1 enzyme that is responsible for 
hypermethylation of snRNPs and snoRNPs m7G cap structure. The hypermethylation event is 
essential for the complete maturation of both snRNPs and snoRNPs. 
Thus, the aim of this project was to perform functional studies for both mutations. We carried out the 
experiments with fibroblast cell line of patient carrying p.Gly259Ser mutation (L1266) and 
lymphoblastoid cell line of patient carrying p.Asn704Ser mutation (343). First, we evaluated TGS1 
and SMN expression in whole cell lysate. Western blot in patients showed two bands of TGS1 protein, 
but no difference of TGS1 expression was observed in both patients (Fig.10). While SMN expression 
was evaluated only in patient carrying p.Gly259Ser mutation (L1266) and no differences were 
observed between L1266 and three control cell lines. The further experiments have been carried on 
just for L1266 since for lymphoblastoid cell line of patient 343 it was not possible to perform TGS1 
or SMN immunofluorescence analysis. TGS1 staining in L1266 sample showed that TGS1 was 
expressed in both nucleus and cytoplasm and no difference was observed between L1266 and the 
three control cell lines (Fig.12). Immunofluorescence experiment was performed in L1266 patient, 
three healthy controls and one SMA type III patient (7384). Interestingly, 7384 sample showed a 
decreased expression of the short isoform of TGS1, when compared to L1266 and the other three 
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controls. Thus, the study was extended to other three SMA patients and one of these showed the same 
reduction of TGS1 short isoform (Fig.12). The decrease of TGS1 protein expression in fibroblast cell 
lines from SMA patients was further confirmed by western blotting analysis in whole cell lysates 
(Fig.10 and 11).  
After the expression of SMN protein was evaluated. Western blot of SMN from cell lysates showed 
no reduction in L1266 patient cell line (Fig.9). However, SMN staining pointed out some 
differences compared to controls (Fig.13). L1266 showed 40% of increased numbers of gems 
within the nucleus than the controls. Together with the gem counts, was performed the count of 
positive cells (cells with at least one gem inside the nucleus) to highlight if the higher number of 
gems was due to a higher number of positive cells or an increased gems number inside each 
nucleus. This study allowed to clarify that L1266 sample is characterized by a higher number of 
gems inside each cell (Fig.14). The increased amount of gems number could be explained with a 
gain of function effect of p.Gly259Ser mutation. TGS1 is involved in the methylation steps for the 
conversion of the 7-monomethylguanosine (m7G) caps to a 2,2,7-trimethyguanosine (m2,2,7G or 
TMG) cap structure. TMG cap structure represents together with Sm core a bipartite nuclear 
localisation signal required to promote the nuclear uptake of snRNPs. Then, an increased activity of 
TGS1 may lead to increased snRNPs importation followed by higher gems formation. Moreover, 
the functional effect of p.Gly259Ser mutation was studied even in neuronal cell lines. Two lentiviral 
vectors were generated: one carrying wild-type full-length TGS1 and the other carrying 
p.Gly259Ser mutation. After the generation of two lentiviruses, transduction experiments in SH-
SY5Y cells were carried out in order to highlight possible alteration in neurite outgrowth. Three 
different multiplicity of infection were used: MOI 1, MOI 15 and MOI 70. These cell lines were 
then differentiated into neurons and the efficiency of differentiation was verified using the antibody 
against the neuron-specific class III beta-tubulin. In cell lines derived from transduction with MOI 
1, no significant differences were observed compared to untreated cells. They did not show 
modifications in neurite outgrowth or in the localization of TGS1 and SMN protein (Fig.17 and 18). 
Even the gems count did not show any difference (Fig.19). While in cell lines transduced with MOI 
15 and MOI 70 it has been possible to point out some specific phenotypic features (Fig.21 and 24). 
βIII-tubulin staining in differentiated cells showed the presence of defects in neuron development. 
Interestingly, the same development defects have been detected in SH-SY5Y cells transduced with 
wild-type or mutant lentiviruses. Cells transduced with wild-type and mutant lentivirus showed in 
the majority of cells short neurites with numerous branch points and tips compared to the untreated 
control characterized by long neurites. These morphologic features are observed even in SMA 
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disease71, 76,142. Since this particular phenotype has been observed in both cell lines with an 
overexpression of wild-type or mutant TGS1, it suggests that the neurons degeneration is due to an 
increased activity of TGS1 protein. Therefore, even transduction experiments in SH-SY5Y cells 
allowed to hypothesize a gain of function effect of p.Gly259Ser mutation. As it has been 
hypothesized in the previous experiments. 
Furthermore, transduction experiments were performed even in fibroblast cell lines of one healthy 
control, two SMA type III patients and one SMA type II patient. The multiplicity of infection used 
for fibroblast was MOI 1 and it turned out to be quite toxic in particular for SMA fibroblast cell 
lines. SMA Type II fibroblast cell line died after transduction while in SMA type III patients few 
cells alive showed reduced cell growth and not spindle shape, characteristics of fibroblast cell. 
However, this toxicity was not observed in cell line of the healthy control (Fig.25). In these 
transduced cell lines, SMN and TGS1 staining were performed. Interestingly, even in this case, the 
phenotypic features observed have been the same in cell lines transduced with wild-type or mutant 
vectors. SMA fibroblast cell lines showed an increased level of SMN protein inside the nucleus. 
The same happens in the healthy control even if less evident than in SMA cell lines. It remains to 
investigate if the increased amount of SMN protein is organized in gems structure. However, even 
this result could be explained with a gain of function effect of p.Gly259Ser mutation since 
fibroblast cell lines transduced with wild-type and mutant vectors showed the same phenotype with 
an increase in SMN protein within the nucleus.  
All these experiments lead to hypothesize a gain of function effect of p.Gly259Ser mutation with a 
possible involvement in spinal muscular disease. To confirm this hypothesis other three lentiviruses 
were generated. One carrying wild-type TGS1, one carrying p.Gly259Ser mutation and one without 
TGS1 insertion but only with GFP tag (CT vector). The lentiviral vector without TGS1 insertion 
was generated to verify if the phenotype observed in the previous experiments was caused to the 
increased activity of TGS1 or to the toxicity of the viruses. Transduction of SH-SY5Y cells with 
these three lentiviral vectors was followed by cell sorting. The sorting allowed to obtain two 
different populations: one population with low GFP expression and one population with high GFP 
expression. These cells were differentiated and at day 5 some differences were observed (Fig.28). 
Cells transduced with the CT vector were used as controls for evaluating the toxicity of the virus. It 
was then possible to establish that high GFP expression was toxic to the cells since SH-
SY5Y_CT_high GFP showed an alteration in neurite outgrowth. While the population with low 
GFP expression (SH-SY5Y_CT_low GFP) showed a similar phenotype of the untreated cells 
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highlighting the non-toxicity of the virus. Thus, the observation of neurite outgrowth was performed 
only in the populations with low GFP expression. In SH-SY5Y_WT_low GFP and SH-
SY5Y_MUT_low GFP, as in the experiments performed with the first two lentiviruses, an alteration 
in neurite outgrowth was noticed. Even in this case, SH-SY5Y cells transduced with wild-type and 
mutant vectors showed the same phenotype with short neurites.  
In conclusion, our results in this study indicate 1) the gain-of-function dominant negative effect of 
p.Gly259Ser mutation in TGS1 gene on SMN biogenesis and cell survival; 2) this mutation acts 
negatively on cell survival at the presence of SMN deficiency; 3) p.Gly259Ser mutation inhibits 
neurite outgrowth in neuronal cells in vitro and may indicates its pathogenic effect.  
This study has strengthened our starting hypothesis by highlighting a possible involvement of TGS1 
gene in the spinal muscular atrophy-like clinical features. Defects in TGS1 activity could interfere 
with SMA pathogenesis since the function of this enzyme is closely interrelated with SMN function. 
Then, it is likely that alteration in TGS1 function could lead a similar phenotype shown by SMA 
patients. So far, our study was focused on p.Gly259Ser mutation, which seems a pathogenic mutation 
with a gain of function effect. It is possible that an increased function of TGS1 protein causes an 
increase importation inside the nucleus of SMN protein in fibroblast cell lines. Moreover, the 
increased activity of TGS1 seems to induce degeneration of neurons as occurs in spinal muscular 
atrophy disease. However, further analysis is required to complete the study for this mutation and to 
investigate the functional effect of the other missense mutation.  
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Molecular diagnosis of the most common forms of Limb Girdle 
Muscular Dystrophy with autosomal recessive inheritance 
 Abbreviations 
AldoA    Aldolase A 
BMD    Becker muscular dystrophy 
C2L    C2-domain-like 
CaM    Calmodulin 
CAPN1   µ-calpain or calpain 1 
CAPN2   m-calpain or calpain 2 
CAPN3   Calpain 3 
CAPN4   Calpain 4 
CBSW    Calpain-type beta-sandwich domain 
CK    Creatine kinase 
CysPc    Calpain-type cysteine protease domain 
DMAT   Dystal myopathy with anterior tibial onset 
DMD    Duchenne muscular dystrophy 
DYSF    Dysferlin 
EMG    Electromyogram 
iPS    Induced pluripotent stem cell 
LGMD1   Limb girdle muscular dystrophy whit autosomal dominant inheritance 
LGMD2    Limb girdle muscular dystrophy whit autosomal recessive inheritance 
LGMD2A   Limb girdle muscular dystrophy type 2A 
LGMD2B   Limb girdle muscular dystrophy type 2B 
LGMD2I   Limb girdle muscular dystrophy type 2I 
LGMD2J   Limb girdle muscular dystrophy type 2J 
LGMDs   Limb girdle muscular dystrophies 
MARPs   Muscle ankyrin repeat proteins 
MG53    Mitsigumin-53 
MM    Miyoshi myopathy 
MRI    Magnetic resonance imaging 
NGS    Next-generation sequencing 
PEF domain   Penta-EF-hand domain 
PI(4,5)P2   Phosphatidylinositol 4,5-bisphosphate  
 rAVV    Recombinant adeno-associated virus 
RyR    Ryanodine receptor 
WES    Whole-exome sequencing 
  
 ABSTRACT 
Limb Girdle Muscular Dystrophies (LGMDs) are a heterogeneous group of inherited progressive 
muscle disorders affecting predominantly the pelvic and shoulder girdle muscles. LGMDs are 
classified into type 1 or 2 depending on the different inheritance patterns. Type 1 LGMDs are 
inherited with an autosomal dominant pattern and are much less common than the type 2 LGMDs, 
which are inherited in an autosomal recessive pattern. LGMDs disorders result from defects in 
genes required for normal muscle function.  
This project was carried out to achieve a molecular diagnosis for patients with clinical LGMD2 
diagnosis. For that reason, we focused our studies on two genes responsible for the most frequent 
forms of LGMD2. The two most common forms are limb girdle muscular dystrophy type 2A and 
type 2B caused by mutations in CAPN3 and DYSF gene, respectively. Another aim of this project 
was to amplify CAPN3 and DYSF mutations spectrum, contributing to the study of genotype-
phenotype relation in LGMD patients. 
After the screening of 90 patients, seven pathogenic variants have been detected in seven patients 
belonging to five families in CAPN3 gene. While three pathogenic variants have been detected in 
three patients in DYSF gene. Among these mutations, we found two novel variants in CAPN3 gene 
and one novel variant in DYSF gene.  
According to literature, our results highlight the genetic and phenotypic variability present in 
LGMD patients, especially in LGMD2A. In addition to clinical variability among patients, we 
detected intra-family variability in the C1 family. This leads to increase the difficulties to correlate a 
type of mutation with the onset and clinical progression of the disease. Moreover, even in our study, 
we found only one mutation in heterozygous state in three patients. As reported in literature ~22% 
of LGMD2A patients only one mutation is detected but the presence of another mutation is not 
excluded. However, in one of our patients, the presence of a second mutation seems unlikely. Thus, 
this result leads to hypothesize the presence of other factors involved in the pathogenesis of  
LGMD2A disease. 
While for LGMD2B a genetic and phenotypic correlation seems less challenging. Among these 
patients, we found for the first time a mutation in the transmembrane domain of dysferlin protein. 
This case is particularly interesting since this missense mutation was found in the proband and in 
her asymptomatic daughter. We highlighted that this variant leads to an increased protein 
expression followed by a reduction of the protein at sarcolemma level. Then, it is likely that the 
50% of mutant protein fails to insert to the sarcolemma, remaining within the cytoplasm. However, 
 the reduction of dysferlin has been seen only in the proband. It would be interesting to analyze the 
daughter to clarify if the reduction observed is only due to the presence of the missense variant or to 
the presence of another variant not detected. 
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1. INTRODUCTION  
1.1 MUSCULAR DYSTROPHY 
The term muscular dystrophies are reserved for classes of hereditary, progressive muscle diseases 
characterised by necrosis of muscle tissue and replacement by connective and fatty tissue, increase in 
fibre size variation, fibre splitting and centrally located myonuclei. Clinically, these disorders present 
themselves muscle weakness at any age from birth to middle years, frequently accompanied with high 
serum creatine kinase (CK) and result in significant morbidity and disability. These are disorders in 
which the primary pathological change is in the muscle itself and is not a consequence of disease of 
the central or peripheral nervous system (muscle atrophy)1. Muscular dystrophies occur as a result 
from mutations affecting proteins involved in muscle integrity and function. This group of disorders 
display clinical heterogeneity that reflects the heterogeneity of molecular mechanisms responsible for 
them. In fact, muscular dystrophies are among the most genetically heterogeneous human condition 
with up to 165 muscular dystrophies and myopathies-causative genes described2. Muscular atrophies 
differ from muscular dystrophies since muscle defects are not the primary pathological change as in 
muscular dystrophies but it is secondary to the diseases of the nervous system. The first serious 
attempt to separate muscular dystrophy from muscular atrophy was made by Leyden in 18763. 
The first historical report of muscular dystrophy appeared in 1830 when Charles Bell wrote about an 
illness that caused progressive weakness in boys. After that a case was reported by Conte and Gioja 
in 1836, in which they described two brothers with progressive weakness starting at 10 years old. The 
two brothers showed symptoms that are now known to be characteristic of the milder Becker 
Muscular Dystrophy (BMD). At that time, however, Conte and Gioja did not describe that disorder 
as muscular dystrophy thus they did not achieve recognition for their discovery. Successively in 1851, 
Meryon reported a family with four children, all of whom were affected by significant muscle changes 
without abnormality in the central nervous system. Meryon hypothesised that the cause of the disorder 
could be the sarcolemmal defect and hypothesised furthermore that the disorder is genetically 
transmitted through females but affects only males4. The first comprehensive case was described by 
Guillaume Duchenne in 18685. He described 13 patients with the same disease, which he called it 
“paralysie musculaire pseudo-hypertrophique”. However, the term “muscular dystrophy” was first 
used by Wilhelm Heinrich Erb in 18916. He was the first who finally convinced the medical opinion 
that dystrophies are due to primary degeneration of muscle, totally distinct from disorders in which 
muscular wasting is secondary to anterior horn cell disease in the spinal cord.
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Over the next 100 years, genetic and phenotypically distinct forms of muscular dystrophy were 
recognised. The first gene responsible of muscular dystrophy was discovered later in 1970, when 
genetic studies linked the Duchenne gene to chromosome Xp21 and the cDNA and protein product 
were discovered in 19877,8. So far, many other genes have been sequenced and mutations ascribed to 
specific forms of dystrophy. The genetically distinct forms of muscular dystrophies result from 
mutations in genes encoding: 
- Integral structural proteins of the sarcolemmal membrane (α, β, γ and δ sarcoglycan, integrin 
α7) 
- Structural proteins associated with the inner surface membrane (dystrophin, plectin) 
- Structural proteins associated with the outer surface membrane (laminin α2, collagen type VI) 
- Protein localised in specialised regions of the sarcolemma (caveolin 3) 
- Proteins associated with the inner nuclear membrane (emerin, laminin A/C, plectin) 
- Muscle specific proteins kinases (myotonic dystrophy protein kinase) 
- Muscle-specific proteases (calpain) 
- Protein involved in muscle membrane repair machinery (dysferlin) 
The muscular dystrophies have been commonly subdivided on clinical criteria, particularly the pattern 
of muscle involvement, the age of onset and mode of inheritance.  
X-linked muscular dystrophy: 
-Duchenne muscular dystrophy 
-Backer muscular dystrophy 
-Emery-Dreifuss syndrome 
Autosomal recessive muscular dystrophy: 
 -Congenital muscular dystrophy 
 -Limb girdle muscular dystrophy 
Autosomal dominant muscular dystrophy: 
 -Limb girdle muscular dystrophy 
 -Facioscapulohumeral muscular dystrophy 
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1.2 LIMB GIRDLE MUSCULAR DYSTROPHIES 
Limb girdle muscular dystrophies (LGMDs) is a group of neuromuscular disorders inherited with 
dominant and recessive manner. Initially, LGMDs were described as a distinct phenotype but now it 
is well known their heterogeneity. LGMDs are a clinically and genetically heterogeneous group of 
hereditary myopathies that are usually characterised by predominant weakness and atrophy with the 
prevalent involvement of proximal muscles of the hip and shoulder girdles. Moreover, elevated serum 
CK levels and dystrophic findings on muscle biopsy are commonly found and facial muscles are 
generally not involved. Muscle biopsy shows necrosis and regeneration of the muscle fibres with 
various levels of fibrosis and adipose tissue infiltration. The clinical spectrum of LGMDs can vary 
from very mild forms which allow patients to maintain a fairly normal life to much more severe 
deterioration of proximal limb muscles, that cause dramatic physical weakness along with a short-
ended life span9–11. Then, progression, distribution of weakness and wasting, respiratory involvement 
and heart damage vary considerably among individuals and genetic subtypes12,13. The onset of 
symptoms may occur at almost any age, with the exception of infancy, which would indicate the 
presence of a congenital muscular dystrophy14. The clinical involvement is usually limited to skeletal 
muscle, in some cases cardiac and respiratory involvement can be variably presented and cognitive 
impairment is usually absent. Clinical variability is presented among patients of the same subtype, or 
even within the same family. For the clinical heterogeneity has been challenging to reach a 
classification of LGMDs, which it has been revised continuously15–17. 
The first description of LGMDs goes back to late 18th century when Erb and Mobius described 
patients having a weakness with primary involved the shoulder and the hip girdle. Only in 1954 
LGMDs were defined as a distinct nosological entity by John Walton and Federick Nattrass. They 
separated these disorders from the X-linked dystrophinopathies such as Duchenne and Becker 
Muscular Dystrophies (DMD/BMD)15. They defined LGMDs thanks to a few common features:  
- Transmission usually via an autosomal recessive gene. 
- Usually late onset. 
- Muscular weakness in shoulder and/or pelvic girdle, without any facial weakness. 
- Relatively slow course.  
In the late 1980s, the development of immunostaining methods helped to distinguish between 
LGMDs and other conditions such as BMD18. Moreover, in 1995 the European Neuromuscular Centre 
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Workshop established more precise criteria for diagnosis and classification of LGMDs according to 
their onset, progression and mode of inheritance19. Over the last sixty years, the molecular genetic 
investigations and the increased in knowledge of the structure and function of the muscle have 
allowed a more precise classification and improvements in understanding of the pathogenesis of 
LGMD subtypes. In the last five years, new causative genes were identified thanks to high-throughput 
technologies such as whole-exome sequencing (WES) and next-generation sequencing (NGS)20–24. 
To date, over 30 distinct subtypes of LGMD have been identified. LGMDs are classified into two 
main groups depending on the inheritance pattern: 
- LGMD type 1 (LGMD1), autosomal dominant (AD) forms 
- LGMD type 2 (LGMD2), autosomal recessive (AR) forms 
Among these two groups, each LGMD type is indicated with a letter given in the order of gene 
mapping. Of 31 LGMD subtypes recognised to date, 8 dominant forms and 23 recessive forms, each 
corresponding to a different causative gene10,25,26 (Tab.1). 
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Tab1: Description of limb girdle muscular dystrophies with autosomal and recessive inheritance known so far. 
The LGMDs are rare disorders, whose different forms range mainly from 1 in 14500 to 1 in 123000, 
depending on the population. The autosomal recessive forms are much more common compared to 
the autosomal dominant forms that probably represent less than 10% of all LGMD cases; LGMD2A 
is the most frequently diagnosed among LGMDs worldwide followed by LGMD2B25,27.  
From our current state of knowledge and considering the diversity of proteins involved in the different 
forms of LGMDs, no universal treatment can be envisioned. Case by case approaches is necessary. 
1.2.1 Limb girdle muscular dystrophy type 2A  
Limb girdle muscular dystrophy type 2A (LGMD2A; OMIM 253600), also known as calpainopathy. 
It was the first form of limb girdle muscular dystrophy with a recessive inheritance identified and the 
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first disorder discovered caused by a deficiency of a non-structural protein. CAPN3 is the gene 
responsible for LGMD2A and it was mapped to chromosome 15 in 199028. CAPN3 gene encodes a 
muscle-specific nonlysosomal proteolytic enzyme. Mutations lead to absence or reduction in this 
enzyme, but how this result in the dystrophic process is not fully understood. CAPN3 gene was linked 
with the first form of LGMD2 thanks to a molecular genetic study performed in a group of families 
from the island of La Réunion and it has been classified as LGMD2A, in 199129. Only two years later, 
linkage analysis in Brazilian families provided the first evidence of genetic heterogeneity for 
LGMD2A30. 
LGMD2A is the most common subtype between LGMDs and is up to 30% of all recessive LGMD 
cases taken together. The age of onset of muscle weakness range from two to 40 years but the disease 
usually first appears in the second or third decade of life31. The course of the disease is highly variable 
and a wide intra- and iter-familiar clinical variability is reported. Commonly, early onset means more 
severe phenotypes but there are cases in which a later onset leads to rapid progression and inability 
to walk by the third decade32. Use of wheelchair could become necessary during the second through 
the fifth decades, but some patients may remain ambulatory after the sixth decade33. Calpainopathy 
is characterised by the symmetrical and progressive weakness of proximal muscles more than distal 
muscles limbs, trunk and periscapular area. Laxity of the abdominal muscles, joint contractures, 
scapular winging, scoliosis and Achille tendon shortening. Moreover, patients with LGMD2A have 
the tendency to walk on tiptoe, difficulty in running, climbing stairs and in raising the arms above the 
head. Facial, tongue and neck muscles are not usually involved, therefore swallowing problems are 
unlikely. Heart problems and intellectual disability are not reported in this condition. Life expectancy 
is generally a normal range since heart and breathing muscles are usually not affected. 
There is currently no treatment or cure available for LGMD2A, however, some interventions may be 
helpful for certain symptoms of the disease. For example, stretching and physical therapy may help 
prevent or lessen muscle contractures. Technical aids can also compensate for the loss of certain 
motor abilities and surgical intervention may be required for correction of orthopaedic complications. 
There are some studies ongoing to reach a therapy for LGMD2A disease but so far, research is still 
on mouse model. Bartoli et al., evaluated the potential of recombinant adeno-associated virus (rAAV) 
vectors for gene therapy in a murine model for LGMD2A. In this study a muscle-specific promoters 
was used to avoid calpain 3 cell toxicity and it was reported an efficient and stable transgene 
expression in muscle with the restoration of the proteolytic activity and without evident toxicity34.  
Another research group succeeded, thanks to gene editing tools, to correct a LGMD2A patient-
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specific iPS cell line with a homozygous deletion of exon 17 to 24 in the CAPN3 gene. Now some 
transplantation studies are ongoing with corrected iPS cells in order to evaluate the potential of this 
new cell therapy35. 
1.2.2 Limb girdle muscular dystrophy type 2B 
Limb girdle muscular dystrophy type 2B (LGMD2B; OMIM #253601) is due to autosomal recessive 
mutations in DYSF gene localised in chromosome 2p13.2. This disorder is caused by reduction or 
absence in skeletal muscle of dysferlin protein encoded by DYSF gene. Dysferlinopathies are the first 
class of diseases identified where it has been suggested a fault in the process of membrane repair 
rather than a structural weakness of the sarcolemma13,36,37. The classification of different 
dysferlinopathies is based on the initial symptoms of patients. Clinical presentations most commonly 
associated with dysferlinopathies include: classical Limb Girdle Muscular Dystrophy type 2B 
(LGMD2B) characterised by the initial involvement of proximal muscles, Miyoshi Myopathy (MM; 
#OMIM 254130) with the involvement of distal muscles and Distal Myopathy with Anterior Tibial 
onset (DMAT; #OMIM 606768) characterised by predominant involvement in the anterior 
compartment38,39. These are the three main clinical phenotypes associated with mutations in DYSF 
gene. However, even other clinical phenotypes may be produced by similar mutations40,41. 
The existence of a recessive form linked to chromosome 2p was first shown in 1994 and later 
confirmed by Passos-Bueno et al. in other three families. This disorder has been classified as 
LGMD2B42,43. In 1995, the linkage of Miyoshi Myopathy to the same region of chromosome 2p as 
LGMD2B was noted44. But only in 1998, thanks to DYSF gene cloning was clearly demonstrated that 
these two disorders were caused by the same gene defect45. The following year Bushby coined the 
term “dysferlinopathy” in order to group these disorders46. While for the third form of dysferlinopathy 
(DMAT) the linkage to chromosome 2p was noted only in 200138.  
The onset of LGMD2B is usually between the second and the third decades. After the first year of 
evolution, the disease mainly affects lower limbs but later even paravertebral and proximal upper 
girdle muscles are affected. Generally, head, neck and cardiac muscles are spared. No central nervous 
system involvement has been described and respiratory involvement is mild and occurs in the later 
stage of the disease. Patients have difficulty standing on their tiptoes, mild scapular winging may be 
evident at any stage of the disease and patients are characterised by elevated levels of serum CK. One 
of the distinctive phenotype is the early loss of the Achilles’ tendon reflexes, is peculiar of this 
disorder since in other forms of LGMDs is the most preserved reflex. Loss of ambulation usually 
occurs on average after years of disease course47–49. Disease progression is slow, although several 
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patients show abrupt onset and rapid progression to a non-ambulatory state. Moreover, LGMD2B 
show intra- and interfamilial variability in the age of onset, the pattern of muscle involvement and 
rate of disease progression50–53. 
To date there are no specific treatments for LGMD2B, the only therapeutic approaches are palliative 
in order to allow patients to delay loss of ambulation. Possible future therapies, as in LGMD2A, 
including gene therapy replacement of affected gene and use of stem cells54–58. A Phase 1 clinical 
trial (NCT02710500) is ongoing in LGMD2B patients to evaluate the safety and tolerability of 
intramuscular injection of rAAVrh.74.MHCK7.DYSF.DV. This is a rAAV carrying a dysferlin 
transgene under control of a muscle specific promoter.  
1.2.3 Causative genes in LGMD2A and LGMD2B 
Limb girdle muscular dystrophy type 2A is caused by mutations in CAPN3 gene. It is located on 
chromosome 15, covers a genomic region of 52.8kb and consists of 24 exons. CAPN3 gene 
(NC_000015.10) is expressed as a 3.5kb transcript and is translated into a 94kDa protein composed 
of 821 amino acids with proteolytic function. The human CAPN3 gene produces many splicing 
variants and only the full-length isoform is tissue specific and it is expressed exclusively in skeletal 
muscle. The other isoforms are characterised by the splicing of exons 6, 15 and 1659. In human 
lymphoblastoid cell lines in contrast to adult muscle tissue, exon 15 is systematically spliced out. 
White blood cells are characterised by the presence of four different CAPN3 transcripts generating 
by the alternative splicing of exons 6, 15 and 1660. So far, 497 variants have been identified, according 
to the Leiden Muscular Dystrophy database (www.dmd.nl) and they are spread in the entire length of 
the gene with the absence of mutational hot spots. 
Limb girdle muscular dystrophy type 2B is caused by mutations in the DYSF gene (NC_000002.12), 
it encodes for dysferlin protein, a member of the ferlin protein family. DYSF gene spreads over 150kb 
of genomic DNA and is located on chromosome 2p1342. DYSF gene encodes for a 237kDa single 
pass transmembrane protein composed of 2080 amino acids and produces seven different transcripts 
characterised by exon 17 skipping and the insertion of exon 5a and 40a61. These transcripts are 
differentially expressed in skeletal muscle and in white blood cells. The skipping of exon 17 is 
specifically found in white blood cells and does not occurs in skeletal muscle in which in 90% of 
cases the full-length isoform is present. The insertion of exon 5a and 40a happen in both tissues62. So 
far, 511 variants have been identified, according to the Leiden Muscular Dystrophy database 
(www.dmd.nl) and they are spread over the entire length of the gene without mutational hot spots. 
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1.3 OVERVIEW OF PROTEINS INVOLVED IN LGMD2A AND LGMD2B DISEASE 
1.3.1 Calpain 3 
Calpain 3 is a member of calpain protease family. Calpain family was described for the first time in 
1964 by Gordon Guroff. In 1981, the term “calpain” was used by Takashi Murachi but it became the 
official name of this protease family only ten years after63–65 
Calpains belong to the papain superfamily of cysteine proteases, which are a family of complex multi-
domain intracellular enzymes. Calpains are not degradative enzymes but instead, carry out cleavage 
of target proteins in response to calcium signalling. Therefore, calpain is considered to be a modulator 
protease rather than a degrading protease such as proteasomal and lysosomal proteases66. The 
mammalian calpain gene superfamily contains 16 known genes: 14 of these genes encode proteins 
that contain cysteine protease domains while the other two genes encode smaller regulatory proteins. 
These small regulatory proteins join with some of the catalytic subunits to form heterodimeric 
proteases67,68. Until 1989, the two best-studied calpains in mammalian were called “conventional” 
calpains. These are the most abundant and constitutively expressed in all tissues, whereas many other 
isoforms demonstrate tissue-specific expression pattern. These conventional calpains are µ-calpain 
and m-calpain or even called CAPN1 and CAPN2. The term µ- and m- was given for the difference 
in their calcium requirement. The designations µ- and m- are short forms of micromolar and 
millimolar Ca2+ required for their activation. CAPN1 and CAPN2 are heterodimers composed of one 
catalytic subunit of about 80kDa encoded by CAPN1 or CAPN2 genes and a common smaller subunit 
of about 28kDa encoded by CAPN4 gene that is the regulatory subunit69. The primary structure of the 
conventional calpain catalytic subunit was determined in 198470. The structure consists of four 
domains (I-IV): domain I represents the N-terminal region and it has a regulatory role, domain II 
contains a catalytic site called calpain-type cysteine protease conserved (CysPc) domain and it is 
responsible for proteolytic functions. The CysPc domain is composed of two protease core 
subdomains (PC1 and PC2)71–74. This domain is characterised by the presence of the catalytic triad 
residues cysteine129, histidine334 and asparagines358-75. Domain III is known to interact with Ca2+ and 
phospholipids, previously called C2-domain-like (C2L) but now is called calpain-type beta-sandwich 
(CBSW) domain. The last domain represents the Ca2+ binding module containing five EF-hand motifs 
(PEF domain)74,76. Calpains with the same structure as CAPN1 and CAPN2 are called “classical or 
conventional” calpains, while the rest are “non-classical”. In addition to sharing the same structure, 
conventional calpains have a specific endogenous inhibitor: calpastatin, which contains four 
repetitive inhibitory units, each of which inhibits an equimolar amount of conventional calpain77 
(Fig.1). 
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Fig1: Schematic shows the structure of human calpains. The calpains shown in red are predominantly expressed in 
specific tissues or organs while those in black are more widely expressed. (Image taken by Ono et al., 201674). 
Genetics studies have revealed that individual calpains have important and widely divergent 
physiological functions. The calpain family of proteases has been implicated in a variety of calcium-
regulated cellular processes such apoptosis, proliferation, differentiation, signal transduction and 
cellular migration69,78. For example, CAPN1 and CAPN2 are involved in a variety of processes whose 
the best documented role is the remodelling of cytoskeleton for processes such as cell 
movement67,79,80. Before the influx of Ca2+, calpains exist in the cytosol as an inactive enzyme but in 
response to increases in the cellular Ca2+ levels, the heterodimer undergoes multiple structural 
changes to form the active calpain enzyme. Structural events, such as autoproteolysis, subunit 
dissociation, intradomain/interdomain rearrangement and phospholipid binding, are suggested to be 
involved in the complex regulation of activation68,81–83. The influx of Ca2+  is responsible for calpains 
activation. Calpains are inactive until their protease domain, which comprises two core domains (PC1 
and PC2), fuse to form a functional protease, secondary to the binding with Ca2+. When protease 
domain is formed, the activated calpains are able to cleave the target proteins84. Proper for the huge 
number of cellular processes in which calpains are involved, not only a deficiency in CAPN3 leads 
to a LGMD2A but even a deficiency in other calpains lead to numbers of disorders called 
calpainopathies (Tab.2).  
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Tab.2: List of human calpains. (Table modified by Suzuki et al.,200468). 
1.3.1.1 Calpain 3 protein 
Calpain 3 (NP_000061.1), indicated also as CAPN3, p94, nCL-1 and nCANP, was the first non-
ubiquitously expressed calpain to be identified. Discovered  in 1989 by Sorimachi et al., but is still 
not completely characterized, due to its extraordinary instability at least in vitro85. 
Calpain 3 was originally described as a skeletal muscle specific calpain isoform86,87. More precisely, 
calpain 3 is expressed predominantly, rather than exclusively, in skeletal muscle. It is expressed more 
strongly in skeletal muscles, especially in the fast (type II) fibres88. In the heart, CAPN3 mRNA has 
been detected but not its protein. While the protein is expressed in in peripheral blood mononuclear 
cells, in which there are four different splice variants of CAPN354,55,83,84. Structurally, it is categorised 
as a classical calpain and it is approximately 50% identical to CAPN1 and CAPN2. One of the features 
of CAPN3 that distinguish it from CAPN1 and CAPN2 is the insertion of additional regions (known 
as NS, IS1 and IS2). This is the reason why the molecular weight of CAPN3 is 94kDa and not 80kDa 
as the other calpains. NS is an additional N-terminal sequence with unknown function, IS1 is localised 
between the catalytic cysteine126 and histidine334 and IS2 is upstream of the first EF hand motif and 
it contains nuclear translocation signal85 (Fig.1). These sequences are found only in the full-length 
isoform of CAPN3. Several studies have revealed other unique characteristics of this protein that 
diverge greatly from those of the conventional calpains91. For instance, CANP3 shows extremely 
rapid Ca2+ -independent autolytic activity. The extreme rapidity of autolysis depends on IS1 and IS2 
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sequences and seems to be independent of Ca2+ but is activated by Na+. This feature is unique among 
known calpains since Na+ dependence is generally considered a property of extracellular enzymes 
and not intracellular enzyme as calpains86,92. So far, CAPN3 is the only Na+ dependent intracellular 
enzyme known. It is activated by physiological Ca2+   but with levels much lower than other classical 
calpains. CAPN3 is activated additively by both ions and the Na+ and Ca2+ required for autolysis are 
100 and 0.1mM, respectively74. This unique features present in calpain 3 depend on the presence of 
IS1 and IS2 insertion. The deletion of these sequences completely abolishes Na+ dependent activation 
without changing its Ca2+ dependent activity92. The lower levels of Ca2+ required for CAPN3 
activation could be explained by the presence of IS1 and IS2 insertions which probably add more 
flexibility to the protein, leading to the formation of the catalytic active site with less Ca2+ levels91. 
Thanks to these two activation signals, CAPN3 molecules undergoes intramolecular autolysis in IS1 
insertion. This event is followed by activation of CAPN3 molecules which received the activation 
signals, these fully activated molecules can thereafter activate other CAPN3 molecules which have 
not received the activation signal by intermolecularly autolysis. This ultimate step generates an 
amplification cascade leading to global activation of CAPN3 pool93. The intra- or intermolecular 
cleavage leads to the formation of two fragments that remain together by non-covalent binding to 
form the active enzyme. For the disassembling of autolyzed fragments is needed cleavage of IS2 
sequence94.  
As in other PEF domain proteins, the EF-hands of calpain 3 are paired: EF1 paires with EF2, EF3 
paires with EF4 and EF5 of one subunit pairs up with EF5 of the other subunit to form an 
homodimer95,96. This is another distintive fature of CAPN3 since EF5 domain of other calpains is 
used exclusively to form heterodimers with small regulatory subunits. Moreover EF5 of calpain 3 
compare to the other calpains is able to bind Ca2+ ion97. Finally, CAPN3 differs to other calpains by 
the interaction with connectin/titin, the giant sarcomere protein and by the presence of different 
inhibitors compared to the other conventional calpains. For example, calpastatin has no effect on 
CAPN3 autolysis. However, other inhibitors exist to control CAPN3 activity since proteolysis, which 
leads to irreversible modifications, is a widely used and powerful means to regulate cellular functions. 
Uncontrolled proteolysis may be deleterious for the cell. Then, multiple strategies exist to control 
such events. Given the very low calcium requirement of CAPN3 and its high instability, it has been 
hypothesized that cellular activators and inhibitors of CAPN3 must exist in order to modulate its 
function. It has been shown that the interaction with the sarcomere protein titin suppresses IS2 
autolysis suggesting that titin is important for the stabilizing and the regulating of CAPN398. For non-
sarcomere associated CAPN3, the titin function is performed by the protein PLEIAD, which 
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moderates the protease activity of the enzyme99. Recently, it has been shown the presence of a positive 
regulator of CAPN3 activity, calmodulin (CaM) that is able to binds and facilitates CAPN3 autolytic 
activation100.  
1.3.1.2 Main functions of CAPN3 
The specific role of CAPN3 and its link to deficits in muscle adaptation is still under investigation. 
The research of specific substrates of calpain 3 has been so far unsuccessful and despite intense 
research, the physiological functions of calpain 3 and its pathophysiological implications remain 
elusive. CAPN3 protein is located at several different cellular sites and may possess both proteolytic 
and non-proteolytic functions and it is important for homeostasis of skeletal muscle. CAPN3 is 
associated with the sarcomere in skeletal muscle, thanks to the binding with titin. However, calpain 
3 has been observed in other cellular compartments beside the sarcomere, such as the membrane in 
myogenic cells or the triad associated protein complex, suggesting that calpain 3 has multiple 
functions within the muscle tissue74,101,102. 
The most well known function of calpain 3 is its role in the maintenance of sarcomere integrity via 
the regulation of sarcomeric protein turnover. This function is performed by the pool of CAPN3 
associated with the sarcomere, which is the major pool of calpain 3. It may play a role in signalling 
pathways and in releasing damaged proteins to facilitate myofibrillar proteins turnover in order to 
maintain an effectively functioning muscle101. The full-length mature CAPN3 is incorporate into 
myofibrils via titin only once the sarcomere structures are fully mature103. In response to external 
stress, CAPN3 is redistributed from the M-line to the N2A region of titin thanks to its protease 
activity. The redistribution of the protein leads to dissociation of muscle ankyrin repeat proteins 
(MARPs) from titin. MARPs are a family of titin-associated stress responsive molecules and are 
putative transducers of stretch-induced signalling in skeletal muscle104. Their dissociation from titin 
is followed by the translocation to the nucleus to transmit signals of mechanical 
perturbation101,103,105,106. In addition of this, CAPN3 seems to be involved in myofibrillar protein 
turnover. Myofibrillar proteins must be removed from the myofibril before they can be turned over 
metabolically and CAPN3 seems to be involved in this step acting upstream of ubiquitin-proteasome 
pathway by the cleavage and release of myofibrillar proteins107.  
A portion of cellular CAPN3 is concentrated at the triad, in which is necessary for the triad-associated 
protein complex74,102. In this case, CAPN3 has a structural role rather than a proteolytic one, since it 
is necessary for proper recruitment of two components of the triads: the glycolytic enzyme Aldolase 
A (AldoA) and ryanodine receptors (RyRs). CAPN3, in this case, doesn’t proteolyze ryanodine 
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receptors or Aldo A but plays a role in the recruitment and for the proper localization of these two 
triad components108. Indeed, in the absence of CAPN3, the concentration of both proteins in triad 
fractions is reduced and the calcium release upon activation is significantly decreased.  
Calpain 3 is also found in the membrane of myogenic cells where is involved in the myogenic 
differentiation process participating in the generation of a pool of reserve cells. This due by 
decreasing the transcriptional activity of the key myogenic regulator MyoD via proteolysis 
independently of the ubiquitin-proteasome degradation pathway. This means a potential rule of 
CAPN3 in the muscular regeneration process by promoting the renewal of the satellite cell 
compartment109. Regeneration of adult skeletal muscle is a process requiring the activation, 
proliferation and fusion of satellite cells, to form new muscle fibres110. The myogenic differentiation 
of satellite cells and their myoblast progeny is regulated by various transcriptional factors including 
MyoD111,112. In the early stage of myogenic differentiation, calpain 3 is involved in the regulation of 
the myogenic regulatory factor MyoD by inducing its destabilization and leading myoblasts to 
quiescence. Calpain 3 induces the proteolysis of MyoD and promotes the generation of a pool of 
reserve cells. 
CAPN3 seems even to participate in membrane repair machinery with dysferlin protein, that is one 
of the proteins involved in this. In normal myofibers CAPN3 is inactive through interaction with titin, 
but with the injury of the membrane, Ca2+ influx leads CAPN3 activation. Active calpain 3 may 
contribute to the patch repair response by cleaving proteins to mediate disassembly of the damaged 
actin cytoskeleton. After that, intracellular vesicles are aggregated to form an endomembrane patch 
that is trafficked to the site of disruption. Dysferlin molecules present on repair vesicles and on the 
plasma membrane mediate the docking and fusion of the patch113,114.  
1.3.2 Dysferlin 
Dysferlin belongs to the ancient ferlin family. Ferlins are detected in all eukaryotic kingdoms, 
including unicellular phytoplankton and protozoans115. They are a group of single-pass 
transmembrane proteins that possess multiple tandem cytosolic C2 domain, from five to seven, 
variable numbers of Fer and DysF domains and a short C-terminal extracellular domain. There are 
six known human ferlins including dysferlin, otoferlin and myoferlin (Fig.2).  
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Fig.2: Structure of three of the six known human ferlins. The structure is characterized by a short C-terminal 
transmembrane domain, five to seven tandem C2 domains and a variable number of DysF and Fer domains. (Image taken 
by Cardenas et al., 201653).  
The function of Fer and DysF domains remains unknown. Most actions of ferlins appear to be 
mediated by their C2 domains, which mediate lipid and protein binding. Moreover, many C2 domains 
coordinate calcium ions, within a negative charged binding pocket, to regulate calcium-dependent 
events123,124. 
The ferlins were identified and named based on homology to a Ceanorhabditis elegans 
spermatogenesis factor Fer-1, required for fusion of vesicles with the spermatid cell membrane116. 
Much currently remains unknown about the fundamental function of this gene family, however, 
mutations in the two most well-characterized members, dysferlin and otoferlin, have been implicated 
in human disease43,117. Dysferlin like myoferlin is abundantly expressed in the plasma membrane, and 
both proteins are involved in membrane repair and muscle regeneration119–122. Whereas otoferlin 
mainly localized in intracellular compartments where it plays a role in exocytosis53,118.  
Dysferlin is ubiquitously expressed with high expression in skeletal muscle, heart and brain. Dysferlin 
is a 230 kDa type II anchored membrane protein with a single C terminal helix buried in the 
membrane. The structure of the protein consists of seven C2 domains (C2A to C2G), three Fer 
domains (FerA, FerB and FerI), two couple of DysF domains and a C terminal trans-membrane 
domain. In dysferlin, C2A domain binds phospholipids in a calcium dependent manner and it is 
essential for phosphatidylserine accumulation at the membrane repair site125. The other C2 domains 
show calcium independent binding to phospholipids126,127. Dysferlin is a sarcolemmal protein distinct 
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from the dystrophin-glycoprotein complex (DGC) in human muscle. It is not only localised in the 
sarcolemma but it shows localisation to intracellular and endosomal vesicles and there is even a minor 
portion associated with the T-tubule system as well102,128,129. Dysferlin in T-tubule membranes 
contributes to the maintenance of the T-tubule system and it colocalizes with dihydropyridine 
receptor, caveolin-3, MG53, annexin A1 and AHNAK128,130. Dysferlin contributes to the biogenesis 
and remodelling of the T-tubule systems since it is able to recruit the phosphatidylinositol 4,5-
bisphosphate (PI(4,5)P2), that is an important component of the T-tubule complex131.  
1.3.2.1 Main function of DYSF 
Dysferlin has been implicated in various cellular processes, such as muscle cell-cell fusion during 
regeneration, muscle growth and cell adhesion132–137. An increasing number of dysferlin interacting 
proteins have been described including caveolin-3, affixin, annexins A1 and A2, calpain 3, myogenin 
and AHNAK114,130,132,138–141. However, the major function of dysferlin is its role in sarcolemma repair 
machinery since is involved in patch formation to reseal the membrane lesion. Dysferlin is a critical 
component of muscle membrane repair system. Mechanical and chemical stress lead to plasma 
membrane distruption142. Tiny membrane injuries can be repaired spontaneously while for larger 
injury is required the help of an active membrane repair machinery. It is proper in the active 
membrane repair machinery that dysferlin plays a key role. The membrane disruptions cause a 
massive entry of Ca2+ to the cell, with the consequent recruitment of vesicles that fuse with each other 
and with the plasma membrane to form the patch for resealing membrane lesion143.  
The exact mechanism of membrane repair is still unclear, what we know so far is the presence of two 
membrane repair machinery, one Ca2+-dependent and the other Ca2+-independent. The first step after 
membrane injury is the accumulation of mitsigumin-53 (MG53) at injury sites, not in a Ca2+-
dependent manner but in an oxidation-dependent manner 144,145. This step is essential for active 
trafficking of intracellular vesicles to the sarcolemma and is required for the movement of dysferlin 
to the site of cell injury during membrane repair patch formation146,147. During the Ca2+-dependent 
phase of membrane repair, the influx of ions leads to the activation of m-calpain and µ-calpain, but 
not calpain 3, and strong depolarization of L-type calcium channels (L-type VGCC). Activated 
calpains cleave dysferlin releasing a C-terminal fragment called mini-dysferlin C27
149
. The calpain 
cleavage site in dysferlin is predicted to residue in exon 40a150. After that cleavage mini-dysferlin C27 
isoforms are rapidly recruited to sites of membrane injury and fuse with MG53 in a process 
coordinated by L-type VGCC. In the site of injury dysferlin molecules present on repair vesicles and 
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on the membrane plasma membrane mediate docking and fusion of the patch, sealing the membrane 
breach and preventing a further influx of Ca2+ (Fig.3).  
 
Fig.3: Model of membrane repair after injury. The first five seconds after the membrane injury are characterised by a 
promiscuous influx of calcium at the sites of membrane injury that leads the local activation of calpains and strong 
depolarization of L-type VGCCs. In the meantime, MG53 is mobilized and targeted to the injury site in a Ca2+-
independent manner. With the activation of calpains, dysferlin is cleaved releasing the mini-dysferlin C27. Mini-dysferlin 
C27 are recruited inside the vesicles to the sites of injury and fuse with MG53 in a calcium-dependent process coordinated 
by L-type VGCCs. Between 2 and 10 s after injury, mini-dysferlin C27 fuses into the plasma membrane and undergoes 
calcium-dependent phospholipid binding via its C2 domains. While between 90 and 120 s mini-dysferlin C27 and MG53 
compartments infiltrate the plasma membrane surrounding the membrane injury, forming a lattice to stabilize the plasma 
membrane as it extends to reseal the membrane injury. This process is helped by annexin A1. (Image taken by Lek et al., 
2013149). 
1.4 GENOTYPE-PHENOTYPE CORRELATION 
In LGMD2A is difficult to establish genotype-phenotype correlations for the high phenotypic 
variability (intra- and inter-familial variability) of symptom and severity, even among patients with 
the same CAPN3 genotype31,151. There is no correlation between the age of onset and the time in 
which the patient became wheelchair bound. Moreover, the type of mutations in CAPN3 gene seems 
to be not a risk factor for becoming dependent on a wheelchair at a determined age. However, it has 
been shown that patients with two null mutations or homozygous null mutation have a greater risk to 
have a severe phenotype and to loss of ambulation earlier than patients with at least one missense 
mutation. Anyway, the precise moment of needing a wheelchair appears to be independent of the type 
of muatation151,152. The amount of calpain 3 protein appears to have a relative prognostic value, then 
patients carried mutations that lead to degradation of the protein usually are characterised by early 
onset of the disease. However, this is not always true since absent or markedly reduced protein levels 
were also found in patients with late or adult onset. On the contrary, almost all patients with normal 
levels of calpain 3 protein had late or adult onset152. This high variability shows in LGMD2A, 
probably implies the existence of additional factors, that could be genetic and/or environment, that 
76 
 
might regulate the expression of the phenotype, even within the same family. Intra-family variability 
has been shown since 1998, in which two siblings carried the same two mutations showed two 
different phenotypes. The brother presented a classical phenotype of LGMD while the sister a 
metabolic myopathy phenotype153. Another case was observed in two siblings with the same 
mutations but with 10-year difference in becoming wheelchair bound151. Moreover, the clinical-
molecular correlation is complicated even for the presence of double heterozygosity. In fact, two 
different mutations have a different functional impact on the activity of the protein.  
In conclusion, for LGMD2A we can try to study a genotype-phenotype correlation only with 
mutations that lead to the absence of the protein, that in almost all cases are null mutations. Patients 
with two null mutations had a tendency toward slightly earlier onset than patients with two missense 
mutations. While no define correlation can be drawn from two missense mutant alleles, either 
homozygote or compound heterozygote characterised by a variable clinical features151,152,154.  
Even LGMD2B is characterised by high variability, just considering the fact that different mutations 
in the same gene give rise different phenotypes and even the same mutations may lead to a 
phenotypically different muscular dystrophy155,156. Moreover, the same mutation is even associated 
with a wide inter- and intra-familiar variation in clinical phenotype. Then, the type of mutation does 
not correlate with phenotypic severity. All attempts to correlate phenotypes with DYSF gene 
mutations have been unsuccessful. It is still not found any genotype-phenotype correlation either with 
regard to the nature of the mutation and severity or with the phenotype and age at presentation157,158.   
1.5 DIAGNOSTIC APPROACH IN LGMD 
Considering the wide clinical and genetic variability of LGMDs, achieving a precise diagnosis might 
be difficult and requires access to multiple specialities. Clinical examination, laboratory testing, 
muscle imaging and histological appearances of muscle are required9,11. In addition to the clinical and 
genetic variability, there is even an overlap with a number of other diseases including myofibrillar 
myopathy, pompe disease and congenital muscular dystrophy.  
For a certain diagnosis is required first a clinical assessment for directing further investigations. The 
medical evaluation includes family history, physical examination, serum CK levels and muscle MRI, 
CT scan and electromyogram (EMG)  are used to determine distinct patterns of muscle 
involvement159. Medical evaluation is followed by muscle biopsy analysis, even if is not crucial for 
all forms of LGMD. For example, deficiency of CAPN3 is not evaluated with immunohistochemistry 
or in some cases, protein deficiency documented by immunohistochemistry in muscle may be a 
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secondary deficiency due to mutations in other genes. However, muscle biopsy still represents an 
important step in the diagnostic process in order to investigate the presence or absence of specific 
muscle proteins (such dystrophin, dysferlin, sarcoglycans and glycosylated α-dystroglican). All these 
exams just described lead in many cases to targeted genetic testing. In fact, diagnosis is confirmed by 
detection of pathogenic variants in the causative gene of the disease160,161. However, even if direct 
sequencing of the coding regions of the genes responsible for the different form of LGMDs is the 
most common method, it remains often insufficient due to the size and numbers of genes involved. 
Today with next generation technique is possible to sequencing genome or exome, and there are even 
commercially kits which include loci for the diagnosis of neuromuscular disorders. This is a big step 
forward for the diagnosis of LGMDs, thanks to that is possible to analyse a big number of genes at a 
reasonable cost without invasive muscle biopsies26,162. Unfortunately, there is a limitation that is 
related to insufficient exon coverage, leading to a potential lack of representative examination of all 
exons163. However, for the approach to heterogeneous hereditary conditions with huge phenotypic 
variability and large size of many associated genes such as muscular dystrophies, NGS techniques 
represent a powerful tool to identify genetic variations164. So far, exome and genome sequencing 
strategies are not the first test used for skeletal muscle disorder but thanks to the technological 
improvements and the cost decreased will soon replace the single gene testing. 
1.5.1 Diagnostic approach in LGMD2A 
Diagnosis of LGMD2A is challenging for the high phenotypic variability, lack of precise protein 
analysis in muscle biopsies and absence of mutational hot spots in the CAPN3 gene. Clinical 
evaluation and the clinical tests help to direct the further analysis. One of the clinical tests is the 
examination of serum creatine kinase (CK) concentration that is always elevated (5-80 times normal) 
from early infancy on, particularly during the active stage of the disease. Serum CK concentration 
decreases with disease progression, as muscles become more and more atrophic165. Another clinical 
test is the muscle imaging with CT-scan and EMG that is used to discover the pattern of muscle 
involved. After the initial clinical work up and exclusion of the more common conditions with 
overlapping phenotypes, laboratory tests are performed. Unlike the other types of LGMDs, in 
LGMD2A is not possible to perform immunohistochemistry analysis for diagnosis. Anyway, the 
muscle biopsy of most individuals shows the typical features of an active dystrophic process 
(increased fiber size variability, increased fibrosis, regenerating fibers, degenerating and necrotic 
fibers), others have mild and non-specific myopathic features166–168. For evaluated the expression 
level of the protein western blot is performed. However, western blot results need to be interpreted 
with caution for the lack of specificity, since calpain 3 protein levels can be partially reduced in other 
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muscular dystrophies such as LGMD2B/2I/2J140,151,169. Moreover, calpain 3 is highly susceptible to 
degradation. Then, it is important to avoid technical artefacts that could be introduced when the 
biopsy sample is processing and might lead to protein degradation170. For example is important to 
exclude Na+ from any buffer since CAPN3 rapidly autodegrades in solutions containing Na+. 
Anyway, loss of all calpain 3 bands means with a high probability mutations in CAPN3 gene but it is 
not a certanty152. It has been shown cases in which absence of CAPN3 protein in western blot was 
not linked to mutations in CAPN3 gene151. Moreover, it has been described patients with two 
mutations that showed normal full-sized calpain 3 protein171. Therefore, western blot analysis is not 
a diagnostic test but in some cases help to obtain a complete diagnosis. 
Genetic analysis is necessary to confirm or not the clinical suspect, but unfortunately, the lack of 
defined mutational hot spots makes the analysis of the 24 exons and the flanking intronic sequences 
laborious and expensive. Moreover, in ~23% of patients believed to have LGMD2A only one 
mutation can be detected151,152. In these cases is essential even cDNA analysis in order to investigate 
the presence of a deep intronic variant. So far, the absence of the second mutation is hard to explain. 
Last year, Duno’s research group speculated about the possibility of an in frame deletion of 21bp in 
heterozygous state could behave as dominant mutation, but not all scientific community agree with 
him172,173. This explanation is not sharing in the scientific community even because it has been shown 
that heterozygous deletion of one entire allele of CAPN3 doesn’t lead to LGMD2A symptoms, 
indicating that half-normal levels of CAPN3 are sufficient to maintain skeletal muscle174. 
1.5.2 Diagnostic approach in LGMD2B 
Diagnosis of LGMD2B is challenging as well. This is for the high phenotypic variability, the absence 
of mutational hot spots in DYSF gene and for the large size of the gene. Mutation screening of DYSF 
gene is labour intense, expensive and time-consuming.  
Like LGMD2A, the first step is the clinical evaluation and clinical tests. After that, differently to the 
LGMD2A, it is possible to perform immunohistochemistry in order to evaluate the presence of 
dysferlin in the muscle. Immunostaining could reveal absent or decreased levels of dysferlin at the 
membrane with an increased cytoplasmic staining. However, the reduced sarcolemmal 
immunostaining can be secondary and seen in other types of LGMD175. Then, western blot needs to 
be performed on the muscle or white blood cells to confirm a primary deficiency. It is possible to 
perform western blot in both tissues since the expression of dysferlin in peripheral blood monocytes 
correlates with dysferlin expression levels in skeletal muscle in both healthy and dysferlinopathy 
patients176,177. Western blot in blood sample represents a noninvasive method of confirming the 
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diagnosis. Moreover, like in LGMD2A, muscle biopsy shows the typical features of an active 
dystrophic process (variation in fiber size, necrotic events and regenerating fibers). There is often 
evidence of inflammation, sometimes leading to a misdiagnosis of polymyositis38,178. If these tests 
show an absence of dysferlin protein, in the majority of cases indicate the presence of mutations in 
DYSF gene. However, in order to confirm that, molecular and genetic studies are needed to obtain a 
definite diagnosis. 
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2. AIM OF THE PROJECT 
Limb girdle muscular dystrophies are a clinically and genetically heterogeneous group of disorders. 
Then, diagnosis in most of the cases can be really challenging.  
The aim of this project was to obtain a certain diagnosis for 90 patients with LGMD2 clinical features. 
We concentrated on the two most frequent forms of limb girdle muscular dystrophies with autosomal 
recessive inheritance. The gold standard for LGMD diagnosis is the study of proteins involved either 
by immunoblot or immunohistochemistry based on clinical phenotypes, followed by a mutation study 
in candidate genes. For that reason, it was set up genetic screening for CAPN3 and DYSF gene, 
immunoblot and immunohistochemistry analysis. Both genetic and biochemical analysis resulted 
essentially for obtaining a diagnosis in patients in which only one mutation has been identified. 
In addition to obtaining a certain diagnosis, this project was carried out for increase the mutational 
spectrum in LGMD2A and LGMD2B and to contribute to the phenotype and genotype correlation 
studies.  
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3. MATERIAL AND METHODS 
3.1 ETHICS 
All patients in this study provided written informed consent for muscle, skin biopsy and genetic 
analyses. All the procedure are in accordance with the Helsinki Declaration of 1975. 
3.2 CELL CULTURE MAINTENANCE 
Skin biopsies from patients and healthy controls were washed twice and broken into small pieces 
under sterile condition for primary fibroblasts isolation. After 15' incubation with trypsin at 37°C, 
tissues were placed in 25ml plastic flasks with 1 ml of  DMEM (D5671, Sigma) supplemented with 
10% fetal bovine serum (D8537, Sigma), 1% GlutaMAXTM Supplement (35050061, Thermo Fisher 
Scientific) and 1% Penicillin-Streptomycin (P4458, Sigma). The flasks were incubated vertically 
overnight at 37° C with 5% CO2 and after that were returned to horizontal position. Then 5ml of 
DMEM 10% was added to plastic flasks and cells were grown in standard conditions.  
3.3 PRIMER DESIGN 
Before primers design, repeated sequences have been identified using RepeatMasker Web Server 
(http://www.repeatmasker.org/cgi-bin/WEBRepeatMasker), while SNPs, small deletions and 
duplication using 1000 Genomes Project (http://grch37.ensembl.org/index.html). PCR primers were 
designed using Primer 3 (http://primer3.ut.ee/) with the following conditions: 
- Melting temperature between 56°C and 63°C 
- Less than 2°C difference in melting temperature between the two primers 
- GC content between 40-60% 
- Length between 18-22bp  
- Avoiding secondary structure or sequence complementary at 3’ends 
Finally, the specificity of primer pairs was tested with UCSC In Silico PCR 
(http://rohsdb.cmb.usc.edu/GBshape/cgi-bin/hgPcr). Nucleotide sequences are listed in Table 3. 
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Tab.3: Panel A: specific primers designed for amplified all coding exons and flanking regions of DYSF gene. Panel B: 
specific primers designed for amplified all coding exons and flanking regions of CAPN3 gene. 
3.4 DNA ANALYSIS 
Total genomic DNA was extracted from peripheral blood samples with MasterPure Complete DNA 
Purification Kit (MCD85201, Epicentre), according to manufacturer’s instructions. The quantity and 
quality controls were carried out with the spectrophotometer NanoDrop-1000 (Thermo Scientific). 
The exons and adjacent intron regions of CAPN3 gene (NC_000015.10) were amplified in a pool of 
20 different PCR. While exons and adjacent intron regions of DYSF gene (NC_000002.12) were 
amplified by 55 PCR with specific primers. 
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PCR reactions were performed in 50 µl reaction volumes containing 100 ng of template DNA, 0.2 
pmol forward and reverse primers, 0.4 mM deoxynucleotide triphosphate (dNTP), 1.5 mM MgCl2, 
1X reaction buffer, and 1.25 U Red Hot DNA Polymerase (AB0406B, Thermo Fisher Scientific), 
using a DNA thermal cycler (PTC-200; MJ Research). The products of individual PCR reactions were 
separated electrophoretically on 1.5% agarose gels (16500500, Thermo Fisher Scientific) and 
revealed with ethidium bromide staining (E1510, Sigma). Polymerase chain reaction products were 
sequenced by automated sequencer ABI 3730 (Applied Biosystems). Obtained results were analysed 
using Sequence Scanner software (Technelysium) and compared with human CAPN3 gene sequence 
(NG_008660.1) or human DYSF gene sequence (NG_008694.1).  
Novel variants have been identified, a new extraction and amplification were done in order to be sure 
that no contamination events have occurred.  
3.4.1 Real time qPCR 
Real time qPCR was performed in LGMD2B patients to confirm the homozygosity of mutations 
and exclude the presence of large deletions. Six assays were designed: exon 19, exon 27, exon 37, 
exon 42, exon 51 and exon 54 of the DYSF gene. Before carried on the experiments, validation of 
each assay was performed in order to check the reaction efficiency. For validation, DNA template 
from a healthy control was used and the standard curve prepared with four serial dilutions. The 
construction of a standard curve enabling the determination of the efficiency, linear dynamic range 
and reproducibility of a qPCR assay. Selected assays were those with 90-105% range of efficiency, 
the R2 value close to one and similar Cq values in the replicates. The qPCR reactions have been 
performed with CFX Connect™ Real-Time PCR Detection System using SsoAdvanced TM SYBR® 
Green Supermix (1725271,  Bio-Rad) according to the manufacturing instructions. Nucleotide 
sequences are listed in Table 4.  
 
Tab.4: Primers designed for quantitative PCR on DYSF gene. 
Three reference genes (Sel1L, RBM11 and ZNF80) were evaluated as endogenous controls and 
ZNF80 was selected for data normalization, as it showed the most constant expression and stability 
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in all the tested samples. The reactions were performed in 15µl containing 20ng of DNA. In the 
present study, data normalization was performed with the Bio-Rad CFX Manager 3.1 Software by 
using both the Normalized Expression Method (ΔΔCt). Data shown in the present study represent 
the mean of three different experiments, calculated by the Gene Study tool of the CFX Manager 
Software. 
3.4.2 Restriction fragment length polymorphism analysis 
Restriction fragment length polymorphism (RFLP) analysis was used to exclude the possibility that 
new mutations identified were small nuclear polymorphisms normally present within the population. 
RFLP was carried on in 320 chromosomes of controls. For the identification of restriction enzymes 
sites that cleave the region of our interest NEBcutter V2.0 (http://nc2.neb.com/NEBcutter2/) was 
used.  
For c.526G>A (p.Val176Met) in CAPN3 gene, the reaction was performed in 40 µl reaction volumes 
containing 5U of NlaIII restriction enzyme (R00125S, New England BioLabs®Inc), 1X reaction buffer 
and 5 µl of PCR product. The samples were incubated at 37°C overnight. The enzyme cut the wild-
type sequence two times generating three fragments of 355bp, 55bp, 30bp. While in the mutant allele, 
the enzyme cut three times generating four fragments of 195bp, 160bp, 55bp and 30bp. The digested 
samples were examined by electrophoresis through 2% agarose gel. In order to recognize species-
specific banding patterns, the yielded restriction profiles were compared with molecular weight 
marker VIII (11209264001, Sigma). 
For c.2458T>C mutation (p.Tyr820His) in CAPN3 gene, no restriction enzymes were identified with 
NEBcutter V2.0, then modified oligonucleotide was designed in order to generate a restriction site 
for RsaI enzyme (R0167S, New England BioLabs®Inc) within the wild-type sequence. The reaction 
was performed in 40 µl reaction volumes containing 5U of RsaI restriction enzyme, 1X reaction 
buffer and 5 µl of PCR product. The samples were incubated at 37°C for 1h. The digested samples 
were examined by electrophoresis through 2% agarose gel. The enzyme recognized only one 
restricted site in the wild-type allele generating two fragments of 140bp and 45bp. In order to 
recognize species-specific banding patterns, the yielded restriction profiles were compared with Gene 
RulerTM 50bp DNA Ladder (SM0373, Thermo Fisher Scientific). 
3.4.3 In silico analysis 
The possible effect of the variants identified was assessed with software tools: Mutation Taster 
(http://www.mutationtaster.org/), PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), PROVEAN 
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(http://provean.jcvi.org/index.php), snSNPAnalyzer (http://snpanalyzer.uthsc.edu/), SIFT 
(http://sift.jcvi.org/),  MutPred (http://mutpred.mutdb.org/) and PMut (http://mmb.pcb.ub.es/PMut/).  
 3.4.5 Conservative analysis  
Conservative analysis was performed with multiple alignment of amino acid sequence of human 
CAPN3 (NP_000061.1) with the orthologous proteins of Macaca mulatta (XP_001103220.1), Mus 
musculus (NP_031627.2), Rattus norvegicus (NP_058813.1), Bos taurus (NP_776685.1), Alligator 
mississippiensis (XP_006258549.1), Danio rerio (NP_001004571.1), Gallus gallus 
(NP_001004405.2) and Xenopus leavis (NP_001087053.1) using ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). 
While conservative analysis was performed with multiple alignment of amino acid sequence of 
human DYSF (NP_003485.1) with the orthologous proteins of Macaca mulatta (XP_014968118.1), 
Mus musculus (XP_006506233.1), Rattus norvegicus (XP_017448122.1), Bos taurus 
(XP_015328883.1), Alligator mississippiensis (XP_019351176.1), Danio rerio (XP_005172350.1), 
Gallus gallus (XP_015141556.1) and Xenopus tropicalis (XP_017946387.1) using ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). 
3.4.6 3D modeling   
CAPN3 3D structure was predicted by utilizing Automated Mode of SWISS-MODEL software 
(http://swissmodel.expasy.org/). The 3D structure was generated with the alignment of human m-
calpain (NP_001739.2, 1kfuL) and it was displayed by PyMol (PyMOL v.1.7.0.1; Python v.2.7.2). 
Only regions with perfect alignment were analysed in order to obtain a good reliability of the 
prediction. 
3.5 RNA EXTRACTION AND RETROTRANSCRIPTION 
Total RNA, isolated from fibroblast or form PBLs, was processed immediately using RNeasy Mini 
Kit (74104, QIAGEN), following the manufacturer's instruction. RNA was treated with DNAse I for 
15 minutes at RT (79254, Qiagen). The concentration and purity of total RNA samples were 
quantified using the spectrophotometer NanoDrop-1000 (Thermo Scientific).  
For each sample, 1 µg of total RNA was reverse transcribed using ImProm-II ™ Reverse 
Transcriptase (A3800, Promega) and random oligonucleotides in a 20µl volume. cDNA was used for 
both qualitative and quantitative analysis. 
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3.5.1 Qualitative analysis  
cDNA was amplified into five overlapping regions in order to analyse the whole coding region of the 
CAPN3 gene with primers designed by Blazquez et al., 200860. Then, cDNA was compared with the 
CAPN3 human isoform 1 (NM_000070.2). While the whole coding region of DYSF was amplified 
into thirteen overlapping regions with primers shown in table 5 and cDNA was compared with the 
DYSF human isoform 8 (NM_003494.3). The products of individual PCR reactions were separated 
electrophoretically on agarose gels or polyacrylamide gels and revealed with ethidium bromide 
staining. 
 
Tab.5: Specific primers designed for DYSF cDNA. 
3.5.2 RT-qPCR 
The expression levels of mRNA in each sample were investigated by a quantitative Real-Time 
Polymerase Chain Reaction (qRT-PCR) using SsoAdvanced TM SYBR® Green Supermix with CFX 
Connect™ Real-Time PCR Detection System. Each experiment was performed in three independent 
experiments with triplicate. The reaction specificity was confirmed by single peak in melt curve 
analysis and relative RNA expression was performed according to the 2-ΔΔCt method, with internal 
control genes. 
3.5.2.1 Dysferlin RT-qPCR  
The expression levels of dysferlin transcript were evaluated in blood samples and 5ng of cDNA was 
used for RT-qPCR. Three assays were designed in order to cover the middle and the end of the 
transcript:  between exon 42 and 43, exon 54 and the last assay should be around exon 34. The assay 
around econ 34 was designed and validated by Bio-Rad (qHsaCID0012070) and then the exact 
localization is not known. Before carried on the experiments, validation of the first two assays was 
performed in order to check the reaction efficiency as done for qPCR. Experiments have been 
performed with CFX Connect™ Real-Time PCR Detection System using SsoAdvanced TM SYBR® 
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Green Supermix according to the manufacturing instructions. Nucleotide sequences are listed in Table 
6.  
 
 Tab.6: Primers designed for RT-qPCR to evaluated the expression levels of dysferlin transcript. 
The experiments were carried out with cDNA from a healthy control that was used as calibrator. 
While hypoxanthine phosphoribosyltransferase 1 (HPRT1, qHsaCID0016375) and TATA box 
binding protein (TBP)-associated factor (TAF15, qHsaCID0021632) were used as endogenous 
controls to normalize each sample. Reference genes were provided and validated by Bio-Rad.  
3.5.2.2 Calpain 3 RT-qPCR 
The expression levels of calpain 3 transcript were evaluated in skin samples and 5ng of cDNA was 
used for RT-qPCR. Three assays were designed and before carried on the experiments, validation of 
them were performed in order to check the reaction efficiency as done for qPCR. Experiments have 
been performed with CFX Connect™ Real-Time PCR Detection System using SsoAdvanced TM 
SYBR® Green Supermix according to the manufacturing instructions. Nucleotide sequences are listed 
in Table 7.  
 
Tab.7: Primers designed for RT-qPCR to evaluate the expression levels of calpain 3 transcript. 
The experiments were carried out with cDNA from a healthy control that was used as calibrator. 
While hypoxanthine phosphoribosyltransferase 1 (HPRT1, qHsaCID0016375) and beta 
glucuronidase (GUSB, qHsaCID0011706) were used as endogenous controls to normalize each 
sample from skin samples. Reference genes were provided and validated by Bio-Rad.  
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3.6 PROTEIN EXTRACTION 
Muscle samples were lysed on ice with Tissue Protein Extraction Reagent T-PER™ (78510, 
Thermo Fisher Scientific) and Complete Mini Anti-protease Cocktail Tablets (11836153001, 
Roche) according to the manufacturers' instructions. Fibroblast and lymphocyte samples were lysed 
with Mammalian Protein Extraction Reagent M-PER™ (78501, Thermo Fisher Scientific) and 
Complete Mini Anti-protease Cocktail Tablets according to the manufacturers' instructions. The 
protein concentration was determined by Lowry method. 
3.6.1 Western blot analysis 
Calpain 3 and dysferlin expression were evaluated by western blot analysis. 90μg protein from muscle 
samples, 40μg protein for skin samples and 50 μg protein from lymphocyte samples were used. 
Samples were separated by 7% SDS-polyacrylamide gel electrophoresis. Gels were run at 150 V for 
1 hour and another hour at 120 V. Gels were electrophoretically transferred to nitrocellulose 
membrane (1620115, Bio-Rad) for 1h at 350mA. Membranes were then blocked with 1.5%BSA 
(A7030, Sigma) for CAPN3, 3% BSA for DYSF and 5% BSA for GAPDH in TBS/Tween 0.05%  
(P1379, Sigma) for 1 hour at RT followed by incubation overnight at 4°C of primary antibodies.  
- CAPN3 antibody (1:25) (NCL-CALP-12A2, Leica Biosystems). 
- DYSF antibody (1:200) (JAI-1-49-3, Abcam). 
The following day, membranes were washed four times for 5 minutes with PBS-T and then incubated 
with secondary antibodies for 1 hour at RT. 
- Anti-rabbit secondary antibody, HRP (1:15000) (HAF008, R&D Systems) 
- Anti-mouse secondary antibody, HRP (1:15000) (HAF018, R&D Systems) 
In each experimental session, a patient and a control were analysed in parallel gel/blots and GAPDH 
(ZG003, Thermo Fisher Scientific) was used as internal reference to normalize protein expression. 
The amount of proteins were detected by Clarity TM Western ECL Substrate (1705060, Bio-Rad) 
according to the manufacturer’s instructions. The relative amounts of CAPN3 and DYSF protein were 
analysed by densitometry using ImageJ software. 
3.7 IMMUNOSTAINING  
Dysferlin immunofluorescence was performed in muscle sections from patients and controls. The 
muscle sections of 10µm were fixed in 4% paraformaldehyde (15710, Electron Microscopy Sciences) 
in PBS 1X at room temperature (RT) for 15 minutes. In fixed cells were added ice cold methanol for 
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5 minutes at -20°C. Then cells were washed three times with PBS 1X for 5 minutes each and blocked 
in 5% horse serum (AB7484, Abcam) diluted in PBS 1X for 1 hour at RT. After blocking, cells were 
incubated with RabMab Rabbit monoclonal (1:100) (JAI-1-49-3, Abcam) diluted in blocking solution 
overnight at 4°C. The day after the cells were washed with PBS 1X three times for 5 minutes each 
and incubated with Alexa 594 goat anti-rabbit (1:200) (R31632, Thermo Fisher Scientific) secondary 
antibody for 1 hour at RT. After that, three washes for 5 minutes each with PBS 1X followed by 
Hoechst (33342, ImmunoChemistry) staining for nuclei.   
The cells were examined by fluorescence microscopy (ZEISS AxioCam MRc5). 
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4. RESULTS 
4.2 DYSF PATIENTS 
4.2.1 D1_Clinical features 
The first patient (D1), a 55-year-old man presented weakness of the pelvic and shoulder girdle. 
Muscle biopsy revealed the presence of dystrophic features with increased variation in fiber size, 
substitution of muscle with fibro-adipose tissue, increased number of internal myonuclei and fiber 
necrosis. 
4.2.1.1 D1_Genetic analysis 
Direct sequencing of DYSF gene showed the already reported missense mutation c.6124C>T 
(p.Arg2042Cys) in exon 54 in homozygous state (Fig.4). Presumed homozygosity could be formally 
confirmed by sequence analysis of parental DNA, unfortunately, the parents of this patient were not 
available for sequence analysis. Therefore, the homozygous state or the possible large deletions in 
the other allele were detected by real-time PCR assays (Fig.6). 
 
 
Fig.4: Panel A: Electropherogram shows c.6124C>T variant in the homozygous state in exon 54. Panel B: 
Electropherogram of a negative control. 
4.2.1.2 D1_Conservative and in silico analysis 
Multiple alignments of the amino acid sequence of human DYSF (NP_003485.1) with the 
orthologous proteins of nine different species have shown that arginine in exon 54 (p.Arg2042) is 
highly conserved among all species (Fig.5A).  
In silico analysis shows the pathogenic nature of p.Arg2042Cys (Fig.5B). 
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Fig.5: Panel A: Multiple alignment of  amino acid sequence of human DYSF (NP_003485.1) with the orthologous 
proteins of Macaca mulatta (XP_014968118.1), Mus musculus (XP_006506233.1), Rattus norvegicus 
(XP_017448122.1), Bos taurus (XP_015328883.1), Alligator mississippiensis (XP_019351176.1), Danio rerio 
(XP_005172350.1), Gallus gallus (XP_015141556.1) and Xenopus leavis (XP_017946387.1). p.Arg2042 is highlighted 
with the arrow. Panel B: In silico analysis results for the amino acid substitution p.Arg2042Cys. 
4.2.1.3 D1_qPCR and qRT-PCR analysis 
qPCR in D1 patient was performed since relatives were not available for the genetic testing, 
moreover D1 showed all SNPs in homozygous state in dysferlin gene. It could be possible that the 
second allele has not been analysed with the only gene screening. Then, the homozygosity of the 
variant c.6124C>T was verified with qPCR in genomic DNA of the proband and a healthy control 
using five assays. No large deletions were detected and homozygosity of the variant was confirmed 
(Fig.6). 
 
Fig.6: Results of qPCR show no large deletion in DYSF gene in D1 patient (shown in red) compared to the healthy control 
(K1, shown in blue). ZNF80 was used for data normalization. 
 
qPCR was followed by the analysis of the expression levels of DYSF mRNA by qRT-PCR using 
three different assays. As shown in figure 7, DYSF transcript in blood sample was significantly 
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increased compared to healthy control. Currently, no muscle biopsy was available for western blot 
analysis.  
 
Fig.7: Histograms show the expression levels of dysferlin in blood samples. In red is shown D1 patient while in blue the 
healthy control (K2). Dysferlin mRNA is significantly increased in D1 patient compared to healthy control. 
4.2.1.4 D1_DYSF immunofluorescence  
Dysferlin immunofluorescence in muscle sample showed a significantly decreased of DYSF protein 
at the sarcolemma. Dysferlin protein is still present at sarcolemma but levels are extremely 
decreased compared to a healthy control (Fig.8). 
 
Fig.8: Panel A-B-C: Dysferlin staining (A), Hoechst staining (B) and merge image (C) in the sarcolemma of healthy 
muscle. Panel D-E-F: Dysferlin staining (D), Hoechst staining (E) and merge image (F) in the sarcolemma of D1. 
Images took with the same setting at 20X magnification (scale bar = 50µm). 
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4.2.2 D2_Clinical features 
The second patient (D2), a 48-year-old man presented limb-girdle weakness. The first symptoms 
started at 24 years of age with weakness and ipertrofic features of the pelvic and shoulder girdle 
muscles. Last clinical examination showed hyperlordosis, waddling gait and severe weakness of 
proximal muscles. EMG showed myopathic changes and TC showed adipose degeneration of limb 
girdle, thigh and bilateral leg. There was no cardiac or respiratory involvement. Muscle biopsy 
showed a complete substitution of muscle with fibro-adipose tissue and increased numbers of 
internal myonuclei. 
4.2.2.1 D2_Genetic analysis 
In the second patient, a homozygous missense variant was identified c.5509G>A (p.Asp1837) in 
exon 49 (Fig.9A). Genetic testing was extended to the father (D2_A) which carried the same variant 
in heterozygous state (Fig.9B). 
 
Fig.9: Panel A: Electropherogram shows c.5509G>A variant in homozygous state in exon 49 in D2 sample. Panel B: 
Electropherogram of D2_A shows c.5509G>A in the heterozygous state. 
 
4.2.2.2 D2_Conservative and in silico analysis  
Multiple alignments of the amino acid sequence of human DYSF (NP_001123927.1) with the 
orthologous proteins of nine different species have shown that aspartic acid in exon 49 (p.Asp1837) 
is highly conserved among all species (Fig.10A).  
In silico analysis shows the pathogenic nature of p.Asp1837Asn (Fig.10B).  
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Fig.10: Panel A: Multiple alignment of  amino acid sequence of human DYSF (NP_003485.1) with the orthologous 
proteins of Macaca mulatta (XP_014968118.1), Mus musculus (XP_006506233.1), Rattus norvegicus 
(XP_017448122.1), Bos taurus (XP_015328883.1), Alligator mississippiensis (XP_019351176.1), Danio rerio 
(XP_005172350.1), Gallus gallus (XP_015141556.1) and Xenopus leavis (XP_017946387.1). p.Asp1837 is highlighted 
with the arrow. Panel B: In silico analysis results for the amino acid substitution p.Asp1837Asn. 
4.2.2.3 D2_qPCR analysis 
For D2 patient only the father was available for genetic CAPN3 screening. However, it is not 
sufficient to confirm the homozygosity state of the variant, moreover D2 showed all SNPs in the 
homozygous state in dysferlin gene. Then, the homozygosity of the variant c.5509G>A was verified 
with qPCR. The analysis was performed in the proband, the father and a healthy control. Six assays 
were used and no large deletions were detected confirming the homozygosity of c.5509G>A (Fig.11). 
 
Fig.11: Results of qPCR showing no large deletion in DYSF gene in D2 patient (shown in red) compared to the father 
(D2_A, shown in yellow) and the healthy control (K1, shown in blue). 
4.2.2.4 D2_DYSF immunofluorescence 
Dysferlin immunofluorescence in D2 muscle sample showed a significantly decreased of DYSF 
protein at the sarcolemma. Dysferlin protein is not present in all fibres and DYSF left at the 
sarcolemma is extremely decreased compared to a healthy control (Fig.12). 
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Fig.12: Panel A-B-C: Dysferlin staining (A), Hoechst staining (B) and merge image (C) in the sarcolemma of healthy 
muscle. Panel D-E-F: Dysferlin staining (D), Hoechst staining (E) and merge image (F) in the sarcolemma of D2. 
Images took with the same setting at 20X magnification (scale bar = 50µm). 
4.2.3 D3_Clinical features  
The third patient (D3), a 55-year-old woman presented limb-girdle weakness. The first symptoms 
started at childhood with difficulty in raising the arms above the head and got worse at 40 years of 
age with lower back pain and recurrent falls for muscular weakness. Last clinical examination 
showed waddling gait, severe weakness of proximal muscles and increased serum CK (743 U/L). 
Muscle biopsy revealed the presence of dystrophic features with increased connective tissue, 
increased variation in fiber diameter and inflammatory infiltrate. Immunohistochemical analysis 
revealed normal staining of dystrophin, sarcoglycans and telethonin. 
4.2.3.1 D3_Genetic analysis  
D3 patient, a heterozygous missense variant was identified c.6139A>G (p.Ile2047Val) in exon 54 
(Fig.13A). Genetic testing was extended to the father (D3_B) and the daughter (D3_A). The father 
did not show the variant while the daughter carried the same heterozygous variant even if she didn't 
show dysferlinopathy phenotypes (Fig.13B and C).  
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Fig.13: Panel A: D3 electropherogram shows c.6139A>G variant in the heterozygous state in exon 54. Panel B: D3_B 
electropherogram does not show c.6139A>G variant. Panel C: D3_A electropherogram shows c.6139A>G variant in the 
heterozygous state. Panel D: D3 family pedigree. D3 is highlighted with the arrow and is clinically affected carrying only 
one heterozygous mutation. D3_A is shown with a black dot since she is asymptomatic even if she carrying c.6139A>G 
variant. 
 
In the proband, genetic screening was extended to CAPN3 gene as well. No pathogenic variants were 
detected. 
4.2.3.2 D3_Quantitative analysis 
The entire cDNA, retrotranscribed from a blood sample, was analysed to detect the presence of a 
possible second variant not observe with DYSF screening. No splicing defects were detected in D3 
and D3_A. The variant c.6139A>G in both cDNA is presented in heterozygous state (Fig.14). 
 
Fig.14: Panel A: Electropherogram of proband cDNA shows c.6139A>G variant in the heterozygous state. Panel B: 
Electropherogram of daughter cDNA shows c.6139A>G variant in the heterozygous state as well.  
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4.2.3.3 D3_Conservative and in silico 
Multiple alignments of the amino acid sequence of human DYSF (NP_003485.1) with the 
orthologous proteins of nine different species have shown that isoleucine in exon 54 (p.Ile2047) is 
conserved among the species, except for two species (Fig.15A).  
In silico analysis shows conflicting results for the nature of p.Ile2047Val (Fig.15B). 
 
Fig.15: Panel A: Multiple alignment of  amino acid sequence of human DYSF (NP_003485.1) with the orthologous 
proteins of Macaca mulatta (XP_014968118.1), Mus musculus (XP_006506233.1), Rattus norvegicus 
(XP_017448122.1), Bos taurus (XP_015328883.1), Alligator mississippiensis (XP_019351176.1), Danio rerio 
(XP_005172350.1), Gallus gallus (XP_015141556.1) and Xenopus leavis (XP_017946387.1). p.Ile2047 is highlighted 
with the arrow. Panel B: In silico analysis results for the amino acid substitution p.Ile2047Val. 
4.2.3.4 D3_qRT-PCR analysis 
The expression levels of DYSF mRNA, in the proband and in the asymptomatic daughter, were 
analysed in blood samples. No differences were observed in both samples compared to healthy 
control (Fig.16). 
 
Fig.16: Histograms showing DYSF transcript levels in lymphoblastoid cells of the proband shown in red, the daughter 
shown in yellow and a healthy control shown in blue  
4.2.3.5 D3_Dysferlin immunofluorescence 
Dysferlin immunofluorescence in D3 muscle sample showed a reduction of DYSF staining 
compared to the control. Dysferlin protein left at the sarcolemma is decreased compared to a 
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healthy control. The majority of the fibers showed a weaker staining and regenerating fibers are 
characterized by dysferlin accumulation within the cytoplasm (Fig.17). 
  
Fig.17: Panel A-B-C: Dysferlin staining (A), Hoechst staining (B) and merge image (C) in the sarcolemma of healthy 
muscle. Panel D-E-F: Dysferlin staining (D), Hoechst staining (E) and merge image (F) in the sarcolemma of D3. 
Images took with the same setting at 20X magnification (scale bar = 50µm). 
4.2.3.6 D3_Western blot analysis  
Contrary to immunofluorescence results, western blot analysis on lymphocyte samples highlighted 
an overexpressed amounts of DYSF protein in D3 and D3_A compared to normal control. D3 
patient and her daughter showed about 2-fold increase in dysferlin protein (Fig18). 
 
Fig.18: Panel A: Western blot analysis of DYSF performed on lymphocyte samples of normal control (K5), D3 and 
D3_A. Panel B: DYSF expression normalized with respect to GAPDH expression. 
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4.3 CAPN3 PATIENTS 
4.3.1 In silico analysis 
Before starting in silico analysis, the software tools were checked for prediction of the effects of a 
collection of 160 known pathogenic variants, acquired from literature and databases, in order to attest 
the rate of correct predictions relatively to mutations affecting CAPN3 gene. The test proved a 
sensibility of 97% for Mutation Taster, 90% for PolyPhen-2, 78% for PROVEAN, and 77% for 
snSNPAnalyzer while SIFT, Panther, MutPred and PMut showed a low sensibility. 
 
4.3.2 C1_Clinical features 
In C1 family, three siblings born to unrelated parents presented limb-girdle muscle weakness. In the 
family pedigree, the mother was reported to present muscle weakness. Patient C1 was a 59-year-old 
man presenting with gait difficulties since 20 years. The patient’s early development was normal and 
the past medical history was unremarkable. Over the following years, he was repeatedly referred to 
our hospital due to easy fatigability and progressive muscle weakness. EMG showed myopathic 
changes. Serum CK was highly increased (2341 U/L). He showed waddling gait, calf hypertrophy 
and scapular winging. He presented severe and symmetrical weakness of shoulder or pelvic girdles. 
Pulmonary and cardiac functions were normal. Muscle biopsy was consistent with chronic 
dystrophic-like features including variability in myofiber diameters, atrophic and hypertrophic fibers, 
fiber splitting and increase in adipose and fibrous tissue. Degenerating and/or regenerating fibers 
were also present. Immunohistochemical studies showed a normal membranous pattern of staining 
with antibodies to dystrophin and sarcoglycans. 
The 56-year-old sister (C1_A) presented progressive weakness in his right biceps brachii muscle 
starting at 40 years of age, followed by diffuse muscle weakness. EMG showed myopathic changes, 
serum CK was increased (2118 UI/l at the age of 48, 1413 Ul/l at the age of 51). In the last 
neurological examination, the patient showed a clinical condition similar to his brother. Muscle 
biopsy showed variation in fibers size with atrophic fibers and internal nuclei. There were no 
degenerating or regeneration fibers. Immunohistochemical studies showed a normal membranous 
pattern of staining with antibodies to dystrophin and sarcoglycans. 
The 55-year-old sister (C1_B) referred progressive muscle weakness since 40 years. EMG showed 
myopathic changes and serum CK was elevated (1767 UI/l). Neurological examination showed limb 
girdle muscle weakness although less severe than her siblings. Muscle biopsy showed the presence 
100 
 
of atrophic and hypertrophic fibers, without necrosis. Immunohistochemical studies showed normal 
expression of dystrophin and sarcoglycans. 
4.3.2.1 C1_Genetic analysis 
C1 patient showed two known pathogenic variants in heterozygous status: c.755T>G 
(p.Met252Arg) in exon 5 and c.1746-20C>G in intron 14. Genetic testing was extended to siblings, 
one of them carried both mutations in heterozygous status (C1_A) whereas the other carried only 
the heterozygous c.755T>G variant (C1_B) (Fig.19). Both variants were detected even in cDNA in 
heterozygous state as well. 
 
Fig.19: Panel A: Family pedigree. C1 is highlighted with the arrow Panel B: Electropherograms show c.1746-20C>G 
variant in intron 14 and c.755T>G variant in exon 5 both in the heterozygous state. 
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4.3.2.2 C1_Conservative, 3D and in silico analysis 
Multiple alignments of the amino acid sequence of human CAPN3 (NP_000061.1) with the 
orthologous proteins of nine different species have shown that p.Met252 is conserved among species 
except for Xenopus leavis (Fig.20A).  
In silico analysis shows the pathogenic nature of p.Met252Arg (Fig.20B). 
Within the 3D structure of CAPN3 p.Met252 is located in a α-helix within the 3D structure inside the 
domain II (Fig.20C). 
 
Fig.20: Panel A: Multiple alignment of  amino acid sequence of human CAPN3 (NP_000061.1) with the orthologous 
proteins of Macaca mulatta (XP_001103220.1), Mus musculus (NP_031627.2), Rattus norvegicus (NP_058813.1), Bos 
taurus (NP_776685.1), Alligator mississippiensis (XP_006258549.1), Danio rerio (NP_001004571.1), Gallus gallus 
(NP_001004405.2) and Xenopus leavis (NP_001087053.1). p.Met252 is highlighted with the arrow. Panel B: In silico 
analysis results for the amino acid substitution p.Met252Arg. Panel C: Representation of the 3D structure of CAPN3. In 
green is shown domain I, in white domain II, in blue domain III and in yellow domain IV. While in red is shown the 
localization of p.Met252 within the 3D structure of the protein. 
Using the mutagenesis tool in PyMOL, it was possible to highlight that p.Met252Arg variation 
doesn’t generate a steric hindrance for the similar dimension of both amino acids. However, the 
addition of the arginine positive charge within the 3D structure could be neutralized by a negative 
charge nearby. It is likely that the negative charge of aspartic acid in position 402 interacts with the 
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positive charge of arginine. Since the distance between the two amino acids is 3.5Å, which is 
compatible with electrostatic interaction and/or hydrogen bonding (Fig.21).  
 
Fig.21: Panel A: p.Met252 shown in red within a α-helix of CAPN3. Panel B: Representation of p.Arg252 using 
mutagenesis wizard of PyMol. Panel C: Yellow arrow highlights the distance between p.Arg252 and p.Asp402 (p.Asp402 
is shown in orange). 
4.3.2.3 C1_RT-qPCR analysis 
Analysis of the transcript levels were performed in proband, siblings and healthy control, with three 
couple of primers localized in different regions of the transcript. RT-qPCR highlighted increased 
levels of the transcript in C1 and C1_A compared to healthy control (K3). In all assays, transcript 
levels are almost two times more compared to control. Unlike C1 and C1_A, C1_B did not show a 
significant increase of the transcript. In exons 5/6 and exons 9/10 transcript levels are comparable to 
the healthy control. Only exons 10/11 showed an increase of the transcript even if lower than C1 and 
C1_A (Fig.22). 
 
Fig.22: Relative normalized expression of calpain 3 transcript levels. Histograms represent total transcript level of calpain 
3 in C1 shown in red, C1_A shown in yellow, C1_B shown in orange compared to a healthy control (K3) shown in blue. 
4.3.3 C2_Clinical features  
Patient C2 was a 74-year-old woman presented limb-girdle weakness. The first symptoms started at 
45 years of age and she was faced with a gradually developing difficulty of going up and downstairs 
and standing. Clinical examination showed scapular winging, waddling gait severe weakness of upper 
and lower girdle muscles. EMG showed myopathic changes and serum CK was elevated (1169 UI/l). 
There was no cardiac or respiratory involvement. Muscle biopsy showed increased fiber size 
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variability with 10% central nuclei and diffuse increased connective tissue. Immunohistochemical 
studies showed normal expression of dystrophin, sarcoglycans, dysferlin. 
4.3.3.1 C2_Genetic analysis 
CAPN3 screening showed three previously reported pathogenic mutations: a single base pair 
mutation encoding a premature stop codon c.967G>T (p.Glu323*) in exon 7, a single amino acid 
deletion c.1401_1403delGGA (p.Glu467del) in exon 11 and a missense mutation c.2257G>A 
(p.Asp753Asn) in exon 21 (Fig.23). Segregation analysis allowed us to establish that mutations 
c.1395_1397delGGA and c.2257G>A were localized in the same allele. All variants were detected 
in cDNA in heterozygous state as well. 
 
Fig.23: Panel A: Electropherogram shows c.967G>T variant in exon 7 in the heterozygous state. Panel B: 
Electropherogram shows the deletion of three nucleotides c.1401_1403delGGA in exon 11 in the heterozygous state. 
Panel C: Electropherogram shows the missense variant c.2257G>A in exon 21 in the heterozygous state. 
4.3.3.2 C2_Conservative, 3D and in silico analysis 
Multiple alignments of the amino acid sequence of human CAPN3 (NP_000061.1) with the 
orthologous proteins of nine different species have shown that the glutamic acid deleted in exon 11 
(p.Glu467) and the aspartic acid in exon 21 (p.Asp753) are conserved among species except for 
Xenopus leavis (Fig.24A and B). 
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In silico analysis was performed only for the missense mutation and the results of four reliable 
software are conflicting (Fig.24C). 
The 3D analysis was performed in two of the three variants identified. The mutation 
c.1395_1397delGGA leads to deletion of glutamic acid and it occurs in the domain III of CAPN3. 
Deletion is located inside a loop pointed towards the external surface of the protein. While the amino 
acid substitution p.Asp753Asn is localized on the surface of CAPN3, inside one of the five EF-hand 
(PEF) domains (Fig.24D). 
 
Fig.23: Panel A: Multiple alignment of  amino acid sequence of human CAPN3 (NP_000061.1) with the orthologous 
proteins of Macaca mulatta (XP_001103220.1), Mus musculus (NP_031627.2), Rattus norvegicus (NP_058813.1), Bos 
taurus (NP_776685.1), Alligator mississippiensis (XP_006258549.1), Danio rerio (NP_001004571.1), Gallus gallus 
(NP_001004405.2) and Xenopus leavis (NP_001087053.1). p.Glu467 is highlighted with the arrow. Panel B: Multiple 
alignment of amino acid sequence of human CAPN3 (NP_000061.1) with the orthologous proteins of Macaca mulatta 
(XP_001103220.1), Mus musculus (NP_031627.2), Rattus norvegicus (NP_058813.1), Bos taurus (NP_776685.1), 
Alligator mississippiensis (XP_006258549.1), Danio rerio (NP_001004571.1), Gallus gallus (NP_001004405.2) and 
Xenopus leavis (NP_001087053.1). p.Asp753 is highlighted with the arrow. Panel C: In silico analysis results for the 
amino acid substitution p.Asp753Asn. Panel D: Representation of the 3D structure of CAPN3. In green is shown domain 
I, in white domain II, in blue domain III and in yellow domain IV. While in red are shown the localization of p.Asp753 
inside domain IV and p.Glu467del inside domain III.  
Using the mutagenesis tool in PyMOL, it was possible to highlight that p.Asp753Asn variation does 
not generate a steric hindrance, since the similar dimension of both amino acids and even because the 
substitution is found in the surface of the protein, characterised by more flexibility (Fig.25A). 
However, p.Asp753Asn is localized in EF3 domain that is crucial for the binding of Ca2+ ions. The 
changing of one charged amino acid with a polar one could modify that interaction. While the deletion 
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of glutamic acid (p.Glu467del) occurs inside a loop pointing to the external surface. Deletion of one 
amino acid in that region does not interfere with protein folding but it could disturb the linkage of 
calpain 3 with the sarcomere protein titin, essential for control the autolytic function of CAPN3. Since 
p.Glu467 is localized close to the binding site needed for the interaction with titin (Val575-Leu580). 
It is possible that the negative charge of the glutamic acid interacts with the charged p.Lys575, since 
the distance between the two amino acids, is compatible for interaction (Fig.25C).  
 
Fig.25: Panel A: p.Asp753 shown in red within the α-helix on the external surface of CAPN3. Panel B: Representation 
of p.Asn753 using mutagenesis wizard of PyMol. Panel C: Distance between p.Glu467 shown in red and p.Lys575 shown 
in orange. Potential interaction is shown as a yellow dots. While in magenta is shown the titin binding site (Val575-
Leu580). 
4.3.4 C3_Clinical features 
Patient C4 was a 21 years old woman born to unrelated parents presented limb-girdle muscle 
weakness. Even her cousin shows a clinical pattern compatible with limb girdle muscular dystrophy. 
The first symptoms started at 16 years of age with hyposthenia especially of lower girdle muscles 
compared to upper girdle muscle and got worse after pregnancy. Moreover, she showed waddling 
gait, difficulty raising the arms above the head and serum CK was highly increased (3856 U/L in 
2016 and 5018 U/L in 2017). Pulmonary and cardiac functions were normal. Muscle biopsy showed 
atrophic and hypertrophic fibers, internal nuclei and necrosis. Immunohistochemical studies showed 
a normal membranous pattern of staining with antibodies to dystrophin and sarcoglycans. 
4.3.4.1 C3_Genetic analysis 
CAPN3 screening showed a single missense mutation c.2257G>A (p.Asp753Asn) in exon 21 in 
heterozygous state (Fig.26). Same variant detected in C2 patient. 
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Fig26: Electropherogram shows c.2257G>A variant in exon 21 in the heterozygous state. 
4.3.4.2 C3_Conservative, 3D and in silico analysis 
Conservative analysis of p.Asp753 is shown in figure 23B, in silico analysis in figure 24C while 3D 
analysis in figure 24D, 25A and B. 
4.3.4.3 C3_Western blot analysis 
Western blot analysis, in muscle sample, showed no modification in CAPN3 protein levels, while 
an increased DYSF protein levels compared to the healthy control (Fig.27). 
 
Fig.27: Panel A: Western blot analysis of CAPN3 and DYSF on skeletal muscle of healthy control (K4) and C3 patient. 
Panel B: CAPN3 and DYSF protein expression normalized with respect to GAPDH expression. 
4.3.4.4 C3_DYSF immunofluorescence 
Dysferlin staining in C3 patient showed increased levels of DYSF compared to control. This result 
is an accordance with western blot analysis. Dysferlin protein is not only localized at the 
sarcolemma level but even accumulated into the cytoplasm (Fig.28). 
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Fig.28: Panel A-B-C: Dysferlin staining (A), Hoechst staining (B) and merge image (C) in the sarcolemma of healthy 
muscle. Panel D-E-F: Dysferlin staining (D), Hoechst staining (E) and merge image (F) in the sarcolemma of C3. 
Images took with the same setting at 20X magnification (scale bar = 50µm). 
4.3.5 C4_Clinical features 
Patient C4 was a 60-year-old man presenting easy fatigability and progressive limb-girdle muscular 
weakness since adolescence (15 years). Last clinical examination showed waddling gait with 
weakness in the shoulder and pelvic girdles. Serum CK was 191 Ul/l. Muscle biopsy showed mild 
variation in fiber size and internal nuclei. Immunohistochemical analysis revealed normal stain of 
dystrophin and sarcoglycans.  
4.3.5.1 C4_Genetic analysis 
CAPN3 screening in C4 patient showed only one missense mutation in exon 4, c.526G>A 
(p.Val176Met) in heterozygous state (Fig.29B). Genetic testing was extended to close asymptomatic 
family members. This variant has been detected in mother, sibling, daughter and niece in 
heterozygous state as well. p.Val176Met is a new variant not yet reported, then PCR-RFLP analysis 
was performed to evaluate the presence of this new variant within 320 chromosomes. PCR-RFLP 
analysis showed the absence of p.Val176Met in 320 chromosomes (Fig.29C-D). 
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Fig.29: Panel A: C4 pedigree Panel B: Electropherogram shows c.526G>A variant in heterozygous state. Panel C: 
Schematic representation of sites for restriction enzyme NlaIII. In blue is shown the two sites recognized on wild-type 
allele and the three fragments generating (355bp, 55bp, 30bp), while in red is shown the adding site recognized on mutant 
allele and the four fragments generating (195bp, 160bp, 55bp and 30bp). Panel D: Electrophoresis through 2% agarose 
gel of 20 samples with C4 (positive control, CP) and not digested sample (ND). The yielded restriction profiles were 
compared with molecular weight marker VIII. 
The genetic screening was extended even for DYSF gene but no pathogenic variants were detected. 
4.3.5.2 C4_Conservative, 3D and in silico analysis 
Multiple alignments of the amino acid sequence of human CAPN3 (NP_000061.1) with the 
orthologous proteins of nine different species have shown that valine in exon 4 (p.Val176) is highly 
conserved among all species (Fig.30A). 
In silico analysis shows the pathogenic nature of p.Val176Met (Fig.30B). 
The 3D analysis shows that p.Val176Met is located in a beta sheet within the 3D structure inside the 
domain II of the protein (Fig.30C). 
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Fig.30: Panel A: Multiple alignment of  amino acid sequence of human CAPN3 (NP_000061.1) with the orthologous 
proteins of Macaca mulatta (XP_001103220.1), Mus musculus (NP_031627.2), Rattus norvegicus (NP_058813.1), Bos 
taurus (NP_776685.1), Alligator mississippiensis (XP_006258549.1), Danio rerio (NP_001004571.1), Gallus gallus 
(NP_001004405.2) and Xenopus leavis (NP_001087053.1). p.Val176 is highlighted with the arrow. Panel B: In silico 
analysis results for the amino acid substitution p.Val176Met. Panel C: Representation of the 3D structure of CAPN3. In 
green is shown domain I, in white domain II, in blue domain III and in yellow domain IV. While in red is shown the 
localization of p.Val176 within domain II on a β-sheet pointing to a central α-helix. 
Using the mutagenesis tool in PyMOL, it was possible to highlight that p.Val176Met variant is 
localised within a well defined 3D structure. There is a central α-helix surrounded by other secondary 
structures. Substitution of valine versus methionine generates a steric hindrance since the dimension 
of these two amino acids is completely different (Fig.31).  
 
Fig.31: Panel A: In red is shown pVal176 within a β-sheet of CAPN3 domaini II. Panel B: Representation of p.Met176 
using mutagenesis wizard of PyMol.  
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4.3.5.3 C4_Qualitative analysis 
The entire cDNA, retrotranscribed from skin sample, was amplified into five overlapping regions to 
detect the presence of a possible second variant not observe with CAPN3 screening. However, no 
alterations were observed and the variant c.526G>A has been found in the heterozygous state even 
in the transcript (Fig.32). 
 
Fig.32: Electropherogram of the transcript shows c.526G>A variant in heterozygous state. 
4.3.5.4 C4_DYSF immunofluorescence  
Even if no pathogenic variants were detected with dysferlin screening, immunofluorescence was 
performed to evaluate the presence of a possible secondary reduction of DYSF protein. No 
differences were observed between C4 and healthy control in dysferlin staining, the patient did not 
show reduced plasma membrane expression of dysferlin protein (Fig.33). 
 
Fig.33: Panel A-B-C: Dysferlin staining (A), hoechst staining (B) and merge image (C) in the sarcolemma of healthy 
muscle. Panel D-E-F: Dysferlin staining (D), hoechst staining (E) and merge image (F) in the sarcolemma of C4. 
Images took with the same setting at 20X magnification (scale bar = 50µm). 
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4.3.5.5 C4_Western blot analysis 
Western blot analysis in muscle sample showed a reduction of CAPN3 protein levels in patient C4 
compared to the healthy control. Calpain 3 showed a reduction of 30%. Interestingly, CAPN3 
expression was evaluated even in patient’s skin sample, which showed the same reduction of 30% 
compared to healthy control (Fig.34). 
 
Fig.34: Panel A: Western blot analysis of CAPN3 on muscle and fibroblast samples of healthy control (K4) and patient 
C4. Panel B: CAPN3 expression normalized with respect to GAPDH expression. 
4.3.6 C5_Clinical features  
C5 was a 51-year-old man presenting with gait difficulties since the age of 35 years and progressive 
limb-girdle muscular weakness. Clinical examination showed waddling gait with diffuse muscle 
wasting, scapular winging. Severe weakness in the shoulder and pelvic girdles were also present. 
Pulmonary and cardiac functions were normal. Muscle biopsy revealed the presence of dystrophic 
features with increased connective tissue, increased variation in fibers size, internal nuclei and several 
lobulated fibers. There were also necrosis and degenerating/regenerating fibers. 
Immunohistochemical analysis revealed normal stain of dystrophin, sarcoglicans, dysferlin, caveolin. 
4.3.6.1 C5_Genetic analysis 
C5 patient showed one novel missense mutation in exon 24 in the heterozygous state: c.2458T>C 
(p.Tyr820His) (Fig.35A). Since the non-availability of the sample, it has not been possible carry on 
additional molecular analysis. PCR-RFLP analysis confirmed the absence of amino acid variation in 
320 chromosomes (Fig.35B-C). 
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Fig.35: Panel A: Electropherogram shows c.2458T>C variant in heterozygous state. Panel B: Schematic representation 
of sites for restriction enzyme RsaI. In blue is shown the site recognized on wild-type allele and the two fragments 
generating (140bp, 45bp), while the enzyme does not recognize any restriction site on mutant allele. Panel C: 
Electrophoresis through 2% agarose gel of 9 samples with C5 (positive control, CP) and not digested sample (ND). The 
yielded restriction profiles were compared with molecular weight marker VIII. 
4.3.6.2 C5_Conservative, 3D and in silico analysis 
Multiple alignments of the amino acid sequence of human CAPN3 (NP_000061.1) with the 
orthologous proteins of nine different species have shown that tyrosine in exon 24 (p.Tyr820) is 
conserved among species except for Xenopus leavis (Fig.36A).  
In silico analysis with the four reliable software shows in three software the pathogenic nature of 
p.Tyr820His (Fig.36B). 
For the last patient, it was not possible to analyze the variant p.Tyr820His into the 3D structure of 
CAPN3 since the amino acid substitution is located in a region not perfectly aligned with human m-
calpain. However, the amino acid before the mutation in position 819 is localised in the domain IV 
inside the EF5-hand. Therefore is highly possible that p.Tyr820His is localised in the EF5-hand as 
well (Fig.36C). 
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Fig.36: Panel A: Multiple alignment of  amino acid sequence of human CAPN3 (NP_000061.1) with the orthologous 
proteins of Macaca mulatta (XP_001103220.1), Mus musculus (NP_031627.2), Rattus norvegicus (NP_058813.1), Bos 
taurus (NP_776685.1), Alligator mississippiensis (XP_006258549.1), Danio rerio (NP_001004571.1), Gallus gallus 
(NP_001004405.2) and Xenopus leavis (NP_001087053.1). p.Tyr820 is highlighted with the arrow. Panel B: In silico 
analysis results for the amino acid substitution p.Tyr820His. Panel C: Representation of the 3D structure of CAPN3. In 
green is shown domain I, in white domain II, in blue domain III and in yellow domain IV. While in red is shown the 
localization of p.Met819 within EF5-hand of CAPN3 domain IV. 
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5. DISCUSSION  
5.1 DYSFERLIN PATIENTS 
5.1.1 D1 patient 
DYSF screening highlighted, in a 55-year-old man presented limb-girdle weakness, one missense 
mutation (p.Arg2042Cys) in exon 54 in homozygous state. This variant c.6124C>T (p.Arg2042Cys) 
has been already reported in several papers but never in homozygous state45,176,179–181 (Tab.8) 
 
Tab.8: Reported cases in which p.Arg2042Cys has been detected. 
As shown in the table p.Arg2042Cys is correlated with two different phenotypes: LGMD2B and 
MM. In the present study p.Arg2042Cys was detected for the first time in homozygous state and it 
is correlated with LGMD2B phenotype. 
We found that p.Arg2042Cys mutation significantly increased the expression of the gene (Fig.7) 
and this finding seems to be in contrast with immunofluorescence analysis, which showed a notably 
decreased of DYSF protein at the sarcolemma level (Fig.8). p.Arg2042Cys mutation is localized 
close to transmembrane domain (2045-2067) and could interfere with insertion of the protein in the 
sarcolemma, explaining low level of DYSF protein in this region. However, this is just one 
hypothesis since it was not possible to perform western blot analysis to quantify dysferlin protein. 
Western blot analysis would have been conclusive to assess if the big amount of dysferlin transcript 
correspond to a big amount of mutant proteins. Because it could be even possible that the increased 
transcriptional activity does not correspond to increase quantity of protein. 
5.1.2 D2 patient 
D2 patient, a 48-year-old man, showed the first clinical symptoms at 24 years old with weakness 
and ipertrofic features of the pelvic and shoulder girdle muscles. D2 harboured a pathogenic 
homozygous missense mutation p.Asp1837Asn already reported in several papers, even in 
homozygous state50,176,179,181,182 (Tab.9). 
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Tab.9: Reported cases in which p.Asp1837Asn has been detected. 
Dysferlin immunofluorescence in D2 muscle sample showed a severe reduction of dysferlin at 
sarcolemma level (Fig.12). This is in agreement with Rosales’ paper, describing a patient carrying 
the same variant in homozygous state. Rosales reported a male, in which the first symptoms 
appeared at 17 years old with weakness in distal lower extremity. The patient showed LGMD2B 
phenotype characterized by the absence of dysferlin protein both in western blot and 
immunofluorescence analysis. The onset and the phenotype are similar to our patient, in which the 
first symptoms appeared at 24 years old with LGMD2B phenotype and weakness in both distal and 
proximal muscles.  
5.1.3 D3 patient 
DYSF screening showed in D3 patient only one missense mutation, p.Ile2047Val, in exon 54 in 
heterozygous state. Genetic testing was extended to the daughter (D3_A) and the father (D3_B) and 
the variant was detected in heterozygous state in the asymptomatic daughter. The presence of large 
deletions on RNA level was evaluated in order to check a possible second mutation not detected by 
Sanger sequencing. The entire cDNA was analysed but no splicing defects were detected in both 
samples. Moreover, we evaluated the protein expression levels by western blot analysis on 
lymphocyte samples of D3 and D3_A. Both samples showed 2-fold increase in dysferlin protein 
expression compared to healthy control (Fig.17). While, dysferlin staining in D3 muscle showed a 
reduction of the protein at sarcolemma level with an increased level of dysferlin within the 
cytoplasm (Fig.16). Unfortunately, the muscle sample of the daughter was not available for the 
staining, thus it has not been possible to detect dysferlin localization. The discrepancy observed 
between western blot results and dysferlin staining has been already reported. In a patient with 
overexpressed amounts of protein in western blot analysis and absence of dysferlin in muscle 
staining50. Probably the mutant protein is unable to insert itself into the muscle membane. 
p.Ile2047Val mutation is located within the transmembrane domain (2045-2067) and it could be 
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possible that 50% of mutant proteins generated from c.6139A>G variant fails to insert at 
sarcolemma level. However, in order to confirm this hypothesis is essential to perform 
immunofluorescence analysis even in the asymptomatic daughter. This analysis could help us to 
clarify the functional consequences of p.Ile2047Val mutation. If the daughter will show the same 
reduction and localization of the protein in muscle sample of D3 this will assess the pathogenic role 
of p.Ile2047Val. So far, functional studies about DYSF mutation within TM domain are scarce, then 
it will be interesting to carry on further analysis. 
5.2 CALPAIN PATIENTS 
5.2.1 C1 family 
C1 family included three siblings born to unrelated parents presented progressive muscle weakness 
with elevated serum CK. The proband (C1) and one of his sister (C1_A) showed severe limb girdle 
muscular weakness. Muscle biopsy showed both in C1 and C1_A dystrophic features including 
variability in fibers diameters and atrophic and hypertrophic fibers. In addition to that, C1 showed 
other dystrophic features not presented in C1_A as degenerating and/or regenerating fibers, fiber 
splitting and increase in adipose and fibrous tissue. The younger sister C1_B showed limb girdle 
muscle weakness although less severe than her siblings. Less severe phenotype of C1_B was 
examined both during neurological examination and in muscle biopsy analysis. 
Since, clinical evaluation and muscle biopsy analysis were compatible with a LGMD2A phenotype, 
CAPN3 screening was carried out. Two known pathogenic variants (c.1746-20C>G, p.Met252Arg) 
in heterozygous state were detected in C1 and C1_A, while just one variant (p.Met252Arg) was 
detected in C1_B. 
The intronic variant c.1746-20C>G, presents in C1 and in C1_A, has been described in several 
reports. In 2005, it was described for the first time in 2 individuals in simple heterozygous state and 
other 2 cases in compound heterozygous state183. The following years it was described in trans with 
c.598_612del in a male patient characterised by the absence of calpain 3 at western blot analysis167. 
This variant was described even in other papers and its deleterious effect has been demonstrated by 
Nascimbeni et al., 2010 at translational and transcriptional levels as well184. The intronic variant 
c.1746-20C>G leads to the activation of the cryptic acceptor splice sites carrying the retention of 
19, 86, 122 and 305 bp of intron 13. The pathogenic effect of this variant was observed only when it 
is associated with another mutant allele and it always resulted in severely reduced protein quantity. 
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The missense variant p.Met252Arg found in siblings, has been already reported, more than 10 years 
ago by Fanin's research group152. This variant was described in simple heterozygous state in an 
asymptomatic male of 48 years old, characterized by high serum creatine kinase levels and a 
reduction of 50% of calpain 3 in western blot analysis.  
Western blot analysis was performed by another laboratory only in C1 patient, showing 50% 
reduction of calpain 3 levels, likely due to the missense mutation p.Met252Arg, as reported in 
literature.  
In silico analysis showed the missense variant as likely pathogenic since the amino acid substitution 
is located in a highly conserved region (Fig.20B). Moreover, 3D analysis highlighted that p.Met252 
is located internally in α-helix within the 3D structure of calpain 3. The substitution of nonpolar 
amino acid as methionine for a charged amino acid as arginine provides increased polarity in this 
region due to the addition of a positive charge. The addition of a charge within a 3D structure could 
interfere with protein folding. Moreover, it is even possible that the positive charge of arginine is 
neutralized by the negative charge of aspartic acid at position 402. Since the distance between the 
two amino acids is 3.5 Å, distance compatible with electrostatic interaction and hydrogen bond. In 
this case, loss of a negative charge could interfere with the correct function of the protein. Then, in 
both scenarios p.Met252Arg seems to have a pathogenic effect in 3D structure of calpain 3 (Fig.21). 
The intronic variant, c.1746-20C>G has been found associated with another mutant allele, leading 
to a severely reduced protein quantity184. Then, this could explain the severe phenotype shown by 
C1 and C1_A, carrying the intronic variant associated with the missense pathogenic mutation. 
However we detected in C1 and C1_A significantly increased levels of the transcript compared to 
healthy control and C1_B (Fig.22). Higher transcript levels were probably due to the intronic 
variant c.1746-20C>G, which leads to the activation of the cryptic acceptor splice sites generating 
four alternative transcripts with the retention of some nucleotides of intron 13184. This finding could 
explain why C1_B had different calpain transcript levels compared her sibling. 
In conclusion, our study confirms the pathogenic role of c.1746-20C>G and p.Met252Arg in 
patients C1 and C1_A. As reported by Nasmibeni’s paper, showing the pathogenic effect of the 
intronic variant when it is associated with a second mutation. However, even if C1 and C1_A are 
characterized by the same CAPN3 genotype they do not show the same phenotype and the same age 
of onset of the disease. C1_A showed a less severe phenotype compared to C1. However, this is 
common in LGMD2A which is characterised by high phenotypic variability, considering the fact 
that the first case was reported in 1998. 
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While in C1_B only one mutation was detected and compared to the other cases reported in 
literature with only one mutation in CAPN3 gene the presence of a second variant seems unlikely. 
In almost 22% of LGMD2A, only one variant is found but is not excluded the presence of another 
variant. However our case is different, then it could be possible that other factors are involved in the 
pathogenesis of LGMD2A. 
5.2.2 C2 patient 
In patient C2, three mutations were detected in CAPN3 gene, already reported as pathogenic. 
Nonsense mutation c.967G>T (p.Glu323*) and deletion of one amino acid c.1401_1403delGGA 
(p.Glu467del) have been described in compound heterozygous state and in homozygous state183. 
While the missense variant c.2257G>A (p.Asp753Asn) was described several times in simple 
heterozygous state12,151,152,185. This variant seems to be associated with a moderate phenotype and 
slow clinical progression. 
In our patient, segregation analysis showed that p.Glu467del and p.Asp753Asn variants were 
localized in the same allele while p.Glu323* in trans. Even if the presence of two pathogenic 
variants in cis seemed unlikely, previous studies have confirmed the pathogenic role of both of 
them18312,151,152,185. Both p.Glu467 and p.Asp753 are highly conserved among species. p.Glu467 is 
localized close to the region required for the interaction with titin, and is essential for the autolytic 
CAPN3 function. Moreover, the negative charge of the glutamic acid may interacts with the 
charged p.Lys575, which is one of the amino acids involved in titin interaction (Fig.25C). Then, the 
deletion of glutamic acid could modify the ability of CAPN3 to interact with titin leading to 
CAPN3 autolysis. While, p.Asp753Asn is localized in EF3-hand that contains a Ca2+ bound, amino 
acid modification within this domain could interfere during Ca2+ signalling. 
In conclusion our studies are in agreement to what reported in literature, in which both mutations 
are described as pathogenic. 
5.2.3 C3 patient 
Patient C3 came to our attention at 16 years of age, manifesting hyposthenia especially of lower 
girdle muscles compared to upper girdle muscle and increased levels of serum CK (5018 U/L). 
CAPN3 direct sequencing showed one heterozygous mutation in exon 21 c.2257G>A 
(p.Asp753Asn). This variant in simple heterozygous state, has been reported in several 
papers12,151,152,185, as shown in table 10. 
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Tab.10: Reported cases in which p.Asp753Asn has been detected in single heterozygous state. 
p.Asp753Asn mutation seems not correlate with calpain 3 protein levels since patients with the 
same variant showed complete absence, 50% reduction and normal protein expression (our case). 
Then, it is possible that the differences in CAPN3 expression are due to the presence of a second 
mutation not detected. Even the age of onset seems not correlate with the mutation but the variant 
seems link to a mild disease manifestation and slow clinical progression. Interestingly, as the patient 
described by Tudorova the first symptoms of C3 got worse after pregnancy.  
Moreover, in the present study, we evaluated not only CAPN3 expression but also DYSF 
expression. Both western bot and immunofluorescence analysis showed increased levels of 
dysferlin protein compared to healthy control. Further informations are required to understand the 
functional implications of that.  
5.2.4 C4 patient 
CAPN3 and DYSF screening in C4 patient showed only one novel missense mutation in, 
p.Val176Met, in heterozygous state in CAPN3 gene. The presence of large deletions have been 
excluded with the sequencing of the whole CAPN3 transcript. The missense variant is reported in 
the public database ExAC with a low allele frequency, but has not been found in previously 
reported calpin patients and in our in house healthy control. p.Val176 is highly conserved amino 
acid and all reliable software showed the pathogenic nature of the variant. 3D analysis led us to 
evaluate the effect of amino acid variation within the protein structure. p.Val176 is located 
internally in a β-sheet pointed towards the central α-helix. The substitution of valine versus 
methionine generates a steric hindrance, which may lead to structural reorganization of the protein. 
Moreover, western blot analysis in muscle and skin samples showed a protein reduction of 30%.  
All these datas seem to confirm a possible pathogenic role of this variant. However, the genetic 
testing was extended to asymptomatic family members and p.Val176Met variant has been detected 
in mother, sibling, daughter and niece in heterozygous state as well. Then, among all family 
members carrying p.Val176Met variant, C4 patient is the only one with clinical LGMD 
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manifestation. This could be explained, as for the intronic variant c.1746-20C>G, that the 
pathogenic effect of p.Val176Met is observed in association with another mutant allele, that, in our 
case, has yet to be found. 
5.2.5 C5 patient 
CAPN3 screening in C5 patient showed one heterozygous novel missense mutation in exon 24, 
c.2458T>C (p.Tyr820His). The missense variant was not reported in the literature, in public 
databases and in house healthy controls. In silico analysis showed the pathogenic role of 
p.Tyr820His and multiple alignments highlighted the conservatively of tyrosine among species 
except for Xenopus leavis. Moreover, p.Tyr820His is localized within the EF5 of the protein and 
this domain is essential for the homodimerization of calpain 3. Therefore, amino acid substitution 
inside EF5 domain could interfere with the binding and consequently with the function of the 
protein. C5 patient showed among our LGMD2A patients the most severe clinical phenotype, with 
severe weakness in the shoulder and pelvic girdles. The immunohistochemical analysis highlighted 
dystrophic features as variation in fibers size, internal nuclei, necrosis and 
degenerating/regenerating fibers. We didn’t perform further molecular analysis, since the 
unavailability of muscle biopsy to study the CAPN3 expression. 
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6. CONCLUSION 
 
Limb-girdle muscular dystrophies (LGMDs) is the generic name for a group of neuromuscular 
disorders inherited either with dominant (LGMD1) and recessive manner (LGMD2). LGMDs are 
characterized by predominantly weakness and atrophy with the prevalent involvement of proximal 
muscles of the hip and shoulder girdles. The autosomal recessive forms are much more common 
compared to the autosomal dominant forms, that represent less than 10% of all LGMD cases, and 
limb-girdle muscular dystrophy type 2A (LGMD2A) is the most frequently diagnosed among 
LGMDs worldwide followed by limb-girdle muscular dystrophy type 2B (LGMD2B). Both 
diseases show high phenotypic variability (intra- and inter-familial variability) of symptoms and 
severity, even among patients with the same genotype. Therefore, it is difficult to establish 
genotype-phenotype correlations among these conditions.  
Our study allowed to amplify the mutation spectrum in two genes involved in the most frequent 
forms of LGMD2 with the finding of two novel mutations in CAPN3 gene and one novel mutation 
in DYSF gene. Our study pointed out the difficulty to establish genotype-phenotype correlations, as 
reported in literature, especially for LGMD2A. These patients showed high phenotypic variability, 
even intra-family variability in C1 family. The type of mutations is not correlate with the age of 
onset or the phenotype. We concluded that is really challenging to correlate a certain phenotype 
with certain mutations, especially for missense ones. Interestingly, the presence of three mutations 
in one patient (C2) does not mean an earlier age of onset or a more severe phenotype. C2 became 
symptomatic at 45 years old and the patient is still ambulant at 70 years old. Even the presence of a 
single heterozygous mutation does not correlate with a less severe phenotype or later onset. For 
example, in C3 patient only one missense mutation c.2257G>A (p.Asp753Asn) was detected and 
the patient showed the first clinical symptoms at 16 years old with a moderate phenotype. 
Moreover, our study is in line with the literature in which numerous LGMD2A patients are reported 
with just one heterozygous mutation. In all these patients is likely the presence of a second mutation 
not detected. However in one of our cases (C1_B patient) the presence of a second mutation is 
unlikely. This result points out the possibility of involvement of other factors in the pathogenesis of 
LGMD2A. 
The LGMD2B study allowed us to correlate two homozygous mutations with a certain phenotype in 
accordance with literature. Moreover, we found a novel mutation in DYSF gene in heterozygous 
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state in D3 patient. This is the first time in which has been found an amino acid substitution in the 
transmembrane domain of dysferlin protein. The functional studies in p.Ile2047Val are not yet 
finished but this variant seems to correlate with an increased protein expression and a reduction of 
dysferlin at sarcolemma level. Immunofluorescence analysis highlighted a reduction at plasma 
membrane of dysferlin protein with an accumulation of dysferlin inside the cytoplasm. Dysferlin 
reduction at sarcolemma level could be due to the generation of a mutant protein that fails in the 
insertion at the sarcolemma. However, we need further analyses for clarifying the functional effect 
of p.Ile2047Val variant. It would be interesting to perform immunofluorescence analysis in the 
asymptomatic daughter carrying the same variant in heterozygous state as well. 
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